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Abstract 
 
Background.   
Currently, pregnant women are screened using ultrasound at booking and around the middle of 
pregnancy. Ultrasound scans thereafter are performed for clinical indications only.  
 
Objectives.   
We sought to assess the case for offering universal late pregnancy ultrasound to all nulliparous women 
in the UK. The main questions addressed were to determine the diagnostic effectiveness of universal 
late pregnancy ultrasound to predict adverse outcome, and the cost effectiveness of either 
implementing universal ultrasound or conducting further research in this area.  
 
Design  
We performed diagnostic test accuracy reviews of five ultrasonic measurements in late pregnancy. 
We conducted cost effectiveness and value of information (VoI) analysis of screening for fetal 
presentation, screening for small for gestational age (SGA) fetuses and screening for large for 
gestational age (LGA) fetuses.  We finally conducted a survey and a focus group to determine the 
willingness of women to participate in a future randomised trial.  
 
Data sources  
We searched Medline, EMBASE and the Cochrane library from inception.  
 
Review methods  
The protocol for the review was designed a priori and registered. Eligible studies were identified using 
key words with no restrictions for language or location. The risk of bias in studies was assessed using 
the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Health economic modelling employed 
a decision tree analysed via Monte Carlo simulation. Health outcomes were from the fetal perspective 
and presented as quality-adjusted life years (QALYs). Costs were from the perspective of the public 
sector defined as the (English) NHS and costs of special educational needs. All costs and QALYs were 
discounted by 3.5% per annum and the reference case time horizon was 20 years.  
 
Results  
Umbilical artery Doppler, cerebro-placental ratio (CPR), severe oligohydramnios, and borderline 
oligohydramnios were all either non-predictive or weakly predictive of the risk of neonatal morbidity 
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(summary positive likelihood ratios [LR+] between 1 and 2) and were all weakly predictive of the risk 
of delivering a SGA infant (summary LR+ between 2 and 4). Suspicion of fetal macrosomia is strongly 
predictive of the risk of delivering a large baby but it is only weakly – albeit statistically significantly – 
predictive of the risk of shoulder dystocia. Very few studies blinded the result of the ultrasound scan 
and most studies had high risk of bias through treatment paradox, ascertainment bias or iatrogenic 
harm. Health economic analysis indicated that universal ultrasound for fetal presentation only may be 
both clinically and economically justified on the basis of existing evidence. Universal ultrasound 
including fetal biometry was of borderline cost-effectiveness, and sensitive to assumptions.  VoI 
analysis indicated that future research should be focused on the cost difference between IOL and 
expectant management.    
 
Limitations  
The primary literature on the diagnostic effectiveness of ultrasound in late pregnancy is weak. VoI 
analysis may have underestimated the uncertainty in the literature as it was focused on the internal 
validity of parameters, which is quantified, whereas the greatest uncertainty may be in the external 
validity to the research question, which is unquantified.   
 
Conclusions  
Universal screening for presentation at term may be justified on the basis of current knowledge. 
Universal screening for fetal growth disorders cannot currently be justified.  
 
Future work  
We describe proof of principle randomised controlled trials which could better inform the case for 
screening using ultrasound in late pregnancy.  
 
Study registration: This study is registered as PROSPERO CRD42017064093 
Funding details: The National Institute for Health Research Health Technology Assessment 
programme 
Word count: 37,835 
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Scientific summary 
 
Background  
Currently, pregnant women are screening using two-dimensional ultrasound at booking and around 
the middle of pregnancy. Ultrasound scans thereafter are performed for clinical indications only. 
Ultrasound has a key role in the management of complicated pregnancies, being used in the 
assessment of presentation, fetal size, biophysical indicators of fetal well-being and assessment of 
blood flow using Doppler flow velocimetry. There is evidence that ultrasound might be effective in 
screening low risk and unselected women. Moreover, induction of labour at term is a reasonable 
candidate intervention for women who screen high risk. However, the diagnostic accuracy of many 
ultrasonic features is unknown in low risk populations. Moreover, there is little information on the 
cost-effectiveness of screening and intervention. Finally, it is uncertain whether further research on 
screening low risk women is feasible or cost-effective.  
 
Objectives  
The objectives of the present study, outlined in the original application, were as follows:  
1. To assess the diagnostic effectiveness of late pregnancy ultrasound in nulliparous women based on 
the existing research literature.  
2. Having identified the key ultrasonic findings which identified women as high risk to review the 
existing literature and current guidelines to identify a management plan for women with high risk 
characteristics.  
3. To conduct a health economic analysis of the likely cost-effectiveness of screening and intervention 
based on the best available evidence of the costs, diagnostic effectiveness of ultrasound and clinical 
effectiveness of intervention.  
4. To perform a value of information analysis to determine whether there is a strong economic case 
for funding future research in this area.  
5. Conditional on the above, to outline the design a randomised controlled trial which could 
strengthen the evidence base relating to the issues above.  
 
Methods  
We identified the following as key ultrasound measurements which might be used in late pregnancy 
screening: (i) suspected small for gestational age (SGA), (ii) suspected large for gestational age (LGA), 
(iii) high resistance pattern of umbilical artery Doppler flow velocimetry, (iv) low cerebro-placental 
ratio (CPR), (v) severe oligohydramnios, (vi) borderline oligohydramnios. We found that there was an 
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on-going Cochrane Diagnostic Test Accuracy review for SGA, hence we focused on the other five 
measures. The protocol for the reviews was designed a priori and registered with the PROSPERO 
register of systematic reviews (CRD42017064093). We searched Medline, EMBASE and the Cochrane 
library from inception. The studies were identified using a combination of keywords. Selection criteria 
included cohort or cross-sectional studies with singleton pregnancies which had an ultrasound 
peƌfoƌŵed шϮϰǁkGA. Case-control studies were excluded. We included all studies in which the 
ultrasound was performed as part of universal ultrasound screening (the ultrasound was offered to all 
women regardless of indication), studies that were done in low-risk populations (those that excluded 
pregnancies with any maternal or fetal complication) and studies with mixed risk population (the 
ultrasound was offered selectively based on current clinical indications). We excluded studies that 
were focused only on high risk populations. The literature search, study selection, and analysis ware 
performed independently by two researchers using Review Manager 5.3. Any differences were 
resolved in discussion with the senior author. The risk of bias in each included study was assessed 
using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS 2) tool as described in the 
Cochrane Handbook of Diagnostic Test Accuracy Studies. We used a pre-designed data extraction form 
to extract information on study characteristics (year of publication, country, setting, study design, 
blinding), patient characteristics (inclusion and exclusion criteria, sample size), the index test 
(gestation at scan, Doppler indices and cut-off values used), reference standard (pregnancy outcome, 
gestation at delivery, and interval from scan to delivery).   
 
From each study we extracted the 2 x 2 tables for all combinations of index tests and outcomes and 
we calculated the sensitivity, specificity, positive and negative likelihood ratios (LRs) respectively. For 
the data synthesis we used a hierarchal summary receiver operating characteristic curve model. 
Whenever four or more studies were available, estimates of mean sensitivity and specificity and 
respective variances at a specific threshold were additionally generated using the bivariate logit-
normal model. We also pooled the diagnostic odds ratios (DORs) using the method described by Deeks 
aŶd used the Deeks͛ fuŶŶel plot asǇŵŵetƌǇ test foƌ puďliĐatioŶ ďias iŶ ǁhiĐh P<Ϭ.Ϭϱ ǁas defiŶed as 
significant asymmetry. For the statistical analyses we used the METANDI, METAN and MIDAS packages 
from STATA version 14 (StataCorp LP, College Station, TX).  
 
We included studies regardless of blinding of the ultrasound to the clinicians but this was reported in 
the study characteristics. However, revealing the scan result has the potential for multiple biases. We 
had access to the original data from the Pregnancy Outcome Prediction study (Lancet 2015). This is 
the larger of only two studies that performed blinded ultrasonic assessment near term in nulliparous 
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women. The other study (Genesis, Perinatal Ireland) has not yet been widely reported. Given the 
importance of blinding we performed a number of new analyses of the POP study dataset.  
 
Health economic modelling employed a decision tree analysed via Monte Carlo simulation (repeated 
sampling from input parameter distributions) and coded in R (an open source statistical software 
package). Health outcomes were from the fetal perspective and presented as quality-adjusted life 
years (QALYs). Costs were from the perspective of the public sector, defined as NHS and cost of special 
educational needs. All costs and QALYs were discounted by 3.5% per annum and the reference case 
time horizon was 20 years. The health economic analysis evaluated three different strategies for 
ultrasound screening in late pregnancy, defined as a scan between 36+0 weeks and 36+6 weeks: (i) 
͚“eleĐtiǀe U“͛ ;i.e. ǁheƌe ultƌasouŶd is oŶlǇ peƌfoƌŵed folloǁiŶg ĐliŶiĐal iŶdiĐatioŶ of its ŶeedͿ, the 
current standard of care in England, (ii) ͚UŶiǀeƌsal U“ foƌ pƌeseŶtatioŶ oŶlǇ͛, i.e. sĐaŶ ǁith the sole 
puƌpose of deteĐtiŶg ďƌeeĐh pƌeseŶtatioŶ, aŶd ;iiiͿ ͚UŶiǀeƌsal U“ foƌ fetal size͛ i.e. a sĐaŶ peƌfoƌŵiŶg 
ultrasonic assessment of fetal weight plus assessment of presentation.  
 
We assumed that all identified cases of breech presentation would be offered an external cephalic 
version unless contraindicated, in line with RCOG guidelines. We further assumed that pregnancies 
identified as SGA (whether correctly diagnosed or not) would be given early induction of labour (IOL) 
at ϯϳ ǁeeks͛ gestatioŶ. Hoǁeǀeƌ, foƌ pƌegŶaŶĐies diagŶosed as LGA, theƌe is uŶĐeƌtaiŶtǇ as to ǁhetheƌ 
intervention (IOL) is beneficial. For this reason, expectant management of suspected LGA pregnancies 
was also an option. We assumed that selective scanning (i.e. only where clinically indicated) with a 
policy of offering ECV for suspicion of breech, and IOL for suspicion of SGA or LGA represents an 
approximation of the status quo from which estimates of incremental net benefit are calculated.  
 
Results  
We identified 13 studies of umbilical artery Doppler that met our inclusion criteria including 67,764 
patients in total. Umbilical artery Doppler had weak/moderate predictive accuracy for detecting SGA 
and severely SGA (<3rd percentile) infants (LR+ between 2.5 and 3.0). However, it did not predict 
neonatal morbidity at term. The results were very similar in both the POP study and the meta-analysis 
(which included the POP study) with the only notable difference being that the association with severe 
SGA in the POP study was slightly stronger. We identified 16 studies of CPR that met our inclusion 
criteria involving 121,607 patients in total. Meta-analysis demonstrated that the CPR may be slightly 
more predictive than UA Doppler in identifying pregnancies at an increased risk of adverse outcome. 
In the case of SGA, the positive LRs were in the region of 3.5 to 4.0. Moreover, unlike UA Doppler, a 
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low level of CPR was associated with an increased risk of neonatal morbidity. However, the association 
with morbidity was weaker with positive LRs of <2.0. Furthermore, in both analyses, there was very 
significant heterogeneity in relation to both SGA and neonatal morbidity. Consequently, the 95% 
confidence intervals for the positive LR are wide and include the point estimates observed for UA 
Doppler for both SGA and severe SGA. We identified 14 studies of severe oligohydramnios that met 
our inclusion criteria involving 109,679 patients in total. Diagnosis of severe oligohydramnios was 
associated with a positive LR for SGA of between 2.5 and 3.0. It was also associated with positive LRs 
for admission to NICU and emergency caesarean section for fetal distress of between 1.5 and 2.5. 
However, these associations are more difficult to interpret. First, for both of these outcomes, the 
association was weaker than it was for SGA. Second, in both cases the associations could be a 
consequence of the scan rather than an outcome predicted by the scan as only two studies containing 
<5% of the patients included in the meta-analysis blinded the results of the scan. We identified 11 
studies of borderline oligohydramnios (including the POP study) that met our inclusion criteria 
involving 37,848 patients in total. Borderline oligohydramnios was weakly/moderately predictive of 
SGA (positive LRs 2.5 to 3.0). This was observed in the meta-analysis of multiple studies of variable 
quality. There was also a comparable association between borderline oligohydramnios and severe SGA 
in the only study where the scan result was blinded, the POP study. We identified 40 studies of LGA 
that met our inclusion criteria involving 66,187 patients in total. Ultrasonic suspicion of fetal 
macrosomia was strongly predictive of the risk of delivering a large baby but was only weakly – albeit 
statistically significantly – predictive of the risk of shoulder dystocia. In the case of delivering an LGA 
baby using the Hadlock formula, the positive LRs were quite strong, in the region of 7 to 12, whereas 
in relation to the diagnosis of shoulder dystocia, the positive LR was ~2. The forest plot of DORs 
indicates that there was significant heterogeneity between the studies in the ability to predict an LGA 
infant.  
 
Based on current information, and assuming a willingness to pay of £20,000 per QALY, offering a 
universal ultrasound (US) presentation-only scan is on average the most cost-effective strategy. This 
is associated with an incremental net monetary benefit of £87.36 (95% CI: 4.88, 205.68) per pregnancy 
compared to current practice.  Scaled up to the English population, this equates to a net benefit of 
£17.1m or 857 QALYs per annual birth cohort. This is the present value of the future flows of expected 
costs and benefits over a time horizon of 20 years. Due to uncertainties in the evidence base 
(parameter uncertainty), there is a only a 44.19% probability that this conclusion is correct, i.e. there 
is a 55.81% probability that this conclusion is incorrect in which case a loss will be incurred.  The 
expected loss associated with this decision uncertainty is £31.56 per pregnancy. Equivalently, this is 
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the expected gain if uncertainty were to be eliminated (expected value of perfect information, EVPI). 
Scaled up to the population of England who could benefit from the information from any future 
studies, this equates to an EVPI of £53.3m.  If it is assumed the results of any future study are 
generalizable to all pregnancies in England, the EVPI is £172.9m.   
 
The parameter with the biggest impact on decision uncertainty was the cost of IOL (specifically, the 
difference in cost between an induced delivery and expectant management). It should be noted that 
this does not simply relate to the cost of a procedure to induce delivery; included within this definition 
is uncertainty as to the timing of IOL, and the impact on for example, antenatal appointments, as well 
as the Đost of the deliǀeƌǇ itself.  A studǇ of ͚ƌeasoŶaďle size͛ to ƌeduĐe uŶĐeƌtaiŶtǇ iŶ this paƌaŵeteƌ 
is likely to yield a positive return on investment. For example, the EVSI of a study of 1000 mothers in 
each arm is worth in excess of £11m. If this was to be delivered for a cost of £1m, it would yield a 
greater than 10-fold return on investment. Of note is that studies on the outcomes from SGA or 
macrosomic deliveries are unlikely to yield a positive return on investment. The results described 
above relate to a willingness to pay threshold of £20,000 per QALY. At a threshold of £30,600 per QALY 
;just aďoǀe the uppeƌ eŶd of NICE͛s stated aĐĐeptaďle range of £20,000 to £30,000, universal scanning 
becomes the most cost-effective option. Furthermore, our one-way sensitivity analyses suggest there 
is scope for universal scanning to be cost effective under other assumptions; for example, the most 
cost-effective option remains a breech-only scan only so long as the time horizon of the analysis is 
below 45 years.  
 
We then considered the potential for an RCT of screening and intervention using late pregnancy 
ultrasound in nulliparous women. For the outcomes of perinatal death or severe morbidity, all sample 
size calculations yielded numbers in excess of 50,000. Hence, trials using these outcomes are unlikely 
to be realistic. When studying a more general outcome of any perinatal morbidity (with or without 
maternal preeclampsia), trials which involved randomising women to being screened or not screened 
generated sample sizes in excess of 10,000 women. Trials screening all women and randomising high 
risk women to having intervention or the result being masked had sample sizes of <10,000 and this 
trial design was acceptable to the majority of women assessed by questionnaire and focus group. 
These trials would also provide data on both screening test performance and the intervention but 
would not capture the benefits of identifying breech presentation.   
 
Conclusions  
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Screening for presentation only is likely to be cost-effective. Scanning for fetal biometry and well-
being has limited value in predicting neonatal morbidity of low risk women directly but the evidence 
base is generally weak. Combining ultrasound and intervention appears to have some potential utility 
but sits at the borderline of acceptable cost effectiveness for the NHS. Better understanding of the 
cost of IOL compared with expectant management could help inform decision making around the use 
of ultrasound screening. There is currently no potential for a trial of screening versus no screening 
with the outcome of perinatal death. However, a range of other options assessing screening and 
intervention are feasible, each with their own strengths and weaknesses. 
 
Study registration: This study is registered as PROSPERO CRD42017064093 
Funding details: The National Institute for Health Research Health Technology Assessment 
programme 
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Plain English summary 
Ultrasound scans allow doctors to check on the health of the unborn baby. Usually all pregnant women 
are scanned at about three months and about five months. After that, women are only offered a scan 
if they have risk factors or a problem develops. Lots of things can go wrong later in pregnancy including 
pƌoďleŵs ǁith ďaďǇ͛s gƌoǁth oƌ ǁhiĐh paƌt of ďaďǇ is ĐoŵiŶg first. Some of these might have been 
prevented if a scan had been done, but scans can also get it wrong. When they do, a woman might 
receive unnecessary treatment, which might even harm her or her baby. 
 
In this study we set out to review previous research about how good ultrasound scanning is at 
detecting babies with a problem. We focused on detecting if the baby was too big or too small. 
Unfortunately, many of the studies had not been done to a high standard. Scanning can detect big and 
small babies pretty well, but it is much less clear whether they can predict complications which might 
harm the baby during birth. We also studied the costs and outcomes of scanning. We calculated the 
extra money that would be needed to scan every woman and compared this with the extra benefits 
from preventing complications. The one thing that came out well was using scan to check whether the 
baby is presenting head first or bottom first ;a ͚ďƌeeĐh pƌeseŶtatioŶ͛Ϳ. Babies presenting by their 
bottom have high risks of complications. Scanning all women to check whether their baby is breech 
seems effective and may even pay for itself, although it depends on how much the scan would cost. 
 
Whether it is worthwhile scanning all babies to see if they are too big or too small is less clear. The 
next step is probably a research study to get some more reliable numbers. We show how such a study 
should be designed, such that a single study could tell us both how well does scans predict bad 
outcomes, and does finding out this information actually help?
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Chapter 1. Background. 
 
Screening for pregnancy complications  
Complications of pregnancy are a major determinant of the Global Burden of Disease, through effects 
on both the mother and baby.1 Identifying and managing risk is a key element of antenatal care which 
aims to reduce the number and severity of adverse outcomes. Current clinical guidelines2 include 
multiple methods of identifying high risk women including: (i) identification of maternal risk factors 
associated with disease (e.g. obesity, age >40 years), (ii) assessment of complications in previous 
pregnancies, (iii) identification of pre-existing medical conditions (e.g. diabetes mellitus), (iv) clinical 
presentation with symptoms which are associated with an increased risk of adverse outcome (e.g. 
antepartum haemorrhage, reduced fetal movements). Additionally, there are multiple tests which are 
applied to pƌegŶaŶt ǁoŵeŶ to assess ƌisk. TakiŶg the eǆaŵple of sĐƌeeŶiŶg foƌ DoǁŶ͛s sǇŶdƌoŵe, 
ǁoŵeŶ͛s ƌisk is fiƌst assessed ďǇ ŵateƌŶal age, this ďaĐkgƌouŶd ƌisk is theŶ adjusted foƌ the ƌesults of 
ultrasonic imaging (nuchal translucency) and biomarkers (pregnancy associated plasma protein A and 
free beta sub-unit of human chorionic gonadotrophin) and the summative risk is used to inform the 
use of invasive testing (https://www.gov.uk/topic/population-screening-programmes/fetal-
anomaly).  
 
Use of ultrasound in pregnancy screening 
The fiƌst tƌiŵesteƌ ultƌasouŶd sĐaŶ eŵploǇed iŶ DoǁŶ͛s sǇŶdƌoŵe screening is an example where all 
pregnant women are offered a scan as part of their assessment of risk. Routine pregnancy care in the 
UK also iŶǀolǀes a seĐoŶd sĐƌeeŶiŶg ultƌasouŶd sĐaŶ, peƌfoƌŵed шϭϴ ǁeeks of gestatioŶal age ;wkGA) 
and <21wkGA, where the primary purpose of the scan is to identify fetuses with structural 
abnormalities (https://www.gov.uk/topic/population-screening-programmes/fetal-anomaly). A 
positive result from this scan might inform decisions around termination of pregnancy (e.g. many 
women would choose to terminate a pregnancy where the fetus had a severe neural tube defect) or 
it might inform the need for targeted follow up and changes to the perinatal care of the infant. For 
example, identification of a congenital diaphragmatic hernia could lead to invasive testing for 
aneuploidy, prenatal discussions with the paediatric surgery team and modification to neonatal 
resuscitation (such as early intubation to avoid expansion of the stomach with air).  
  
In the UK and USA, universal ultrasound is not recommended after the mid-pregnancy anomaly scan.2, 
3 Rather, it is recommended that ultrasound is offered in a targeted manner and only offered to 
women where there is a clinical indication. Such indications could include presentation with symptoms 
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(e.g. antepartum haemorrhage), relevant medical history (e.g. anti-phospholipid antibody syndrome), 
relevant past medical history (e.g. previous fetal growth restriction [FGR]), or through the results of 
physical examination (e.g. the uterus is SGA) on clinical examination. 
 
Use of ultrasound in late pregnancy 
When scans are performed in late pregnancy, a number of features are commonly reported. 
Ultrasound allows the estimation of the size (length and circumference) of fetal parts, termed fetal 
biometry. A variety of methods exist for converting these measurements to an estimated fetal weight 
(EFW)4 and a number of reference ranges exist for EFW in relation to the exact gestational age.5, 6 The 
interpretation of EFW and the individual biometric measurements generally focuses on two 
properties: (i) the position of the value on the distribution for the given gestational age, and (ii) the 
change in the value over serial measurements. Taking the first of these, babies in the smallest 10% of 
measurements for gestational age are referred to as SGA and babies in the largest 10% are referred 
to as large for gestational age (LGA). The second property examines the growth velocity across the 
pregnancy. For example, if a fetus is on the 9th percentile at 36wkGA and it had also been on the 9th 
percentile at 20wkGA, it would be regarded as SGA but with normal fetal growth velocity. SGA infants 
with normal growth velocity are often constitutionally small. SGA combined with evidence of reduced 
fetal growth velocity is regarded as indicating FGR.7 
  
Another major category of measurement in ultrasound in late pregnancy is Doppler flow velocimetry 
;ƌefeƌƌed to as ͞Doppleƌ͟, see HoffŵaŶ aŶd GalaŶ foƌ ƌeǀieǁ.8 In brief, a blood vessel is imaged and 
electronic callipers on the screen are placed over the vessel. The machine then plots out the velocity 
of flow on the Y axis, with time on the X axis. The resultant plot is termed a flow velocity waveform. 
Different blood vessels have different patterns of flow velocity waveform and the pattern is analysed 
both qualitatively and quantitatively. One of the key blood vessels for study is the umbilical artery. 
Flow is characterised qualitatively by the direction of flow in end diastole (i.e. immediately prior to 
the rise in flow that occurs with a heartbeat – systole). The normal state is forward flow, but there can 
be absent flow or even reversed flow. The waveform can also be analysed mathematically, and a 
number of indices have been described, such as the pulsatility index (PI) and resistance index (RI). The 
derivation, calculation and detailed interpretation of these indices is described in detail elsewhere.8 
However, both values correlate positively with the presumed resistance to flow in the vascular bed 
supplied by the artery. Hence, high values of PI and RI in the umbilical arteries are interpreted as 
indicating a high resistance to flow in the fetal vascular tree of the placenta. Correlative studies of 
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umbilical artery Doppler and placental microscopy support this interpretation in cases of FGR 
oĐĐuƌƌiŶg ďefoƌe ϯϲ ǁeeks͛ gestatioŶ.9   
  
The four most common sites for Doppler are the umbilical arteries, the maternal uterine arteries, the 
umbilical arteries, the fetal middle cerebral arteries (MCA), and the ductus venosus.8 In contrast to 
the other three, it is low resistance in the fetal MCA which is thought to indicate compromise. The 
interpretation is that a reduced level of oxygen in the fetal blood leads to cerebral vasodilation, hence, 
reduced measures of resistance in the arteries supplying the brain.  
  
Other features which are examined in late pregnancy include the placenta, the amniotic fluid and fetal 
presentation. Reporting of the placenta generally focuses on its site in relation to the cervix. 
Implantation of the placenta over the cervix is called placenta praevia and it can cause massive 
haeŵoƌƌhage duƌiŶg laďouƌ. ‘eduĐed aŵŶiotiĐ fluid is Đalled ͞oligohǇdƌaŵŶios͟ aŶd iŶĐƌeased 
aŵŶiotiĐ fluid is Đalled ͞polǇhǇdƌaŵŶios͟. AŵŶiotiĐ fluid ǀoluŵe is ƋuaŶtitatiǀelǇ assessed usiŶg 
measurement of the biggest single pool (DVP = deepest vertical pool), or by the sum of the four 
deepest pools in each of four quadrants of the uterus (AFI = amniotic fluid index). Finally, one of the 
simplest findings on scan is the presentation of the fetus. Near term, >95% of fetuses present by the 
head. Women are examined close to term to assess presentation but this approach frequently misses 
babies presenting by the breech.10 Ultrasound unambiguously establishes the presentation at the time 
of a scan. 
 
Coupling interventions to scan results 
There are a limited number of disease modifying interventions which can be coupled to ultrasound 
performed in late pregnancy to alter the outcome of pregnancy. Most of the interventions relate to 
modifications to either the timing of delivery (e.g. IOL) or the mode of delivery (e.g. delivery by pre-
labour caesarean section). One exception to this is breech presentation. It has been known for many 
years that vaginal breech delivery, although safe for the majority of women, could be associated with 
complications which could have severe consequences for the infant. Breech delivery has a number of 
specific complications associated with it, such as increased risks of umbilical cord compression and 
entrapment of the fetal head after delivery of the fetal body. It was demonstrated that vaginal breech 
birth in the UK was associated with an absolute risk of death during labour or in the first four weeks 
of life 8.3 per 1,000. Although the absolute risk was low it was much higher than the risk associated 
with a planned caesarean delivery of 0.3 per 1,000.11 The awareness of the risks associated with 
vaginal breech birth (which long predated the epidemiological study confirming the higher risk of 
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death) were the basis for offering to turn the baby from a breech to a cephalic presentation using 
manual manipulation of the fetus ďǇ a ĐliŶiĐiaŶ, Đalled ͞eǆteƌŶal ĐephaliĐ ǀeƌsioŶ͟ ;ECVͿ. Wheƌe this 
procedure is unsuccessful, generally, delivery by planned caesarean section is recommended.12 This is 
based both on the observational data of increased risks associated with vaginal breech birth and on 
the results of randomised controlled trials of planned caesarean section which have confirmed 
reduced risks of perinatal death with this procedure, compared with planned vaginal breech birth.13 
  
For most of the other diagnoses which might be made by ultrasound, the primary disease modifying 
intervention in the second half of pregnancy is to deliver the baby, either by IOL or planned caesarean. 
However, screening may also be used to inform the assessment of fetal well-being to help inform the 
timing of this intervention. For example, if a baby is found to be SGA and FGR is suspected, there are 
multiple ways that the well-being of the baby might be assessed. However, these simply reflect 
another layer of diagnostic and prognostic tests. Ultimately, they are used to target the timing of the 
disease modifying intervention of delivery. The primary reason for expediting delivery is that IOL 
removes the subsequent risk of stillbirth (intra-uterine fetal death followed by delivery of a baby 
showing no signs of life). Most causes of stillbirth are due to complications which can only occur to 
the fetus in utero (e.g. placental abruption or placental failure), hence, delivery of the fetus removes 
the risk of stillbirth.14 This is confirmed by randomised controlled trials which demonstrate that IOL at 
term is associated with a 67% reduction in the risk of stillbirth.15  
  
While early delivery can safely be performed at term, this is not the case preterm. The Cochrane 
review above described exactly the same reduction in the risk of perinatal death with IOL at term as 
was observed for stillbirth. Perinatal deaths include both stillbirths and neonatal deaths, hence the 
favourable effect of IOL on stillbirth was not cancelled out by an unfavourable effect on the risk of 
neonatal death. However, preterm birth is one of the major determinants of neonatal death, hence, 
if women are routinely induced preterm, the advantage of reduced risks of stillbirth will be 
outweighed by the increased risks of intrapartum stillbirth and neonatal death associated with 
prematurity. The inflection point, i.e. where the risks balance out, has previously been estimated as 
between 38wkGA and 39wkGA.16 Hence, although 37wkGA is strictly term, routinely delivering all 
women at 37 weeks could increase overall perinatal mortality through higher rates of intrapartum 
stillbirth and neonatal death.17 It follows, therefore, that screening using a test with a high false 
positive rate has the potential to cause net harm through increasing iatrogenic prematurity (or early 
term delivery) in false positives.18   
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Evidence for screening using universal late pregnancy ultrasound 
There is strong evidence to support the use of ultrasound in high risk pregnancies. A systematic review 
of umbilical artery Doppler has shown that it reduces perinatal mortality by about 30% in high risk 
pregnancies.19 The mechanism of the effect is likely explained by the fact that its use was also 
associated with lower rates of IOL and caesarean delivery. Hence, it is likely that the use of Doppler 
reduced the risk of perinatal death overall by reducing unnecessary intervention. However, there was 
also a strong trend to a reduced risk of stillbirth, indicating that Doppler may also have been useful in 
targeting intervention to the highest risk cases.   
  
The fundamental role of ultrasound in the care of high risk women led researchers to explore whether 
routinely using the same approaches might improve outcomes in low risk women. Disappointingly, a 
meta-analysis of 13 RCTs including ~35,000 women did not demonstrate any evidence that routine 
ultrasound improved outcome.20 It is this finding which has led to the recommendation that 
ultrasound should not routinely be performed in the second half of pregnancy in the UK and USA. The 
cautious approach is supported by some evidence arising from countries where universal late 
pregnancy ultrasound was introduced, despite the lack of strong evidence supporting its clinical 
effectiveness. A seminal study from France reported rates of adverse perinatal outcome in relation to 
ǁoŵaŶ͛s sĐƌeeŶiŶg status foƌ “GA.21 EaĐh ǁoŵaŶ͛s sĐƌeeŶiŶg status ǁas ideŶtified ;sĐƌeeŶ positiǀe 
for SGA or screened normal [AGA = appropriate for gestational age]) and the actual status of the baby 
at birth was also assessed (SGA or AGA by actual birth weight). The authors subsequently described 
rates of perinatal morbidity and mortality by true positive and false positive status. As one might have 
predicted, false positives had higher rates of multiple adverse outcomes compared to AGA babies 
which were true negatives, and this was explained primarily by higher rates of iatrogenic prematurity 
in the false positives. Interestingly, the true positive SGA babies also had higher rates of adverse 
outcome compared with SGA babies which were missed by scan (false negatives). The former 
observation confirms the potential for iatrogenic harm to false positives. The latter observation 
questions the rationale for screening for SGA in late pregnancy at all. 
 
Critical analysis of the Cochrane review 
While it is generally accepted that a systematic review of RCTs represents the highest level of 
evidence, there are a number of features of the systematic review of RCTs of universal ultrasound20 
that undermine its main conclusions.   
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• The 13 studies included in the meta-analysis all used different definitions of screen positive. 
Moreover, some of the ultrasonic findings were completely divergent. For example, while 
multiple studies analysed some variant of an estimation of fetal size, one large study assessed 
placental calcification without any assessment of any other features of the scan. An implicit 
assumption around combining these studies is that these different ultrasonic tests were all 
comparable effectiveness, which a subsequent systematic review of diagnostic test accuracy 
studies has demonstrated is not the case.22     • None of the studies were preceded by a high quality assessment of the diagnostic 
effectiveness of the test in a low risk population. This is problematic for a number of reasons. 
A key element of study design is a power calculation. It is impossible to perform a power 
calculation without quantitative information on the diagnostic effectiveness of the test. 
Moreover, the tests had generally been developed for and evaluated in high risk populations. 
It is well recognised in screening that test performance differs according to the risk status of 
the population. One of the key properties of a screening test is the positive predictive value 
(PPV), i.e. the proportion of women who screen positive who experience the outcome. The 
positive predictive value of a test is determined by the prior risk of disease multiplied by the 
positive likelihood ratio (LR+ = the proportional increase in the odds among screen positive 
women compared with the whole population). Hence, the higher the prior risk of disease, the 
higher the PPV for a given LR+. Consequently, it is typical that a positive screening test is 
associated with a much lower PPV in low risk population. As the PPV determines the ratio of 
true positives to false positives, this will have a major impact on trials of screening.   • None of the 13 RCTs coupled the screening test to an intervention. In all 13 studies the result 
was revealed to the attending clinicians but there was no specific intervention that was 
planned. It is self-evident that a screening test could only impact on outcome if it is coupled 
to an intervention. Moreover, the tests were performed at a wide range of gestational ages. 
Given that the primary intervention available to the attending clinicians would have been 
delivery of the baby, the potential for this resulting in benefit or harm would vary according 
to the gestational age where the scan was performed. Hence, a positive effect of late 
pregnancy ultrasound and delivery could have been masked by a negative effect of preterm 
pregnancy ultrasound scan with higher rates of iatrogenic harm.  • Although the meta-analysis included 35,000 women, it was still underpowered for the key 
outcome of interest, perinatal death. The risk ratio for perinatal death from the meta-analysis 
was 1.01 with 95% confidence interval (CI) of 0.67 to 1.54. While these CI might seem quite 
narrow, the capacity for reducing the rate of an outcome with a screening trial is different 
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from interventional trials in women with established disease. If we identified a screening test 
for perinatal death with a positive likelihood ratio of 10 with a 5% screen positive rate and if 
we applied an intervention which reduced the risk by 50%, the estimated relative risk would 
be 0.76, which is within the 95% CI of the systematic review. Hence, the Cochrane review is 
underpowered to detect the effect of a highly effective screening test coupled with a highly 
effective intervention. If we use the 5.8 per 1000 perinatal mortality rate in the control group 
of the Cochrane review, a power calculation indicates that a sample size of 110,000 women 
would be required to detect this effect with 90% power. 
 
Parity and the risk of adverse outcome 
One of the most important determinants of adverse pregnancy outcome is past obstetric history, i.e. 
the outcome of previous pregnancies. Many conditions of pregnancy have quite high risks of 
recurrence in subsequent pregnancies, such as preeclampsia,23 preterm birth24 stillbirth25 and FGR26. 
Hence, women experiencing complications in previous pregnancies generally receive enhanced 
antenatal care. Conversely, the experience of uncomplicated previous pregnancies is strongly 
predictive of a normal outcome in future pregnancies. Hence, women who have had a previous vaginal 
delivery of a normally grown live born infant at term following an uncomplicated pregnancy have low 
absolute risks of complications in future pregnancies.27 Past obstetric history is, necessarily, not 
available for women who have not had prior births. Although maternal characteristics, as described 
above, are associated with the risk of pregnancy complications, the associations are generally rather 
weak and perform poorly as a screening test in isolation.28 Moreover, first pregnancies, collectively, 
have high rates of complications than second pregnancies. These qualities have led to the 
identification of first pregnancies are a priority area for research. Quoting an NIH study description of 
nulliparous women:  
͞This large proportion of women lacks previous pregnancy information to guide risk assessment; as 
such, adverse outcomes in these first pregnancies are particularly difficult to predict and prevent.͟29 
 
Summary of the rationale for the focus on nulliparous women in late pregnancy 
The characteristics above provide the rationale for the focus of this review. Screening and intervention 
near term has less of a potential to cause harm than screening and intervention in the preterm period, 
as the primary intervention – delivery of the baby – is less likely to lead to iatrogenic injury. The need 
for screening is greatest in the nulliparous population because they have higher background risks of 
adverse outcome and they lack one of the key discriminating characteristics in risk assessment, 
namely, knowledge of the outcome of prior births. 
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The health economics of screening and intervention 
A critical consideration in relation to screening and intervention using universal ultrasound is whether 
it is cost effective. It is possible that, for the individual woman and baby, having a screening ultrasound 
scan and associated intervention leads to a better outcome but that the impact of the cost of providing 
the screening test and intervention results in net societal harm as it removes resources from other 
more cost effective elements of the health care system. The capacity of all health care systems is finite, 
however, systems differ in their willingness to pay. These questions are addressed quantitatively in 
health economic analysis by calculating the sum of money required to gain one additional quality 
adjusted life year (QALY), a subject which is discussed in detail elsewhere.30 In the English NHS, 
interventions are considered cost effective if the cost of each QALY is below a given threshold and this 
is typically between £20,000 and £30,000. 
 
Providing a late pregnancy ultrasound scan will clearly incur direct costs. Managing women who 
screen high risk will clearly incur further costs. However, these additional costs then have to be set 
against the reduction in harm, i.e. the QALYs gained by the mother or child because of being screened. 
Many of the individual elements required for these calculations are associated with uncertainty. 
Hence, these health economic analyses frequently employ a probabilistic approach running large 
numbers of simulations where the different parameters for the models are sampled from the 
presumed plausible range of values from the literature. These methods and their interpretation are 
discussed in more detail in the relevant chapters. 
 
Value of information (VoI) analysis 
The health economic analyses described above relate to the economic case for implementing a given 
programme of screening and information. VoI analysis addresses the economic case for funding 
research to try and reduce the uncertainty in the evidence base. Generally speaking, a research 
question which will be identified as being cost effective from this perspective will have input values 
which are uncertain, i.e. the confidence intervals for the given parameter in the literature are wide. 
Moreover, questions which are identified as being cost effective in a VoI will often generate highly 
variable results in sensitivity analyses where the input value of the parameter is varied within the 
range of uncertainty. This subject is again dealt with in detail in the relevant chapter. 
 
Designing a randomised controlled trial 
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Randomised controlled trials (RCTs) of screening have certain differences compared with RCTs of other 
interventions. Typically, interventions are evaluated in populations with a disease. Hence, the 
individuals recruited will have high rates of complications as they are experiencing a disease process. 
Moreover, most of the outcomes in the group are likely to be related to the disease process. In 
contrast, screening, by design, focuses on individuals before they manifest disease. Hence, the 
background rate of serious adverse outcomes is likely to be low. Moreover, the experience of adverse 
outcomes within the population is likely to be due to diverse causes, not simply the disease being 
screened for. For example, a randomised controlled trial studying mortality in people with cancer is 
likely to have high rates of death in the different arms of the trial and most of the deaths in both arms 
are likely to be related to the cancer. In contrast, a randomised controlled trial of screening or not 
screening a healthy population for the same cancer is likely to have low rates of deaths in both arms 
and many of the deaths in both arms would be unrelated to the experience of cancer. Both of these 
properties will tend to increase the sample size in the screening study as there is a low incidence of 
adverse outcomes and only a subset of the adverse outcomes will be preventable by the given 
programme of screening and intervention.  
 
We have previously reviewed the approach to screening in pregnancy31 and highlighted an alternative, 
namely, that all women in a population are screened and that randomisation is to either revealing the 
result plus intervention or masking the result with routine care. Using this design, randomisation is 
being performed in a group which has a higher rate of complications (by virtue of the positive 
screening test) and a greater proportion of the adverse events will be related to disease process being 
screened for. This approach has the advantages that the overall number needed to screen for 
statistical power is substantially reduced and that the screening test can be validated in the same 
study design through comparing screen negatives with screen positives randomised to have the result 
masked. These issues are discussed further in Chapter 13 below. 
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Chapter 2. Objectives. 
 
The objectives of the present study, outlined in the original application, were as follows:  
1. To assess the diagnostic effectiveness of late pregnancy ultrasound in nulliparous women based on 
the existing research literature.  
2. Having identified the key ultrasonic findings which identified women as high risk to review the 
existing literature and current guidelines to identify a management plan for women with high risk 
characteristics.  
3. To conduct a health economic analysis of the likely cost-effectiveness of screening and intervention 
based on the best available evidence of the costs, diagnostic effectiveness of ultrasound and clinical 
effectiveness of intervention.  
4. To perform a value of information analysis to determine whether there is a strong economic case 
for funding future research in this area.  
5. Conditional on the above, to outline the design a randomised controlled trial which could 
strengthen the evidence base relating to the issues above.  
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Chapter 3. Identifying the research questions  
 
We performed a survey of members of a number of professional organisations with the aim of 
identifying the ultrasonic features which were thought most likely to be informative in a future 
randomised controlled trial. We also surveyed which outcomes should be prioritised. A web-based 
questionnaire was designed using the SurveyMonkey platform and was approved by the Ethics 
Committee of the School of Humanities and Social Sciences at the University of Cambridge. The survey 
was sent to members of the Royal College of Obstetricians and Gynaecologists, the British Maternal 
Fetal Medicine Society and the British Association for Perinatal Medicine in May-June 2017. It was also 
distributed locally at the Rosie Hospital in Cambridge.   
 
The survey was completed by 54 respondents including 20 Consultant Obstetricians, 8 Obstetricians 
in training, 18 Midwives, 5 Sonographers and 3 Consultant Neonatologists. All the replies were 
anonymous.   
 
The first question was about identifying the most important ultrasonic findings for universal screening 
in late pregnancy. The most important ultrasonic findings (ranked in order of frequency of response) 
were abnormal fetal biometry or growth velocity (83%), malpresentation (63%), abnormal amniotic 
fluid volume (63%), high resistance pattern of umbilical artery Doppler flow velocimetry (32%), and 
abnormal cerebro-placental ratio or middle cerebral artery doppler (22%).   
 
The second question was about identifying the most important adverse pregnancy outcomes (apart 
from perinatal death). The most important outcomes (ranked by frequency of response) were hypoxic 
ischaemic encephalopathy (69%), fetal asphyxia (low umbilical cord blood pH plus a base deficit 
consistent with metabolic acidosis; 64%), SGA or severe SGA 51%, severe shoulder dystocia (46%), 
breech presentation diagnosed in labour (41%), admission to neonatal intensive care unit (28%), and 
low 5-minute Apgar score (21%).   
 
Having completed the survey, we then searched relevant databases (Medline, Embase and Cochrane) 
to identify any other systematic reviews of Diagnostic Test Accuracy (DTA) which might overlap with 
our aims. This yielded a protocol for a Cochrane DTA review of ultrasonic diagnosis of SGA (which was 
subsequently published in 2019).22 Hence, we did not include this in our own plans. We also identified 
a previously published systematic review of DTA on severe oligohydramnios which was published in 
2014 and included publications up to 2011. We selected the studies in this review which were 
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performed in low and mixed risk pregnancies and then we performed a literature search for eligible 
studies that have been published subsequent to the search date the 2014 paper. We then performed 
a meta-analysis of all the relevant studies.   
 
Based on the priorities gleaned from the review and the concurrent Cochrane DTA review, and on 
what we believed was feasible in the time scale, we identified the following ultrasonic markers as the 
priority subjects for systematic review of DTA: 
1. High resistance pattern of umbilical artery Doppler flow velocimetry  
2. Low cerebro-placental ratio (CPR)  
3. Severe oligohydramnios  
4. Borderline oligohydramnios  
5. Suspected fetal macrosomia  
 
All five of these were written up as a single study protocol and the analyses were registered on the  
PROSPERO International prospective register of systematic reviews (CRD42017064093).   
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Chapter 4. Systematic review of the diagnostic effectiveness of universal ultrasonic screening using 
late pregnancy umbilical artery Doppler flow velocimetry in the prediction of adverse perinatal 
outcome. 
 
High resistance patterns of umbilical artery (UA) Doppler flow velocimetry are thought to reflect 
placental vascular resistance. This method is currently in widespread clinical use to monitor high risk 
pregnancies, including those with suspected FGR. A Cochrane review of randomised controlled trials 
(RCTs) has demonstrated that use of UA Doppler ultrasound in high-risk pregnancies appears to reduce 
the number of perinatal deaths and the number of obstetric interventions (risk ratio 0.71, 95% 
confidence interval 0.52 to 0.98).19 However, a Cochrane review of RCTs in low risk pregnancies failed 
to demonstrate any difference in outcome comparing pregnancies screened using UA Doppler 
compared with controls (risk ratio 0.80, 95% confidence interval 0.35 to 1.83).32 This review included 
five studies that compared routine Doppler versus no Doppler but there was no consistent 
management plan for the women with abnormal results. Moreover, although it included 14,185 
women it was underpowered to detect an effect on perinatal death using clinically plausible estimates 
of screening performance and the clinical effectiveness of intervention.31 The authors concluded that 
there is no adequate evidence that the routine use of UA Doppler ultrasound benefits either the 
mother or the baby and they recommended future studies that should be designed to detect smaller 
changes in adverse perinatal outcome. The aim of this chapter was to provide Level 1 evidence on the 
diagnostic accuracy of third trimester UA Doppler to predict adverse pregnancy outcome at term. We 
conducted a systematic review and meta-analysis of all studies focusing in low and mixed risk 
populations. In the above analysis we also included unpublished data from a prospective cohort study 
of nulliparous women, the Pregnancy Outcome Prediction (POP) study.7   
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Methods  
 
Analysis of data from the Pregnancy Outcome Prediction study 
In the systematic review we included unpublished data from a prospective cohort study, the 
Pregnancy Outcome Prediction (POP) study, which was conducted at the Rosie Hospital, Cambridge 
(UK) between 2008 and 2012 and previously described in detail.33 In brief, the study included 
nulliparous women only, and all women who agreed to participate had two research ultrasound scans 
at 28wkGA and 36wkGA which were blinded to the women and the clinicians. About 40% of the 
women had clinically indicated ultrasound scans in the third trimester based on local and national 
guidelines. In the present analysis we included women that attended their 36wkGA research scan and 
had a live birth at the Rosie Hospital. Women who delivered prior to their 36wkGA scan appointment 
were excluded. Screen positive was defined as an umbilical artery pulsatility index (PI) >90th 
percentile. A full description of the conduct of the study, including definition of outcome data, was 
described in a paper in the Lancet,7 which presented the results on the diagnostic effectiveness of 
ultrasound as a screening test for SGA. 
 
Sources for meta-analysis 
The protocol for the review was designed a priori and registered with the PROSPERO International 
Prospective Register of Systematic Reviews (Registration number: CRD42017064093). We searched 
Medline, EMBASE and the Cochrane library from inception to March 2019. The studies were identified 
usiŶg a ĐoŵďiŶatioŶ of ǁoƌds ƌelated to ͞ultƌasouŶd͟, ͞Doppleƌ͟, ͞uŵďiliĐal aƌteƌǇ͟, ͞pƌegŶaŶĐǇ͟ aŶd 
͞pƌeŶatal diagŶosis͟ (see Appendix 1). No restrictions for language or geographic location were 
applied.   
 
Study selection 
Selection criteria included cohort or cross-sectional studies with singleton pregnancies which had an 
ultƌasouŶd peƌfoƌŵed шϮϰǁkGA. Case-control studies were excluded as these overestimate the effect 
size. We included all studies in which the ultrasound was performed as part of universal ultrasound 
screening (the ultrasound was offered to all women regardless of indication), studies that were done 
in low-risk populations (those that excluded pregnancies with any maternal or fetal complication) and 
studies with mixed risk population (the ultrasound was offered selectively based on current clinical 
indications). We excluded studies that were focused only on high risk populations such as pregnancies 
with FGR. We included all reported indices of umbilical artery Doppler such as the Pulsatility Index 
(PI), Resistance Index (RI) or the systolic to diastolic ratio (S/D ratio), as well as all reported cut-off 
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values. Finally, we included studies regardless of blinding of the ultrasound to the clinicians but this 
was reported in the study characteristics. 
 
Study quality assessment and data extraction 
The literature search, study selection, and analysis ware performed independently by two authors 
(AM and TB) using Review Manager 5.3. Any differences were resolved in discussion with the senior 
author (GS). The risk of bias in each included study was assessed using the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS 2) tool as described in the Cochrane Handbook of Diagnostic 
Test Accuracy Studies.34 We used a pre-designed data extraction form to extract information on study 
characteristics (year of publication, country, setting, study design, blinding), patient characteristics 
(inclusion and exclusion criteria, sample size), the index test (gestation at scan, Doppler indices and 
cut-off values used), reference standard (pregnancy outcome, gestation at delivery, and interval from 
scan to delivery). 
 
Statistical and meta-analysis methods 
From each study we extracted the 2 x 2 tables for all combinations of index tests and outcomes and 
we calculated the sensitivity, specificity, positive and negative likelihood ratios (LRs) respectively. For 
the data synthesis we used the hierarchal summary receiver operating characteristic curve (HSROC) 
model of Rutter and Gatsonis.35 Whenever four or more studies were available, estimates of mean 
sensitivity and specificity and respective variances at a specific threshold were additionally generated 
using the bivariate logit-normal model.36 We also pooled the DORs using the method described by 
Deeks.37 For the assessment of puďliĐatioŶ ďias ǁe used the Deeks͛ fuŶŶel plot asǇŵŵetƌǇ test iŶ 
which P<0.05 was defined as significant asymmetry.38 As this method requires a large number of 
studies, we used the most commonly reported outcome for the analysis. For the statistical analyses 
we used the METANDI, METAN and MIDAS packages from STATA version 14 (StataCorp LP, College 
Station, TX). 
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Results  
 
The POP study 
Initially we analysed the previously unpublished data from the POP study. The analysis included 3615 
women that met the inclusion criteria (Appendix 1, Figure 25). All women had a blinded UA ultrasound 
at 36wkGA and 346 (9.6%) had an UA PI >90th percentile (Appendix 1, Figure 25). The maternal age, 
socio-economic status, ethnicity, BMI, and rates of alcohol consumption and smoking were similar 
between the two groups (Appendix 1, Table 18). Moreover, the groups had similar rates of pre-existing 
hypertension, pre-eclampsia, type 1 and 2 diabetes, and gestational diabetes. The gestational age at 
delivery and rate of IOL were similar in both groups which can be attributed to the blinding of the 
ultrasound. The screening performance of UA PI >90th centile is presented in Table 1. A high resistance 
pattern of UA Doppler was associated with an increased risk of delivering an SGA infant or a severely 
SGA infant and the association was stronger for the latter outcome. However, the finding was not 
strongly predictive with positive LRs between 2.5 and 3.5. A high resistance pattern of UA Doppler was 
not associated with an increased risk of a range of indicators of neonatal morbidity in the POP study. 
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Table 1. Diagnostic performance of UA PI >90th centile at predicting adverse pregnancy outcome in the POP study (N=3615). 
 
* See Sovio et al. 2015 for definitions 
 
Outcome  True Positive /  
False Positive 
 
True Negative /  
False Negative  
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
SGA <10th centile 72/274 3016/253 22.2%  
(17.6-26.7%) 
91.7% 
(90.7-92.6%) 
2.66 
(2.11-3.36) 
0.85 
(0.80-0.90) 
SGA <3rd centile 23/323 3215/54 29.9% 
(19.6-40.1%) 
90.9% 
(89.9-91.8%) 
3.27 
(2.29-4.68) 
0.77 
(0.67-0.89) 
Any neonatal morbidity* 32/314 3045/224 12.5% 
(8.4-16.6%) 
90.7% 
(89.7-91.6%) 
1.34 
(0.95-1.88) 
0.97 
(0.95-1.01) 
NICU admission 27/319 3076/193 12.3% 
(7.9-16.6%) 
90.6% 
(89.6-91.6%) 
1.31 
(0.90-1.89) 
0.97 
(0.92-1.02) 
5-min Apgar score <7  4/342 3243/26 13.3% 
(1.2-25.5%) 
90.5% 
(89.5-91.4%) 
1.40 
(0.56-3.50) 
0.96 
(0.83-1.10) 
Metabolic acidosis 4/342 3237/32 11.1% 
(0.8-21.4%) 
90.4% 
(89.5-91.4%) 
1.16 
(0.46-2.95) 
0.98 
(0.88-1.10) 
Severe neonatal morbidity* 3/343 3246/23 11.5% 
(0.7-23.8%) 
90.4% 
(89.5-91.4%) 
1.21 
(0.41-3.52) 
0.98 
(0.85-1.12) 
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Meta-analysis 
 
The literature search PRISMA flowchart is presented in Appendix 1, Figure 26. We identified 13 
studies39-50 that met our inclusion criteria including 67,764 patients in total (these analyses included 
the previously unpublished POP study results). The study characteristics are presented in Appendix 1, 
Table 19. Five studies39, 45, 48, 49 (N=63,436) included unselected pregnancies as part of universal 
screening, four studies40, 43, 44, 50 (N=2634) included only low-risk pregnancies and four studies 41, 42, 46, 
47(N=1694) included mixed risk pregnancies. Three of the studies39, 48, 49 that were done in the same 
hospitals might have had short periods of overlap. Nine studies 40, 41, 43-47, 50(N=8097) were prospective 
and four39, 42, 48, 49 (N=59,687) retrospective. Studies varied in relation to the gestational age at scan 
(ranging from 28wkGA to 41wkGA), as well as the indices and the cut-off points used. The majority of 
patients in the included studies delivered at term. The assessment of study quality is presented in 
Appendix 1, Figure 27. Overall the quality was variable. The main risk of bias was that only six studies40, 
41, 43, 45, 47 (N= 5777) blinded clinicians to the UA Doppler result. However, five of these six studies 
revealed other features of the scan result, such as fetal biometry. Only the POP study blinded both 
the utero-placental Doppler and fetal biometry.   
 
The summary results of the meta-analysis are presented in Table 2. The pattern of results was very 
similar to the POP study. A high resistance pattern of UA Doppler was associated with an increased 
risk of delivering an SGA infant or a severely SGA infant. However, the finding was not strongly 
predictive with positive LRs between 2.5 and 3.0. A high resistance pattern of UA Doppler was not 
associated with an increased risk of a range of indicators of neonatal morbidity. The summary ROC 
curves are presented in Figure 1. For some outcomes such as 5-minute Apgar score <7, caesarean 
section for fetal distress and pre-eclampsia (PET) the Rutter-Gatsonis model could not produce 
summary results despite an adequate number of studies. We additionally performed pooling of DORs 
for all the reported outcomes
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Figure 2) and illustrated the variation between studies using forest plots.  FiŶallǇ ǁe used the Deeks͛ 
funnel plot asymmetry test to assess the risk of publication bias using the outcome of neonatal unit 
admission for the analysis (Appendix 1, Figure 28). The test showed no evidence of publication bias 
(P=0.52). 
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Table 2. Summary diagnostic results of meta-analysis of the umbilical artery Doppler at predicting 
adverse pregnancy outcome. 
 
Outcome  Number 
of studies 
Number of 
patients 
Summary 
Sensitivity 
(95% CI) 
Summary 
Specificity 
(95% CI) 
Summary 
Positive LR 
(95% CI) 
Summary 
Negative LR 
(95% CI) 
SGA <10th centile 8 19,203 21.7% 
(13.2-33.6) 
91.8% 
(86.5-95.1) 
2.65 
(1.89-3.72) 
0.85 
(0.77-0.94) 
SGA <3rd centile 5 53,907 25.4% 
(14.0-41.5%) 
90.4% 
(78.6-96.1%) 
2.65 
(1.92-3.66) 
0.83 
(0.75-0.91) 
NICU admission 8 66,253 13.6 
(6.8-25.3) 
89.9 
(83.5-94.0) 
1.35 
(0.93-1.97) 
0.96 
(0.90-1.03) 
Neonatal 
acidosis 
5 9629 12.0% 
(5.3-25.0) 
91.1% 
(81.0-96.1) 
1.34 
(0.86-2.08) 
0.97 
(0.91-1.02) 
Severe APO* 4 58,866 9.3% 
(4.8-17.5) 
88.3% 
(74.5-95.2) 
0.80 
(0.44-1.46) 
1.03 
(0.95-1.11) 
 
a The definition varied between studies and includes one or more of the following: stillbirth, neonatal 
death, hypoxic ischemic encephalopathy, inotrope support, or severe metabolic acidosis.  
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Figure 1. Summary ROC curves for the UA Doppler at predicting: A. NICU admission, B. Neonatal 
Metabolic acidosis, C. SGA (<10th centile), D. Severe SGA (<3rd centile). 
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Figure 2. Meta-analysis of DORs of UA Doppler at predicting: A. NICU admission, B. Neonatal metabolic acidosis, C. 5-minute Apgar score <7, D. Severe 
adverse perinatal outcome, E. Caesarean section for fetal distress, F. Pre-eclampsia, G. SGA (<10th centile), H. Severe SGA (<3rd centile) 
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Discussion 
 
The main finding of this study was that the umbilical artery Doppler has moderate predictive accuracy 
for detecting SGA and severely SGA infants. However, it did not predict neonatal morbidity at term. 
The results were very similar in both the POP study and the meta-analysis which included the POP 
study and other published studies. The only notable difference between the analysis of the POP study 
and the meta-analysis including the POP study is that the association in the former was slightly 
stronger for severe SGA. The outcome of SGA is used as a proxy for FGR. As discussed in the 
background section, FGR is a theoretical concept with no gold standard. SGA is used a proxy for FGR 
but it is recognised that only a proportion of SGA infants are small due to FGR. As the threshold for 
defining SGA is lowered, the proportion of cases so defined which are truly FGR increases. Hence, the 
stronger association with severe SGA is most likely explained by a true association between high 
resistance patterns of UA Doppler and FGR.  
 
The similar associations between the POP study and the meta-analysis is reassuring. Of all the studies 
evaluated, only the POP study blinded both the Doppler result and fetal biometry. The failure to blind 
studies could lead to bias. First, revealing the results could lead to interventions which then improve 
the outcome of the pregnancy. In this case, an investigation which is truly predictive for adverse 
outcome may not appear to be so when evaluated in a study where the result is revealed as knowledge 
of the result leads to interventions which prevent the adverse outcome. However, revealing the result 
could also lead to a non-informative test being wrongly identified as predictive of adverse outcome. 
The primary intervention following a concerning ultrasound finding is to deliver the baby which, if 
performed preterm or at early term, can cause iatrogenic morbidity. Hence a non-informative test 
could appear to be associated with adverse neonatal outcome when evaluated in a study where the 
result is revealed as revealing the result leads to interventions which cause iatrogenic morbidity. 
Moreover, if outcomes include events that are defined on the basis of the results of the diagnostic 
test being evaluated there is the risk of ascertainment bias. For example, if the presence of abnormal 
UA Doppler is used to define Caesarean section (CS) for fetal distress, there could be an association 
between the two because the test was being used to classify the outcome.  
 
The lack of association between UA Doppler and adverse neonatal outcome is likely explained due to 
two reasons. First, the minority of term SGA infants have abnormal UA Doppler. This study showed 
that about 1 in 5 of the SGA infants born below the 10th birthweight centile and 1 in 4 of those born 
below the 3rd birthweight centile had abnormal UA Doppler. Second, only a small percentage of 
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overall morbidity at term is associated with abnormal fetal growth. For example, previous studies of 
perinatal death at term demonstrated that only 1 in 3 stillbirths at term are associated with abnormal 
fetal growth.51 This association would likely be even weaker for other outcomes such as NICU 
admission which includes morbidity for various reasons not related to the fetal size such as neonatal 
infection. It is plausible that UA Doppler would be more strongly predictive of adverse neonatal 
outcome in fetuses which were actually SGA and this has been confirmed in a previous analysis of the 
POP study.7  
 
Given that UA Doppler appears to be predictive of FGR in low risk women it might be regarded as 
surprising that the RCTs of its use as a screening test failed to demonstrate any benefit. However, a 
previous analysis of required sample sizes of screening and intervention to prevent stillbirth 
demonstrated that, even if a test had a positive LR of 5 for perinatal death, and was observed in 5% 
of women, and even if the test was coupled to an intervention that reduced the risk of perinatal death 
by 50%, an RCT of screen versus no screen would need to recruit ~300,000 to achieve 90% power see 
Supplementary Figure 10 in Flenady et al 2016.52 Thus, the Cochrane meta-analysis of low-risk 
pregnancies is significantly underpowered to identify a reduction in perinatal death. 
 
In conclusion, a high resistance pattern of UA Doppler is somewhat predictive of the risk of delivering 
an SGA infant. The strength of prediction was similar using a blinded 36wkGA scan in unselected 
nulliparous women in the POP study as it was in a systematic review of the wider literature. 
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Chapter 5. Systematic review of the diagnostic effectiveness of universal ultrasonic screening using 
late pregnancy cerebro-placental ratio in the prediction of adverse perinatal outcome. 
 
The preceding chapter details the fact that a high resistance pattern of flow in the umbilical artery is 
most strongly associated with severe SGA, which is thought to be most closely reflective of FGR. The 
abnormal flow in the UA is thought to be related to the pathophysiology of FGR, reflecting impaired 
perfusion of the placenta due to placental dysfunction. The placenta is the site of gaseous exchange 
for the fetus. Hence, a consequence of placental dysfunction is that the fetus may have low levels of 
oxygen in arterial blood. Physiologically, low levels of oxygen are detected by the central and 
peripheral arterial chemoreceptors (PACs).53 Activation of these receptors initiates compensatory 
responses, but these differ comparing fetuses and adults as there is no capacity to reverse the low 
levels of oxygenation by increased ventilation of the lungs (the chemoreceptors stimulate increased 
depth and frequency of ventilation in extra-uterine life). In fetal life, one of the key effects of PAC 
activation is to reduce the resistance to blood flow to the brain. Clinically, this process is assessed 
using Doppler flow velocimetry and, consistent with the foregoing, hypoxia leads to cerebral 
vasodilation and a reduced indices of vascular resistance using Doppler of the fetal middle cerebral 
artery. 
 
One attractive way to develop simple screening tools is to use ratios of values in the presence of 
opposite associations with an outcome of interest. Hence the cerebro-placental ratio was developed 
that it would combine measurement of the cause of FGR (placental insufficiency as measured by the 
UA Doppler) and one of its major consequences (arterial hypoxaemia as measured by MCA Doppler). 
The aim of the current chapter was to assess the ability of this ratio to predict adverse pregnancy 
outcome.  
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Methods 
 
Sources for meta-analysis 
A systematic search was performed using Medline, EMBASE, the Cochrane database of Systematic 
Reviews (CDSR) and Cochrane Central Register of Controlled Trials (CENTRAL). The initial search was 
done in June 2017 and was updated on the 30th of May 2019. No restrictions for language or 
geographic location were applied. The protocol for the review was designed a priori and registered 
with the PROSPERO International Prospective Register of Systematic Reviews (Registration number: 
C‘DϰϮϬϭϳϬϲϰϬϵϯͿ. The studies ǁeƌe ideŶtified usiŶg a ĐoŵďiŶatioŶ of ǁoƌds ƌelated to ͞ultƌasouŶd͟, 
͞pƌegŶaŶĐǇ͟, ͞ĐeƌeďƌoplaĐeŶtal͟, ͞Đeƌeďro-uŵďiliĐal͟, ͞ŵiddle Đeƌeďƌal aƌteƌǇ͟, aŶd ͞fetal ďƌaiŶ 
Doppleƌ͟. We defiŶed the ĐeƌeďƌoplaĐeŶtal ƌatio as the ƌatio of ŵiddle Đeƌeďƌal aƌteƌǇ ;MCAͿ 
pulsatility index (PI) to the umbilical artery (UA) PI. 
 
Study selection 
Selection criteria included cohort or cross-sectional studies with singleton pregnancies where an 
ultƌasouŶd sĐaŶ ǁas peƌfoƌŵed шϮϰǁkGA. We iŶĐluded all studies ǁheƌe the ultƌasouŶd ǁas 
performed as part of universal screening, studies that used low-risk populations only and studies with 
mixed-risk populations. We excluded studies that were focused on high risk patients such as FGR and 
studies that the ultrasound was performed during labour. We included studies regardless of the 
threshold they used to define abnormality of the CPR and regardless of blinding of the result to the 
clinicians.   
 
We included studies that reported the following outcomes: severe adverse perinatal outcome (which 
included stillbirth, neonatal death and hypoxic ischaemic encephalopathy); fetal growth abnormalities 
such as SGA (defined as birthweight <10th centile) and severe SGA (birthweight <3rd of <5th centile); 
adverse neonatal outcomes such as neonatal unit admission, 5-minute Apgar score <7, and neonatal 
metabolic acidosis (as defined in each study); Caesarean section or operative delivery (including both 
Caesarean section and instrumental delivery) for fetal compromise in labour. In cases of significant 
population overlap between studies that reported the same outcomes we included the larger study 
in the meta-analysis. However, if the studies reported different outcomes or performed the 
ultrasound at different gestational ages we included both in the meta-analysis. 
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Study quality assessment and data extraction 
The literature search, study selection, and analysis ware performed independently by two authors 
(AM and TB) using Review Manager 5.3. Any differences were resolved in discussion with the senior 
author (GS). The risk of bias in each included study was assessed using the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS 2) tool as outlined in the Cochrane Handbook of Diagnostic Test 
Accuracy Studies. This tool assesses the included studies for potential bias in four domains: patient 
selection, index test, reference standard and flow and timing. We assessed the risk for flow and timing 
from the perspective of universal ultrasound screening at 36wkGA. We used a pre-designed data 
extraction form to extract information on study characteristics (year of publication, country, setting, 
study design, blinding), patient characteristics (inclusion and exclusion criteria, sample size), the index 
test (gestational age at scan, cut-off values used), reference standard (pregnancy outcome, 
gestational age at delivery, and interval from scan to delivery). We also collected information such as 
parity and rates of IOL when reported. 
 
Statistical and meta-analysis methods 
The statistical methods employed are described in Chapter 4.  
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Results 
 
The literature search flowchart is presented in Appendix 2, Figure 29. We identified 16 studies39, 54-68 
that met our inclusion criteria involving 121,607 patients in total. The study characteristics are 
presented in Appendix 2, Table 20. Four studies 39, 54, 55, 65(N= 85,059) included unselected pregnancies, 
seven studies56, 57, 59, 60, 63, 64, 67 (N= 12,929) included only low-risk pregnancies and five studies58, 61, 62, 66, 
68 (N= 23,619) included mixed risk pregnancies. Nine studies (N= 87,208) were prospective and seven 
(N= 34,399) were retrospective. There was likely population overlap between the Akolekar 2015,54 
Akolekar 2019,39 and Bakalis55 studies. For the first two we reported different outcomes and for those 
outcomes that were the same we employed the data from the larger Akolekar 2019 study in the meta-
analysis. The study published by Bakalis performed ultrasound at 32wkGA compared to the two 
Akolekar studies which performed ultrasound at around 36wkGA. There was also likely population 
overlap between the Khalil,59 Monaghan61 and Morales-Rosello62 studies which reported different 
outcomes at the same tertiary maternity unit. Moreover, there was also likely population overlap 
between the Flatley,58 Sabdia66 and Twomey68 studies. The study published by Twomey performed 
ultrasound at 32wkGA and the other two studies which performed ultrasound between 35 and 38 
weeks reported different rates of nulliparity and different gestational age at delivery (Sabdia included 
preterm deliveries) which indicates that the potential population overlap was not significant. Finally, 
there was a complete population overlap between the studies published by Bligh but the two studies 
reported different outcomes.  
 
The assessment of study quality was performed using the QUADAS-2 tool and is summarized in 
Appendix 2, Figure 30. The main risk of bias was for reference standard due to the lack of blinding in 
the majority of studies. Only five studies 56, 57, 63-65(N=3079) blinded the results to the clinicians. The 
second more common risk of bias was for flow and timing due to the different gestational ages that 
the ultrasound was performed. Bakalis, Rial-Crestelo and Twomey performed ultrasound at around 
32 to 33wkGA, and Prior (both studies) and Stumpfe performed the ultrasound prior to IOL (interval 
between ultrasound and delivery less than 72 hours). Hence, the results of the above studies might 
not be applicable to universal screening at 36wkGA. One study (Maged et al.) had unclear risk of 
selection bias as they did not specify if the selection of patients was consecutive or random.  
 
The summary results for the diagnostic accuracy of CPR at predicting adverse pregnancy outcomes 
are presented in Table 3. Overall, the strongest associations were with the risk of delivering an SGA or 
severely SGA infant and the positive LRs were in the region of 3.5 to 4.0, which was stronger than for 
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UA on its own. Moreover, unlike the UA Doppler in the previous chapter, a low CPR was associated 
with a statistically significantly increased risk of neonatal morbidity. However, the strength of 
prediction was weak, with positive LRs between 1.5 and 3.0.   
 
The summary ROC curves are presented in Figure 3. Generally, the larger studies reported lower 
sensitivities and higher specificities for all the outcomes. We also present the pooling of the DORs in 
Figure 4. These demonstrate that for many of the outcomes there was a very high level of 
heterogeneity between the studies.  
 
FiŶallǇ ǁe used the Deeks͛ fuŶŶel plot asǇŵŵetƌǇ test to assess the ƌisk of puďliĐatioŶ ďias usiŶg the 
outcome of neonatal unit admission for the analysis. The test showed no significant risk of publication 
bias (P=0.28; Appendix 2, Figure 31). 
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Table 3. Diagnostic accuracy of CPR in predicting adverse pregnancy outcome. 
Outcome Studies Patients Summary  
sensitivity 
(95% CI) 
Summary  
specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
Neonatal unit admission 9 52,554 22.9% 
(10.5-42.9%) 
89.1% 
(82.1-93.5%) 
2.10 
(1.60-3.68) 
0.86 
(0.74-1.01) 
5-minute Apgar score <7 8 35,586 13.5% 
(8.8-20.2%) 
92.1% 
(90.0-93.8%) 
1.71 
(1.22-2.40) 
0.94 
(0.89-0.99) 
Neonatal metabolic acidosis 7 16,321 10.9% 
(6.9-16.8%) 
91.2% 
(87.9-93.6%) 
1.24 
(0.94-1.62) 
0.98 
(0.94-1.01) 
Severe adverse perinatal 
outcome 
4 87,429 18.6% 
(10.6-30.6%) 
90.9% 
(87.4-93.5%) 
2.04 
(1.49-2.80) 
0.90 
(0.81-0.99) 
SGA (<10th centile) 5 16,692 26.7% 
(18.0%-37.7%) 
93.0% 
(86.9%-96.4%) 
3.82 
(1.68-8.71) 
0.79 
(0.67-0.92) 
Severe SGA (<3rd or <5th 
centile) 
4 51,297 32.3% 
(20.1-47.5%) 
91.2% 
(84.3-95.3%) 
3.70 
(1.38-9.97) 
0.74 
(0.57-0.96) 
C-Section for fetal distress 9 68,506 25.9% 
(14.9-41.2%) 
90.6% 
(87.6-92.9%) 
2.75 
(1.96-3.88) 
0.82 
(0.70-0.96) 
Operative delivery for fetal 
distress 
5 12,162 19.4% 
(13.2-27.6%) 
92.6% 
(90.1-94.5%) 
2.63 
(1.81-3.83) 
0.87 
(0.80-0.94) 
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Figure 3. Summary ROC curves for the diagnostic performance of abnormal cerebroplacental ratio at predicting adverse pregnancy outcomes. A. Neonatal 
unit admission; B. 5-minute Apgar score <7; C. Neonatal metabolic acidosis; D. Severe adverse perinatal outcome (including stillbirth, neonatal death and 
hypoxic ischaemic encephalopathy); E. SGA (birthweight <10th centile); F. Severe SGA (<3rd or <5th centile); G. Caesarean section for fetal distress; H. 
Operative delivery for fetal distress (including both caesarean section and instrumental delivery) 
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Figure 4. DORs for the diagnostic performance of abnormal cerebroplacental ratio at predicting adverse pregnancy outcomes: A. Neonatal unit admission; 
B. 5-minute Apgar score <7; C. Neonatal metabolic acidosis; D. Severe adverse perinatal outcome (including stillbirth, neonatal death and hypoxic 
ischaemic encephalopathy); E. SGA (birthweight <10th centile); F. Severe SGA (<3rd or <5th centile); G. Caesarean section for fetal distress; H. Operative 
delivery for fetal distress (including both caesarean section and instrumental delivery) 
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Discussion. 
 
The meta-analysis demonstrated that the CPR may be slightly more predictive than UA Doppler in 
identifying pregnancies at an increased risk of adverse outcome. In the case of SGA, the positive LRs 
were in the region of 3.5 to 4.0 compared with 2.5 to 3.0 for UA Doppler. Moreover, unlike UA Doppler, 
a low level of CPR was associated with an increased risk of neonatal morbidity. However, in this case 
the strength of prediction was weaker with positive LRs of <2.0. Moreover, in both analyses, there was 
very significant heterogeneity in relation to both birth weight based outcomes and neonatal 
morbidity. Consequently, the 95% confidence intervals for the positive LR are wide and include the 
point estimates observed for UA Doppler for both SGA and severe SGA. Moreover, given that many of 
the studies were not blinded it is possible that the associations with neonatal morbidity were due to 
bias. However, the association between CPR and SGA indicates that the ratio is likely to predict FGR. 
Overall, this analysis indicates that the CPR is indeed predictive of adverse pregnancy outcome. 
However, it is not clear from the present analysis whether the ratio performs better than simply 
assessing the UA Doppler, which is used in its calculation anyway. Of the indices assessed in these 
sections of the report, only the MCA Doppler was not measured in the POP study, hence, unlike the 
other chapters, we are unable to compare the strength of association in the POP study and the meta-
analysis. Our findings contradict the previously published systematic review69 which concluded that 
CPR at term has a strong association with adverse obstetric and perinatal outcomes. We believe this 
is because the systematic review by Dunn et al.69 included mostly studies done in high-risk 
populations, did not include some large, recently published studies which offered ultrasound as part 
of universal screening (Akolekar39, 54, Bakalis55) and did not produce any pooled analysis. 
 
There are other issues which should be taken into account when considering the use of MCA Doppler 
as a screening test in unselected nulliparous women near term. First, the head often engages earlier 
in nulliparous women and it can be technically difficult to measure MCA Doppler when the head is 
deeply engaged. Second, the safety of ultrasound has been established in RCTs. However, these 
studies did not perform MCA Doppler. The main concern around ultrasound is the potential for harm 
caused by heating tissues. The form of ultrasound that is most strongly associated with heating is 
pulsed wave Doppler ultrasound. Hence, there is a theoretical safety concern about this use of this 
ŵethod thƌough heatiŶg of the ďaďǇ͛s ďƌaiŶ. IŶ high ƌisk pƌegŶaŶĐies, the ďalaŶĐe of risks and benefits 
probably favours gathering additional information. However, screening the entire population using 
this method may raise some safety concerns. Finally, the method also requires a certain level of 
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training and implementation of MCA Doppler as a population based screening methods would involve 
some challenges in relation to implementation.  
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Chapter 6. Systematic review of the diagnostic effectiveness of universal ultrasonic screening using 
severe oligohydramnios in the prediction of adverse perinatal outcome. 
 
Amniotic fluid evaluation is routinely performed in ultrasonic assessment of fetal wellbeing in the third 
trimester. Reduced amniotic fluid is called oligohydramnios and increased amniotic fluid is called 
polyhydramnios. In the second half of pregnancy, the amniotic fluid comes from the fetal urine. 
Fetuses with no kidneys (renal agenesis) typically have no amniotic fluid at the time of the routine 
20wkGA anomaly scan and it remains absent thereafter. However, congenital anomaly is a rare cause 
of oligohydramnios. One of the common causes of oligohydramnios is rupture of the fetal membranes. 
In this event, the overall level of fluid is reduced through vaginal loss. Normal fetal production of urine 
in such cases can be confirmed by filling and emptying of the fetal bladder. However, fetal distress is 
thought to be a potential cause of oligohydramnios. The mechanism is through reduced fetal urine 
production. Stress – such as arterial hypoxaemia – results in activation of a number of compensatory 
responses.53 These include increased release or arginine vasopressin (aka anti-diuretic hormone) 
which has a direct effect on the kidney. Fetal hypoxia leads to a chemoreceptor mediated 
cardiovascular response which increases blood supply to the vital organs (heart and brain) but reduces 
blood flow to the fetal trunk, including the kidneys. The combination of increased arginine vasopressin 
and reduced renal blood flow will reduce fetal urine output and lead to oligohydramnios. Hence, 
assessment of oligohydramnios has been a feature of ultrasonic assessment of fetal well-being for 
many years.  
 
The most common methods of quantitative assessment of amniotic fluid volume are the amniotic fluid 
index (AFI , the sum of the four deepest pockets of amniotic fluid in four quadrants of the uterus)70 
and the single deepest pocket (SDP). Severe oligohydramnios is commonly defined as AFI<5cm or 
SDP<2cm. Given the known association between oligohydramnios and fetal stress, the aim of the 
present study was to produce level 1 evidence of diagnostic effectiveness of severe oligohydramnios 
in predicting adverse pregnancy outcomes at or near term and we performed a systematic review and 
meta-analysis of the literature.  
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Methods 
 
Sources for meta-analysis 
We identified a previous systematic review71 which was published in 2014 and included source 
material from publications up to 2011. However, the review did not limit searches to low or mixed risk 
pregnancies. We updated the systematic review including studies published from 01//01/2011 up to 
the latest search date on the 5th of June 2019. The systematic search was performed using Medline, 
EMBASE, the Cochrane database of Systematic Reviews (CDSR) and Cochrane Central Register of 
Controlled Trials (CENTRAL). No restrictions for language or geographic location were applied. The 
studies ǁeƌe ideŶtified usiŶg a ĐoŵďiŶatioŶ of ǁoƌds ƌelated to ͞ultƌasouŶd͟, ͞pƌegŶaŶĐǇ͟, ͞aŵŶiotiĐ 
fluid ǀoluŵe͟, ͞AFI͟, ͞oligohǇdƌaŵŶios͟, aŶd ͞siŶgle deepest poĐket͟. 
 
Study selection 
Selection criteria included cohort or cross-sectional studies with singleton pregnancies where an 
ultƌasouŶd sĐaŶ ǁas peƌfoƌŵed шϮϰǁkGA. We iŶĐluded all studies ǁheƌe the ultƌasouŶd ǁas 
performed as part of universal screening, studies that used low-risk populations only and studies with 
mixed-risk populations. These criteria were applied to the studies included in the previously published 
review and to the studies published subsequent to that review. We excluded studies that were 
focused in high risk patients such as FGR, studies which included pregnancies with preterm premature 
rupture of membranes, and studies that the ultrasound was performed intrapartum. We included 
studies that reported the following outcomes: stillbirth, neonatal death fetal growth abnormalities 
such as SGA (defined as birthweight <10th centile) and severe SGA (birthweight <3rd of <5th centile); 
adverse neonatal outcomes such as neonatal unit admission, 5-minute Apgar score <7, and neonatal 
metabolic acidosis (as defined in each study); Caesarean section or operative delivery (including both 
Caesarean section and instrumental delivery) for fetal compromise in labour.  
 
Study quality assessment and data extraction 
The literature search, study selection, and analysis ware performed independently by two authors 
(AM and DW) using Review Manager 5.3. Any differences were resolved in discussion with the senior 
author (GS). The risk of bias in each included study was assessed using the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS 2) tool as outlined in the Cochrane Handbook of Diagnostic Test 
Accuracy Studies.34 This tool assesses the included studies for potential bias in four domains: patient 
selection, index test, reference standard and flow and timing. We assessed the risk for flow and timing 
from the perspective of universal ultrasound screening at 36wkGA. We used a pre-designed data 
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extraction form to extract information on study characteristics (year of publication, country, setting, 
study design, blinding), patient characteristics (inclusion and exclusion criteria, sample size), the index 
test (gestational age at scan, cut-off values used), reference standard (pregnancy outcome, 
gestational age at delivery, and interval from scan to delivery). We also collected information such as 
parity and rates of IOL when reported.    
 
Statistical and meta-analysis methods 
The statistical methods employed are described in Chapter 4.  
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Results 
 
The literature search flowchart is presented in Appendix 3, Figure 32. We identified 14 studies72-85 that 
met our inclusion criteria involving 109,679 patients in total. The study characteristics are presented 
in Appendix 3, Table 21. Two studies75, 76 (N= 30,555) included unselected pregnancies, ten studies 72-
74, 78-83, 85(N= 61,047) included low-risk pregnancies only and two studies77, 84 (N= 18,077) included 
mixed risk pregnancies. Six studies 73, 76, 77, 79, 80, 82(N= 5740) were prospective, six 72, 75, 78, 81, 83, 84(N= 
97,022) were retrospective, one74 (N=260) was cross-sectional and one85 (N= 6657) was done as part 
of a clinical trial.   
 
The assessment of study quality was performed using the QUADAS-2 tool and is summarized in 
Appendix 3, Figure 33. The main risk of bias was for reference standard due to the lack of blinding in 
the majority of studies. Only two studies 79, 82(N=1892) blinded the results to the clinicians, one of 
which blinded only the AFI result and not the other aspects of the ultrasound. The second more 
common risk of bias was for flow and timing. Two studies73, 83 performed ultrasound prior to IOL or 
within 4 days from delivery. Two other studies75, 80 did not report the gestational age at either 
ultrasound or delivery. Hence, these results may not be applicable for universal third trimester 
screening at 36wkGA. Two studies had unclear risk of selection bias77, 84 as they did not report how 
they selected their patients and one study74 had high applicability concerns for patient selection as 
they included prolonged ;>ϰϭ ǁeeks͛s gestatioŶͿ pƌegŶaŶĐies oŶlǇ.   
 
The summary results for the diagnostic accuracy of oligohydramnios at predicting adverse pregnancy 
outcomes are presented in Table 4. The most commonly reported outcomes were neonatal unit 
admission and Caesarean section for fetal distress (11 and 10 studies respectively). The stronger 
statistically significant association was with SGA <10th centile with positive LR of 2.8 (Table 4). There 
were also statistically significant associations with NICU admission and Caesarean section for fetal 
distress with positive LRs of 1.7 and 2.2 respectively. The positive LR for neonatal death was 3.7 but 
because of the small number of events the confidence intervals were very large and include unity. The 
summary ROC curves are presented in Figure 5. Generally, the larger studies reported lower 
sensitivities and higher specificities for all the outcomes. Figure 6 illustrates forest plots of DORs. 
Finally we used the Deeks͛ fuŶŶel plot asǇŵŵetƌǇ test to assess the ƌisk of puďliĐatioŶ ďias usiŶg the 
outcome of neonatal unit admission for the analysis (Appendix 3, Figure 34). The test showed no 
evidence of publication bias (P=0.54).
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Table 4. Summary diagnostic performance of low AFI (<5cm) at predicting adverse pregnancy outcome. 
Pregnancy outcome Studies Patients Summary sensitivity 
(95% CI) 
Summary specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
NICU admission 11 106,072 10.9% 
(6.3-18.3%) 
93.7% 
(88.4-96.6%) 
1.73 
(1.15-2.60) 
0.95 
(0.91-0.99) 
5-minute Apgar <7 9 90,536 9.9% 
(5.8-16.4%) 
94.4% 
(89.0-97.2%) 
1.77 
(0.91-3.44) 
0.95 
(0.90-1.01) 
Neonatal metabolic 
acidosis 
5 54,557 9.8% 
(6.1-15.5%) 
92.1% 
(87.1-95.2%) 
1.24 
(0.87-1.77) 
0.98 
(0.95-1.01) 
Caesarean section for fetal 
distress 
10 63,706 18.7% 
(9.6-33.2%) 
91.6% 
(86.1-95.1%) 
2.24 
(1.80-2.78) 
0.89 
(0.80-0.98) 
SGA 4 58,463 10.6% 
(4.4-23.6%) 
96.2% 
(89.4-98.7%) 
2.79 
(1.42-5.46) 
0.93 
(0.86-1.00) 
Neonatal death 4 57,640 12.8% 
(0.4-83.2%) 
96.6% 
(87.5-99.1%) 
3.73  
(0.29-48.8) 
0.90 
(0.59-1.38) 
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Figure 5. Summary ROC curves for AFI <5cm at predicting adverse pregnancy outcome. A. NICU admission; B. 5-minute Apgar score <7; C. Neonatal 
metabolic acidosis; D. Caesarean section for fetal distress; E. SGA (<10th centile); F. Neonatal death 
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Figure 6. Meta-analysis of DORs for AFI <5cm at predicting adverse pregnancy outcome: A. NICU admission; B. 5-minute Apgar score <7; C. Neonatal 
metabolic acidosis; D. Caesarean section for fetal distress; E. SGA (<10th centile); F. Neonatal death. 
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Discussion 
 
This meta-analysis confirms that a diagnosis of severe oligohydramnios is associated with adverse 
pregnancy outcome. The key finding was that severe oligohydramnios had a positive LR for SGA of 
between 2.5 and 3.0. The associations with admission to NICU and emergency Caesarean section for 
fetal distress are more difficult to interpret. First, for both of these outcomes, the association was 
weaker than it was for SGA. Second, in both cases the associations could be a consequence of the scan 
rather than an outcome predicted by the scan. Only two studies containing <5% of the patients 
included in the meta-analysis blinded the results of the scan. Revealing the results of the scan could 
explain both associations. In the case of NICU admission, revealing the scan result could lead to a 
decision to deliver the baby for suspected fetal distress. If this occurs preterm or at early term weeks 
of gestational age it could lead to an association with NICU admission through iatrogenic prematurity. 
In the case of caesarean delivery for fetal distress, revealing the result that there is severe 
oligohydramnios could be used as an indication (in whole or in part) to perform a caesarean section 
for suspected fetal distress. Alternatively, if a caesarean section was performed for failure to progress 
it is possible that the operator may include suspected fetal distress in the indication given the presence 
of the scan finding.  
 
It is, however, also possible that the negative association with adverse neonatal outcome is due to 
treatment paradox. Given that the diagnosis was known in >95% of cases in the meta-analysis, the 
attending clinicians may well have put interventions in place that prevented adverse outcome. These 
could include enhanced levels of fetal monitoring, IOL, or delivery by pre-labour Caesarean section. A 
further complexity is that the aetiology of severe oligohydramnios may differ between studies as some 
excluded women with ruptured fetal membranes whereas others did not.  
 
In conclusion, this analysis confirms that severe oligohydramnios is associated with adverse pregnancy 
outcome. This can confidently be stated as there was an association with SGA which is much less likely 
to arise from biases. However, the association between oligohydramnios and neonatal morbidity is 
less clear. Despite the association with SGA, the positive LR was not very high and its capacity to act 
as a screening test in unselected nulliparous women at 36wkGA is limited. 
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Chapter 7. Systematic review of the diagnostic effectiveness of universal ultrasonic screening using 
borderline oligohydramnios in the prediction of adverse perinatal outcome. 
 
In the preceding chapter, we assessed the association between severe oligohydramnios and the risk 
of adverse pregnancy outcome. Although associated with the risk of SGA, the finding was not strongly 
predictive of SGA and associations with neonatal morbidity were difficult to assess as >95% of the 
patients included in the meta-analysis participated in studies where the ultrasound scan was revealed. 
The aim of this element of the work was to determine the association between borderline 
oligohydramnios and adverse pregnancy outcome. First, we aimed to determine whether there was 
indeed a gradient in the strength of association comparing severe and borderline. Second, by using 
borderline oligohydramnios we were able to analyse previously unpublished data which were 
obtained from the POP study of unselected nulliparous women where a blinded assessment of the 
presence or absence of borderline oligohydramnios. This allowed us to address the true association 
between the finding and the risk of adverse outcome avoiding associated biases, for example, 
treatment paradox and ascertainment bias.  
 
Whereas severe oligohydramnios is defined as AFI <5cm, borderline oligohydramnios can be defined 
as 5cm to 8cm or 5cm to 10cm. In order to establish the predictive associations, we analysed 
unpublished data from the POP study (described above and below) and a systematic review of other 
studies of diagnostic effectiveness.   
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Methods  
 
Analysis of data from the Pregnancy Outcome Prediction study 
In the systematic review we included unpublished data from a prospective cohort study, the 
Pregnancy Outcome Prediction study (POPS), as described in Chapter 4. For the present analysis, 
women who delivered prior to their 36wkGA scan appointment were excluded. Screen positive was 
defined as an Amniotic Fluid Index (AFI) between 5 and 8 cm and screen negative as an AFI between 
8 and 24 cm. The definition of outcome data has previously been described.7 
 
Sources for meta-analysis 
The protocol for the review was designed a priori and registered with the PROSPERO International 
Prospective Register of Systematic Reviews (Registration number: CRD42017064093). We searched 
Medline, EMBASE, the Cochrane database of Systematic Reviews (CDSR) and Cochrane Central 
Register of Controlled Trials (CENTRAL) from inception to June 2019. The studies were identified using 
a ĐoŵďiŶatioŶ of ǁoƌds ƌelated to ͞ultƌasouŶd͟, ͞pƌegŶaŶĐǇ͟, ͞aŵŶiotiĐ fluid iŶdeǆ͟, ͞AFI͟, ͞liƋuoƌ 
ǀoluŵe͟, aŶd ͞pƌeŶatal diagŶosis͟. No ƌestƌiĐtioŶs foƌ language or geographic location were applied. 
 
Study selection 
Selection criteria included cohort or cross-sectional studies with singleton pregnancies where an 
ultƌasouŶd sĐaŶ ǁas peƌfoƌŵed шϮϰǁkGA. We iŶĐluded studies that used a ŵatĐhed desigŶ ďased oŶ 
the ultrasound finding (borderline oligohydramnios versus normal AFI) but excluded case-control 
studies (matched on outcome). We included all studies where the ultrasound was performed as part 
of universal screening (i.e. ultrasound was offered to women regardless of indication), studies that 
were performed in low-risk populations (i.e. those that excluded pregnancies with any maternal or 
fetal complication) and studies with mixed risk population (i.e. those that did not specify the indication 
for the ultrasound). We included studies defining borderline oligohydramnios as either an AFI of 5-8 
cm or 5-10 cm and included studies both where the result was revealed (i.e. the result of the scan was 
reported to the clinician) and those where it was not revealed (clinicians masked to result). We 
excluded studies that were focused only on high risk populations, e.g. pregnancies known to be 
complicated by FGR, and those where the scan was performed during labour. 
 
Study quality assessment and data extraction 
The literature search, study selection, and analysis ware performed independently by two authors 
(AM and IA) using Review Manager 5.3. Any differences were resolved in discussion with the senior 
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author (GS). The risk of bias in each included study was assessed using the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS 2) tool as outlined in the Cochrane Handbook of Diagnostic Test 
Accuracy Studies.34 We used a pre-designed data extraction form to extract information on study 
characteristics (year of publication, country, setting, study design, blinding), patient characteristics 
(inclusion and exclusion criteria, sample size), the index test (gestation at scan, cut-off values used), 
reference standard (pregnancy outcome, gestation at delivery, and interval from scan to delivery). 
 
Statistical and meta-analysis methods 
The statistical methods employed are described in Chapter 4. 
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Results  
 
The POP study 
Initially we analysed the previously unpublished data from the POP study. Applying the inclusion 
criteria described above yielded a total of 3387 women with a blinded scan at 36wkGA out of the 4512 
women recruited (Appendix 4, Figure 35) and 108 (3.2%) of these women had borderline 
oligohydramnios (AFI 5-8 cm, Appendix 4). The maternal age, socio-economic deprivation, ethnicity, 
BMI, and rates of alcohol consumption and smoking were similar between the two groups (Appendix 
4, Table 22). Moreover, the groups had similar rates of pre-existing hypertension and pre-eclampsia. 
The median birthweight was 200g lower in the cases of borderline oligohydramnios with a small 
difference in the gestational age at delivery. The rates of IOL were similar in both groups but women 
with borderline oligohydramnios had higher rates of spontaneous vaginal delivery. The screening 
performance of borderline AFI in the POP study is presented in Table 5. Borderline AFI was associated 
with an increased risk of delivering a severely SGA infant but was not associated with SGA or an 
increased risk of a range of indicators of neonatal morbidity in the POP study. 
 
Meta-analysis 
The literature search flowchart is presented in Appendix 4, Figure 36. We identified 11 studies86-95 
(including the POP study) that met our inclusion criteria involving 37,848 patients in total. The study 
characteristics are presented in Appendix 4, Table 23. Only the POP study (N=3387) included 
unselected pregnancies, three studies88, 94, 95 (N=1890) included only low-risk pregnancies and seven 
studies86, 87, 89-93 (N=32,571) included mixed risk pregnancies. Two studies94 (N=3817) were prospective 
and nine studies86-93, 95 (N=34,031) were retrospective. Seven studies88, 90-94 (N=36,293) defined 
borderline oligohydramnios as between 5 and 8 cm and four studies86, 87, 89 (N=1555) as between 5 
and 10 cm. The majority of patients in all the studies delivered at term. However, four studies86, 89, 92, 
94 reported a significantly higher rate of preterm delivery for those with borderline oligohydramnios.   
 
The assessment of study quality was performed using the QUADAS-2 tool and is summarized in 
Appendix 4, Figure 37. The main risk of bias was lack of blinding of the ultrasound result (which we 
defined as high risk for reference standard) which affected all studies except the POP study. We 
classified one study90 as high risk for selection bias as they used only low risk patients for their 
comparison group and two studies86, 87 as unclear risk of selection bias as they did not specify if they 
enrolled a consecutive or random sample of patients. Moreover, we classified five studies86, 89, 91, 93, 95 
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as having an unclear risk of flow and timing because they did not report the gestational age at 
ultrasound or delivery.   
 
The summary diagnostic performance of borderline oligohydramnios at predicting adverse pregnancy 
outcome is presented in Table 6. The most commonly reported outcomes were SGA <10th centile (9 
studies), NICU admission (8 studies), 5 minute Apgar score less than 7 (8 studies), meconium stained 
amniotic fluid (7 studies) and caesarean section for fetal distress (6 studies). The meta-analysis 
demonstrated a statistically significant association between borderline oligohydramnios and all of the 
outcomes, and the strongest association was with delivery of an SGA infant (positive LR = 2.6). The 
summary ROC curves are presented in Figure 7. Forrest plots of the DORs (Figure 8) demonstrated 
heterogeneity which was statistically significant for SGA and NICU admission. Two studies (POP and 
Petrozella et al) reported SGA below the 3rd centile and three studies reported perinatal death. 
However, we could not generate summary results for outcomes that were reported in less than four 
studies. FiŶallǇ ǁe used the Deeks͛ fuŶŶel plot asǇŵŵetƌǇ test to assess the ƌisk of puďliĐatioŶ ďias 
using the outcome of SGA <10th centile for the analysis (Appendix 4, Figure 38). The test showed no 
evidence of publication bias (P=0.33).
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Table 5. Diagnostic performance of borderline low AFI (5-8cm) at predicting adverse pregnancy outcome at term in the POP study (N=3387). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a One or more of the following: 5 minute Apgar score less than 7, delivery with metabolic acidosis (defined as a cord blood pH <7.1 and a base deficit of 
>10mmol/L), NICU admission. b Term live birth associated with neonatal death, hypoxic ischemic encephalopathy, use of inotropes, mechanical ventilation, or 
severe metabolic acidosis (defined as a cord blood pH <7.0 and a base deficit of >12mmol/L).
Outcome  True Positive / 
False Positive 
True Negative / 
False Negative 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
SGA <10th centile 10/98 2969/310 3.1% 
(1.2-5.0) 
96.8% 
(96.2-97.4) 
0.98 
(0.52-1.86) 
1.00 
(0.98-1.02) 
SGA <3rd centile 6/102 3212/67 8.2% 
(1.9-14.5) 
96.9% 
(96.3-97.5) 
2.67 
(1.21-5.88) 
0.95 
(0.88-1.01) 
Any neonatal 
morbiditya 
6/102 3048/231 2.5% 
(0.5-4.5) 
96.8% 
(96.1-97.4) 
0.78 
(0.35-1.76) 
1.01 
(0.99-1.03) 
 
NICU admission 6/102 3084/195 3.0% 
(0.6-5.3) 
96.8% 
(96.2-97.2) 
0.93 
(0.41-2.10) 
1.00 
(0.98-1.03) 
 
5-min Apgar <7 0/108 3251/28 N/A 96.8% 
(96.2-97.4) 
N/A N/A 
 
Metabolic acidosis 0/108 3245/34 N/A 96.8% 
(96.1-97.3) 
N/A N/A 
Severe neonatal 
morbidityb 
1/107 3256/23 4.2% 
(0.5-27.4) 
96.8% 
(96.2-97.4) 
1.31 
(0.18-9.38) 
0.99 
(0.91-1.08) 
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Table 6. Summary diagnostic performance of borderline low AFI to predict adverse pregnancy outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SGA, Small for gestational age; LR, Likelihood ratio; CI, Confidence intervals 
  
Outcome Studies Patients Summary 
sensitivity 
(95% CI) 
Summary 
specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
SGA <10th 
centile 
9 37,132 31.6% 
(13.0-58.7%) 
87.9% 
(71.9-95.3%) 
2.60 
(1.83-3.69) 
0.78 
(0.61-0.99) 
NICU admission  8 9,747 34.8% 
(15.9-60.1%) 
82.6% 
(69.1-91.0%) 
2.00 
(1.41-2.85) 
0.79 
(0.61-1.02) 
5-minute Apgar 
score <7 
8 9,666 34.0% 
(17.4-55.8%) 
82.0% 
(68.8-90.4%) 
1.89 
(1.47-2.42) 
0.80 
(0.66-0.98) 
C-Section for 
fetal distress 
6 33,517 21.2% 
(7.5-47.2%) 
90.0% 
(74.5-96.5%) 
2.13 
(1.56-2.90) 
0.87 
(0.75-1.02) 
Meconium 
amniotic fluid 
7 2,885 42.1% 
(28.7-56.9%) 
 
74.9% 
(67.7-81.0%) 
1.68 
(1.24-2.28) 
0.77 
(0.62-0.96) 
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Figure 7. Summary ROC curves of borderline AFI at predicting: A. SGA <10th centile, B. NICU 
admission, C. 5-minute Apgar score <7, D. Caesarean section for fetal distress. 
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Figure 8. DORs of borderline AFI at predicting A. SGA <10th centile, B. NICU admission, C. 5-minute Apgar score <7, D. Caesarean section for fetal distress. 
 
DOR = Diagnostic odds ratio 
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Discussion 
 
The main finding of the present study is that borderline oligohydramnios is moderately predictive of 
SGA. This was observed in the meta-analysis of multiple studies of variable quality. There was also a 
comparable association between borderline oligohydramnios and severe SGA in the only study where 
the scan result was blinded, the POP study.   
 
The observation that borderline oligohydramnios was associated only with severe SGA in the POP 
study is of interest. One possible explanation for this is that the scan result was not revealed, hence, 
the finding did not lead to changes in clinical management. The success of the blinding of the result is 
evidenced by the fact that borderline oligohydramnios was not associated with increased rates of IOL. 
in the POP study. A previous RCT of routine early term induction versus expectant management of 
pregnancies where ultrasonic fetal biometry indicated an SGA infant demonstrated that early delivery 
was associated with a significantly decreased the risk of delivering a baby with a birth weight <3rd 
percentile.96 A possible explanation for the POP study association with severe SGA and the meta-
analysis association with all SGA is that a finding of borderline oligohydramnios may have led to 
increased rates of early delivery in studies where the result was revealed, whereas the lack of 
intervention in the POP study led to growth restricted fetuses becoming progressively smaller for 
gestational age as the pregnancy advanced.  
 
The other major difference between the meta-analysis and the POP study may also relate to the lack 
of blinding in the other studies. Borderline oligohydramnios was associated with increased rates of 
neonatal morbidity in the meta-analysis but none of the outcomes of neonatal morbidity were 
associated with this finding in the POP study. However, the confidence intervals were wide and one 
explanation could be the lower statistical power of the POP study. However, plotting the DORs 
demonstrates that, in relation to NICU admission, the 95% CI observed in the POP study excluded the 
point estimate of the meta-analysis. This result could also be explained by the absence of blinding in 
the other studies. If the scan result is revealed the only disease modifying intervention available in 
late pregnancy is early delivery, and this could be late preterm or early term. It is well recognized that 
both are associated with increased rates of neonatal morbidity and NICU admission. Hence, the 
association between borderline oligohydramnios and neonatal morbidity in the meta-analysis could 
be because the finding led to iatrogenic prematurity and the absence of the finding in the POP study 
could be due to the lack of this effect. Assessment of individual studies in the meta-analysis is 
consistent with this interpretation. Gumus et al.89 reported higher rates of IOL in women with 
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borderline oligohydramnios which was associated with higher rates of preterm and early term 
delivery, and higher rates of NICU admission. Similarly, Asgharnia et al.86 offered screening after 28 
weeks, found that those with borderline oligohydramnios had a rate of preterm delivery of 40.4% 
(compared to 14.9% for those with normal AFI) and this is the likely explanation for the strong 
association between borderline oligohydramnios and NICU admission. This association was not found 
in studies that offered ultrasound later in pregnancy such as those by Sahin et al.94   
 
In conclusion, we provide strong evidence that borderline oligohydramnios is associated with an 
increased risk of delivering an SGA infant. However, when the finding of borderline oligohydramnios 
is revealed to clinicians, it may lead to increased risks of neonatal morbidity through earlier delivery. 
Given that the strength of prediction of SGA was not strong and that revealing the result may have led 
to increased risks of neonatal morbidity, the observed association with SGA does not necessarily mean 
that screening unselected nulliparous women near term with this method will result in better clinical 
outcomes. 
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Chapter 8. Systematic review of the diagnostic effectiveness of universal ultrasonic screening using 
fetal macrosomia in the prediction of adverse perinatal outcome. 
 
Birth weight is a basic characteristic which defines an individual: the weight and sex of a baby are key 
themes in discussion following a birth. Similarly, when considering pregnancy outcome and its 
associations with the subsequent health of the infant, birth weight is critically important. Much of the 
focus on birth weight is on babies which are SGA due to its association with perinatal mortality. The 
diagnostic effectiveness of ultrasound in that context was the subject of a Cochrane review of 
diagnostic effectiveness22 and this is discussed extensively in the following chapter. However, being 
born large for gestational age (LGA) is also a predictor of adverse outcome including perinatal 
mortality and morbidity arising from traumatic delivery and this is the focus of the current chapter.  
 
Ultrasonic estimation of fetal weight (EFW) was first described more than 40 years ago.97 The most 
widely employed equation for EFW was published by Hadlock in 19854 and a reference range for EFW 
was published in 19915. A subsequent multi-country study by the World Health Organisation derived 
very similar EFW percentiles as described by Hadlock in Houston (TX, USA) in the early 1990s. Hence, 
the diagnostic tools have been available for many years to identify SGA and LGA fetuses. Moreover, 
an RCT has indicated that routine IOL in the presence of suspected macrosomia may prevent shoulder 
dystocia, one of the key adverse outcomes associated with an infant being LGA.98  
 
Despite the above, it is still not clear whether screening and intervention for suspected fetal 
macrosomia is clinically effective. The HTA is currently funding an RCT of intervention in women 
diagnosed with an LGA infant ;͞Induction of labour for predicted macrosomia: the Big Baby trial͟; 
ISRCTN18229892). However, as universal ultrasound in late pregnancy is not recommended in the UK, 
these women will have received a clinically indicated scan. Although the trial will determine whether 
intervention is useful in that group, it will not resolve whether screening and applying the same 
intervention to screen positive women as it is likely that the diagnostic effectiveness of the test will 
vary between women is clinically effective scanned routinely and those scanned for a clinical 
indication. Hence, the aim of the present study was to quantify the diagnostic effectiveness of 
universal ultrasound in late pregnancy to predict delivery of a large baby and one its major associated 
complications, namely, shoulder dystocia.  
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Methods 
 
Sources for meta-analysis 
A systematic search was performed using Medline, EMBASE, the Cochrane database of Systematic 
Reviews (CDSR) and Cochrane Central Register of Controlled Trials (CENTRAL). The search was done 
on then 22nd of October 2018. No restrictions for language or geographic location were applied. The 
protocol for the review was designed a priori and registered with the PROSPERO International 
Prospective Register of Systematic Reviews (Registration number: CRD42017064093). The studies 
ǁeƌe ideŶtified usiŶg a ĐoŵďiŶatioŶ of ǁoƌds ƌelated to ͞ultƌasouŶd͟, ͞pƌegŶaŶĐǇ͟, ͞estiŵated fetal 
ǁeight͟, ͞EFW͟, ͞ďiƌthǁeight͟, ͞ŵaĐƌosoŵia͟, ͞laƌge foƌ gestatioŶal age͟, ͞shouldeƌ dǇstoĐia͟, aŶd 
͞ďƌaĐhial pleǆus iŶjuƌǇ͟. 
 
Study selection 
Selection criteria included cohort or cross-sectional studies with singleton pregnancies where an 
ultƌasouŶd sĐaŶ ǁas peƌfoƌŵed шϮϰǁkGA. We iŶĐluded all studies ǁheƌe the ultƌasouŶd ǁas 
performed as part of universal screening, studies that used low-risk populations only and studies with 
mixed-risk populations. We excluded studies that were focused in high risk patients such as patients 
with pre-existing or gestational diabetes and studies that the ultrasound was performed intrapartum. 
We included studies regardless of the formula and threshold they used to define macrosomia. We also 
included studies regardless of blinding of the result to the clinicians. We included studies that reported 
the following outcomes: LGA (defined as birthweight > 4000g or >90th centile) and severe LGA 
(birthweight >4500g or above the 97th centile); shoulder dystocia; adverse neonatal outcomes such as 
neonatal unit admission, 5-minute Apgar score <7, and neonatal metabolic acidosis.   
 
Study quality assessment and data extraction 
The literature search, study selection and analysis ware performed independently by two authors (AM 
and NS) using Review Manager 5.3. Any differences were resolved in discussion with the senior author 
(GS). The risk of bias in each included study was assessed using the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS 2) tool as outlined in the Cochrane Handbook of Diagnostic Test Accuracy 
Studies. This tool assesses the included studies for potential bias in four domains: patient selection, 
index test, reference standard and flow and timing. We assessed the risk for flow and timing from the 
perspective of universal ultrasound screening at about 36wkGA. We used a pre-designed data 
extraction form to extract information on study characteristics (year of publication, country, setting, 
study design, blinding), patient characteristics (inclusion and exclusion criteria, sample size), the index 
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test (gestational age at scan, formula and cut-off values used), reference standard (pregnancy 
outcome, gestational age at delivery, and interval from scan to delivery). We also collected 
information such as inclusion or exclusion of patients with pre-existing or gestational diabetes.   
 
Statistical and meta-analysis methods 
The statistical methods employed are described in Chapter 4. 
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Results 
 
The literature search flowchart is presented in Appendix 5, Figure 39. We identified 40 studies99-138 
that met our inclusion criteria involving 66,187 patients in total. The study characteristics are 
presented in Appendix 5, Table 24. Five studies102, 111, 117, 120, 135 (N=8088) included unselected 
pregnancies, nine studies107, 113, 115-117, 119, 126, 128, 136, 137 (N= 6436) included only low-risk pregnancies and 
26 studies99-101, 103-106, 108-110, 112, 114, 118, 121-125, 127, 129-134, 138 (N= 51,663) included mixed risk pregnancies.   
 
The assessment of study quality was performed using the QUADAS-2 tool and is summarized in 
Appendix 5, Figure 40. The main risk of bias was for reference standard because only two studies, 
Sovio 2018 (POP study)135 and Galvin 2017 (GENESIS study)113 blinded the results to the clinicians. The 
second more common risk of bias was for flow and timing. This is because six studies had very short 
interval between ultrasound and delivery (the ultrasound was done either prior to IOL or less than 72 
hours from delivery), two studies had long interval (ultrasound performed prior to 33wkGA) and two 
studies did not specify the gestational age at delivery. Finally, three studies only included prolonged 
(>41 weeks) pregnancies which weƌe Đlassified as haǀiŶg ͞high appliĐaďilitǇ ĐoŶĐeƌŶs due to patieŶt 
seleĐtioŶ͟.   
 
The most commonly reported outcomes were birthweight above 4000g (29 studies) followed by 
birthweight above the 90th centile (7 studies) which we both classified as large for gestational age 
(LGA). We defined as severe LGA a birthweight above 4500g (6 studies) or above the 95th or 97th 
centiles (two studies). Shoulder dystocia was reported in 6 studies. Finally neonatal morbidity (any 
related outcomes) was reported in only two studies, and consequently we could not produce summary 
results for this outcome. The most commonly used formulas for EFW were those described by 
Hadlock4 et al, followed by Shepard. The most common thresholds for suspected LGA on scan were 
4000g (21 studies) and 90th centile for the gestational age (9 studies). The abdominal circumference 
was used in 9 studies with the most common threshold applied being 36 cm (5 studies).   
 
We present the summary diagnostic performance in Table 7. An estimated EFW >4000g or the 90th 
centile had above 50% sensitivity for predicting LGA at birth and this was similar regardless of the 
formula used. The positive likelihood ratios for the Hadlock formulas ranged between 7.5 and 12 and 
for the Shepard formula it was about 5. The AC had similar performance with the EFW. Suspected LGA 
also had about 70% sensitivity at predicting severe LGA at birth. Finally, an EFW >4000g or 90th centile 
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had 22% sensitivity at predicting shoulder dystocia with a statistically significant positive likelihood 
ratio of 2.1.    
 
The summary ROC curves for LGA and shoulder dystocia are presented in Figure 9. We also present 
the pooling of the DORs (Figure 10Ϳ. FiŶallǇ ǁe used the Deeks͛ fuŶŶel plot asǇŵŵetƌǇ test to assess 
the risk of publication bias using the outcome of LGA for the analysis (Appendix 5, Figure 41). The test 
showed potentially significant risk of publication bias (P=0.02).  
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Table 7. Summary diagnostic performance of suspected LGA to predict LGA at birth and shoulder dystocia. 
 Diagnostic test Studies Patients Summary 
sensitivity 
(95% CI) 
Summary 
specificity 
(95% CI) 
Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
 Outcome: Birthweight >4000g (or 90th centile)       
 EFW (any) >4000g (or 90th centile) 29 34,198 53.5% 
(47.3-59.6%) 
93.9% 
(91.8-95.5%) 
8.82 
(6.83-11.4) 
0.49 
(0.44-0.56) 
 EFW (Hadlock-AC/FL/HC/BPD)  9 22,073 63.1% 
(49.1-75.2%) 
94.3% 
(90.9-96.5%) 
11.13 
(8.24-15.04) 
0.39 
(0.28-0.55) 
 EFW (Hadlock- AC/FL/BPD) 10 17,110 55.1% 
(44.1-65.7%) 
92.9% 
(89.7-95.2%) 
7.77 
(5.55-10.89) 
0.48 
(0.38-0.61) 
 EFW (Hadlock- AC/FL/HC) 6 14,801 57.3% 
(47.0-67.0) 
95.2% 
(92.3-97.0%) 
11.89 
(7.81-18.10) 
0.45 
(0.36-0.56) 
 EFW (Hadlock- AC/FL) 9 16,736 60.5% 
(50.7-69.5%) 
92.0% 
(89.4-93.7%) 
7.54 
(6.13-9.29) 
0.43 
(0.34-0.54) 
 EFW (Hadlock- AC/BPD) 6 13,617 62.9% 
(36.1-83.5%) 
93.7% 
(85.9-97.3%) 
9.99 
(6.40-15.58) 
0.40 
(0.21-0.75) 
 EFW (Shepard) 7 14,060 73.7% 
(54.4-86.9%) 
85.1% 
(76.5-90.9%) 
4.96 
(3.29-7.48) 
0.31 
(0.17-0.56) 
 AC >36cm (or 90th centile) 5 10,543 57.8% 
(39.6-74.2%) 
92.3% 
(88.7-94.9%) 
7.56 
(5.85-9.77) 
0.46 
(0.30-0.68) 
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 Outcome: Birthweight >4500g (or 95th centile)       
 EFW (any) >4000g (or 90th centile) 4 5839 70.2% 
(42.6-88.2%) 
89.2% 
(74.4-95.9%) 
6.49 
(2.2-19.1) 
0.33 
(0.14-0.78) 
 Outcome: Shoulder dystocia       
 EFW (any) >4000g (or 90th centile) 6 26,264 22.0% 
(9.9-42.0%) 
89.6% 
(80.8-94.6%) 
2.12 
(1.34-3.35) 
0.87 
(0.74-1.02) 
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Figure 9. Summary ROC curves for the diagnostic performance of EFW > 4000g (or 90th centile) at 
predicting A. LGA at birth (birthweight above 4000g or above the 90th centile) and B. Shoulder 
dystocia. 
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Figure 10. DORs for the diagnostic performance of EFW > 4000g (or 90th centile) at predicting A. 
LGA at birth (birthweight above 4000g or above the 90th centile) and B. Shoulder dystocia. 
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Discussion 
 
The key findings of the present study were that ultrasonic suspicion of fetal macrosomia is strongly 
predictive of the risk of delivering a large baby but it is only weakly – albeit statistically significantly – 
predictive of the risk of shoulder dystocia. In the case of delivering an LGA baby using the Hadlock 
formula, the positive LRs were quite strong, in the region of 7 to 12, whereas in relation to the 
diagnosis of shoulder dystocia, the positive LR was ~2. The forest plot of DORs indicates that there 
was significant heterogeneity between the studies in the ability to predict an LGA infant. The source 
of this heterogeneity is unclear but it could relate to differences in the quality of the performance of 
the diagnostic test, such as the quality of the imaging equipment, the skill and training of sonographers 
and the characteristics of the population.   
 
In this and the preceding chapters we have focused analysis on data from the POP study, as it is 
particularly applicable to the research question addressed in this report, given that late pregnancy 
ultrasound was performed in a large number of nulliparous women using contemporary equipment 
and staff trained using the standards of the English NHS. The POP study analysis of a 36wkGA scan in 
the diagnosis of macrosomia had previously been published135 and this was incorporated into the 
meta-analysis. Interestingly, the DOR (95% CI) from the POP study was 17.1 (12.0 to 24.3) and this was 
virtually identical to the summary estimate from all of the other studies where it was also 17.1 but 
with slightly narrower 95% CI (13.3 to 22.0). These data suggest that the results from the POP study 
are likely to be generalisable.  
 
A recurrent theme in all of the chapters has been the lack of blinding in studies of the diagnostic 
effectiveness of ultrasound in pregnancy screening research. Hence, generally, the POP study has been 
unique as a contemporary study in late pregnancy in nulliparous women. However, in this analysis 
there is a second comparable study, the Genesis study. This was a prospective cohort study of 2772 
nulliparous pregnant women recruited across seven centres in Ireland between 2012 and 2015. 
WoŵeŶ had the ultƌasouŶd sĐaŶ шϯϵǁkGA aŶd <ϰϭǁkGA, i.e. ~ϯ to ϰ ǁeeks lateƌ thaŶ the POP studǇ. 
Although the timing of the scan is slightly later than the research question for the current report, the 
study design makes it particularly useful.    
 
The analysis of fetal macrosomia from the Genesis study has only been published in abstract form. It 
did not report the diagnostic effectiveness of EFW as a predictor of LGA birth weight, but it did report 
shoulder dystocia. Interestingly, the POP study and the Genesis study were the only two large studies 
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(>1000) women not to demonstrate a statistically significant association between macrosomic EFW 
and the risk of shoulder dystocia. Overall, the meta-analysis indicated that ultrasound may be weakly 
predictive. However, as with other analyses in the preceding chapter, these findings could be 
explained by ascertainment bias. Specifically, if a scan is performed and the fetus is suspected to be 
macrosomic, the clinical staff attending the birth may be more likely to institute manoeuvres for 
shoulder dystocia in the event of any delay, or to document a given delay as being due to shoulder 
dystocia. The potential for such biases may explain why the studies with blinded ultrasound were not 
significantly associated and why the meta-analysis as a whole was only weakly predictive of shoulder 
dystocia while it was strongly predictive for macrosomia. A weak association between ultrasonic EFW 
and the risk of shoulder dystocia is not surprising given that the actual birth weight of the baby is not 
strongly predictive of shoulder dystocia and that the majority of cases of shoulder dystocia do not 
involve a macrosomic infant.139 
 
Finally, the relationship between fetal macrosomia is an area where there is good evidence around 
the potential for revealing a scan result to change the experience of complications in women who are 
false positives. Multiple studies have demonstrated that a false positive diagnosis of fetal macrosomia 
is an independent risk factor for emergency Caesarean delivery.140-142 These observations underline 
the possibilities that screening low risk women has the potential to cause harm and that researching 
methods of screening using a study design where the results are revealed to the attending clinician 
has the potential to cause associations which are a consequence of the scan, not a true prediction 
arising from it. 
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Chapter 9. Conclusions regarding the evidence around universal ultrasound screening of nulliparous 
women in late pregnancy. 
 
The preceding chapters outline the association between umbilical artery Doppler, CPR, severe 
oligohydramnios, borderline oligohydramnios, and fetal macrosomia and the risk of adverse 
pregnancy outcome. The main overall conclusions are as follows:  
1. Umbilical artery Doppler, CPR, severe oligohydramnios, borderline oligohydramnios and fetal 
macrosomia were all either non-predictive or weakly predictive of the risk of neonatal morbidity.  
2. Umbilical artery Doppler, CPR, severe oligohydramnios, borderline oligohydramnios were all weakly 
predictive of the risk of delivering an SGA infant.  
3. The vast majority of the studies did not blind the result of the index test. Hence, interpreting the 
results in relation to prediction of adverse neonatal outcome could be biased against not seeing 
associations where true associations exist (e.g. through treatment paradox) or biased towards seeing 
associations where no true associations exist (e.g. through ascertainment bias or iatrogenic harm).  
4. Only the POP study has reported the range of ultrasonic findings in late pregnancy in unselected 
nulliparous women, which is the optimal study design and was conducted in the target population. A 
second study conducted in Ireland (Genesis) also performed blinded ultrasound scans in late 
pregnancy in nulliparous women but has not published widely on the results.  
5. The results of the POP study in relation to both SGA and LGA (outcomes which are objectively 
defined and less prone to biases) were comparable to the summary estimates across all studies. 
 
During the period of the current project, a systematic review of diagnostic test accuracy in relation to 
ultrasonic diagnosis of SGA, using EFW was published.22 In searching the literature, they made the 
following observation regarding blinded ultrasonic assessment of fetal growth:  
͞Sovio 2015 [POP study] blinded clinicians to the results of the universal ultrasonography and Weiner 
2016 blinded clinicians to results of all ultrasound methods other than the one they conducted, but in 
the majority of studies clinicians either were not blinded to test results or this was not reported͟. 
 
The Weiner et al. (2016)143 study was performed on 405 women during active labour and compared 
clinical assessment of fetal size versus ultrasonic EFW. Hence, the conclusion of the Heazell systematic 
review is that the only study which performed blinded ultrasonic assessment of SGA relevant for 
population screening in the antenatal period was the POP study. 
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We were aware of the Heazell review and did not, therefore, address ultrasonic diagnosis of SGA in 
the present review.  
They reported detection of SGA (birth weight <10th percentile) as follows:   
For a specificity of 88%, ultrasonic suspicion of SGA had  a sensitivity of 74% (95% confidence intervals 
64% to 83%). In the POP study, the sensitivity was 57% for a specificity of 90%.  The meta-analysis 
reported detection of severe SGA (birth weight <3rd percentile) as follows:   
For a specificity of 87%, ultrasonic suspicion of SGA had  a sensitivity of 66% (95% confidence intervals 
56% to 76%). In the POP study, the sensitivity was 77% for a specificity of 87%. The Heazell review is 
slightly surprising in that one would have predicted better prediction of the more severe outcome. 
The inconsistency between these two analyses may reflect inclusion of different studies which may 
have included different populations. However, the review does suggest that the data observed in the 
POP study were generally comparable to the studies included in the Heazell review. 
 
A further level of complexity in considering these issues is that, generally, an ultrasonic assessment of 
the fetus typically includes measurement of multiple parameters simultaneously. Hence, a further 
issue in trying to apply the findings of the Heazell review and our own reviews to health economic 
analysis and trial design is that none of the reviews completely captures what might be expected to 
happen clinically. This issue is affected by another layer of complexity, namely, defining the features 
on a scan that the majority of clinicians would accept as indicating FGR. This last question has been 
addressed by researchers employing the Delphi consensus method to generating an agreed ultrasonic 
diagnosis of FGR. The paper arising from this process was published in 2016.144 These authors 
described the following criteria for diagnosis of late FGR (32wkGA or beyond): 
 
EFW or AC <3rd percentile 
OR 
2 or more of the following: 
(i) EFW/AC <10th (ii) EFW/AC falling 2 quartiles, or (iii) CPR <5th percentile or UA Doppler >95th 
 
In a paper in Lancet CAH in 2018145, the POP study data were used to compare the Delphi definition 
of late FGR using the blinded 36wkGA scan with simply an EFW <10th as a predictor of the risk of 
delivering an SGA infant with complications. The results are reproduced in the Table 8 below: 
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Table 8. Diagnostic effectiveness of ultrasonic screening at 36wkGA for subsequent delivery of an 
SGA infant associated with either maternal preeclampsia or perinatal morbidity or mortality. 
       
Screening test  Positive LR 
(95% CI) 
Negative LR 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
       
 Ultrasonic EFW <10th  5·1 
(4·2-6·3) 
0·38 
(0·26-0·54) 
 
67·2 
(53·8-78·3) 
86·9 
(85·8-88·0) 
 Delphi definition of late FGR  5·9 
(4·7-7·4) 
0·43 
(0·31-0·60) 
 
61·4 
(47·9-73·4) 
89·6 
(88·6-90·6) 
From Gaccioli et al (2018), Lancet CAH.145 
 
In fact, the diagnostic effectiveness appeared to be quite similar comparing the two approaches. It is 
worth acknowledging that, due to the absence of MCA Doppler, we were unable to include a specific 
subset of fetuses that would have been defined as FGR by the Delphi method, namely, those where 
the CPR was <5th but the umbilical artery Doppler was <95th, the EFW>3rd and AC>3rd but the baby 
filled one of the other two criteria (EFW/AC <10th or EFW/AC falling 2 quartiles). However, given the 
lack of association between CPR and neonatal morbidity described in Chapter 5, we not believe that 
it is likely that inclusion of this group would have profoundly altered the results. 
 
Taking the totality of the data, the approach we employed for the health economic analysis was that 
we defined screen positive as either ultrasonic EFW<10th (suspected SGA) or ultrasonic EFW>90th 
(suspected LGA). The Heazell et al review demonstrated good diagnostic effectiveness for SGA and 
the analysis in Chapter 8 demonstrated that ultrasonic suspicion of macrosomia was strongly 
associated with the risk of delivering a large baby. The attractiveness of this approach was underlined 
by the fact that there were Cochrane reviews which reported meta-analysis of RCTs of IOL in both 
situations, and there are extensive epidemiological data on the outcome of SGA and LGA pregnancies. 
There was one additional further exposure which is detectable by scan and where management is 
informed by RCT evidence, namely, breech presentation near term. Ultrasound establishes fetal 
presentation with 100% accuracy at the time of the scan (although the presentation will sometimes 
change spontaneously after the scan). Hence, we included this in subsequent analyses.  
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Chapter 10. Evidence based protocol for the care of screen positive women. 
 
The preceding chapter identified three elements in a late pregnancy ultrasound scan where there was 
evidence that the screening result identified a high risk fetus, namely, breech presentation, an SGA 
fetus, or an LGA fetus. We next sought to determine the evidence base which existed to inform 
interventions in women who had these features and employed the search engine of the National 
Institute for Health and Care Excellence, at https://www.evidence.nhs.uk/ 
 
Management plan for breech presentation 
This search identified an existing UK based guideline from the RCOG, Management of Breech 
Presentation (Green-top Guideline No. 20b).12 In brief, women who do not have a contraindication to 
external cephalic version are offered this procedure (turning of the fetus by manual manipulation of 
an un-anaesthetised woman). Where the procedure is contraindicated, declined or unsuccessful 
women would then have a discussion regarding attempting vaginal breech birth. Where vaginal 
breech birth was contraindicated or declined, a planned caesarean section would be scheduled at 39 
weeks (in the absence of a clinical indication for earlier delivery) with the proviso that the woman 
would be delivered by emergency caesarean section if she presented in labour before the scheduled 
date. Women who had a successful ECV would have routine care thereafter, but with midwife checks 
that the baby had not reverted to breech. In practice, given that the target population is nulliparous, 
it would be a small minority who would opt for vaginal breech birth and no women took up this option 
in the POP study.10 For the purposes of the Markov chain modelling and health economic analysis we 
used the effeĐt estiŵates of a CoĐhƌaŶe ƌeǀieǁ ǁhiĐh ƋuaŶtified ͞the effeĐts of plaŶŶed Caesarean 
section for siŶgletoŶ ďƌeeĐh pƌeseŶtatioŶ at teƌŵ oŶ ŵeasuƌes of pƌegŶaŶĐǇ outĐoŵe͟ .13 Other 
parameters were obtained from the literature and are detailed in the chapters below. 
 
Management plan for diagnosis of SGA 
We next used the NICE evidence search engine to identify existing guidelines around the management 
of SGA. This search identified an existing UK based guideline from the RCOG, Small-for-Gestational-
Age Fetus, Investigation and Management (Green-top Guideline No. 31).146 Much of this guideline was 
focused on early pregnancy identification of risk factors and the management of the preterm SGA 
fetus. However, the following were key points in relation to the detection and management of SGA at 
term. 
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• ͞IŶ the terŵ “GA fetus ǁith Ŷorŵal uŵďiliĐal artery Doppler, aŶ aďŶorŵal ŵiddle Đereďral 
artery Doppler (PI < 5th centile) has moderate predictive value for acidosis at birth and should 
be used to time delivery. • In the SGA fetus detected after 32 weeks of gestation with normal umbilical artery Doppler, a 
senior obstetrician should be involved in determining the timing and mode of birth of these 
pregnancies. • Delivery should be offered at 37 weeks of gestation. • In the SGA fetus with umbilical artery AREDV delivery by caesarean section is recommended. • In the SGA fetus with normal umbilical artery Doppler or with abnormal umbilical artery PI but 
end–diastolic velocities present, induction of labour can be offered but rates of emergency 
caesarean section are increased and continuous fetal heart rate monitoring is recommended 
froŵ the oŶset of uteriŶe ĐoŶtraĐtioŶs.͟ 
 
The same search also identified an NHS England Care Bundle which aimed to reduce rates of perinatal 
death, ͞“aǀiŶg Baďies’ Liǀes Version Two: A care bundle for reducing perinatal mortality͟. This 
guideline had a section on management of SGA at term and the following were key relevant sections. • ͞Accepting the proviso that all management decisions should be agreed with the mother in 
the cases of fetuses <3rd centile and with no other concerning features, initiation of labour 
and/or delivery should occur at 37+0 weeks and no later than 37+6 weeks gestation.  • Fetuses between 3rd – 10th centile will often be constitutionally small and therefore not at 
increased risk of stillbirth. Care of such fetuses should be individualised and the risk assessment 
should include Doppler investigations, the presence of any other high risk features for example, 
recurrent reduced fetal movements, and the mother’s ǁishes. IŶ the aďseŶĐe of aŶy high risk 
features delivery or the initiation of IOL should ďe offered at 39+0 ǁeeks.͟ 
 
However, the context for both the RCOG and NHS England guidelines was the management of women 
who were identified through the current approach of targeting ultrasound to high risk women. As 
outlined in the preceding chapter, we have not found evidence that these additional ultrasonic tests 
are diagnostically effective when used as a screening test. Hence, the management protocol for SGA 
employed in the health economic analysis is to offer IOL. For the purposes of the health economic 
aŶalǇsis ǁe used the effeĐt estiŵates of a CoĐhƌaŶe ƌeǀieǁ ǁhiĐh ƋuaŶtified ͞ the effeĐts of iŵŵediate 
delivery versus expectant management of the term suspected compromised baby on neonatal, 
maternal and long-teƌŵ outĐoŵes͟ 147. In practice, 90% of the women included in the review came 
from a trial of IOL for suspected FGR 96. IOL took place in the intervention group of this trial at an 
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average of 38 weeks gestational age and we have incorporated this into our management protocol 
(see below). This does not represent an extreme intervention as a large scale NIH-funded RCT 
demonstrated no adverse effect of routine IOL at 39 weeks in nulliparous women who lacked risk 
factors 148. Other parameters were obtained from the observational literature and are detailed in the 
chapters below. 
 
Management plan following diagnosis of LGA. 
We next used the NICE evidence search engine to identify existing guidelines around the management 
of LGA. The only guidelines which we identified using this search related to women with diabetes. 
These women are routinely scanned during pregnancy and have specific issues and the 
recommendations relating to this group are not generalisable to the population of interest in the 
current report. However, the search did identify a number of systematic reviews which addressed IOL 
and one of these was a Cochrane review.149 The Cochrane review had the following conclusions: 
͞iŶduĐtioŶ of laďour for suspeĐted fetal ŵaĐrosoŵia results iŶ a loǁer ŵeaŶ ďirthǁeight, aŶd feǁer 
birth fractures and shoulder dystocia... [the] trials included in the review suggest that to prevent one 
fracture it would be necessary to induce labour in 60 women. Since induction of labour does not appear 
to alter the rate of caesarean delivery or instrumental delivery, it is likely to be popular with many 
women... the advantages and disadvantages of induction at or near term for fetuses suspected of 
being macrosomic should be discussed with parents. Although some parents and doctors may feel the 
evidence already justifies induction, others may justifiably disagree. Further trials of induction shortly 
ďefore terŵ for suspeĐted fetal ŵaĐrosoŵia are Ŷeeded.͟ 
 
Consistent with this recommendation, the HTA has funded an RCT [͞IŶduĐtioŶ of laďouƌ foƌ pƌediĐted 
ŵaĐƌosoŵia: the Big BaďǇ tƌial͟ ;I“‘CTNϭϴϮϮϵϴϵϮͿ]. Given the uncertainty in the evidence base, it is 
not possible to develop a robust management plan for management following diagnosis of 
macrosomia. For the purposes of the Markov chain modelling and health economic analysis, we 
addressed this uncertainty by comparing multiple strategies, including expectant management, early 
term IOL and planned caesarean delivery. The effects in relation to IOL were taken from the Cochrane 
review, as this was assessed as the highest quality evidence available at the time of writing. About 
70% of the women came from a single trial98 where the most common week for IOL was 38wkGA. 
Other parameters for the modelling and health economic analysis were obtained from the 
observational literature and are detailed in the chapters below. A summary management plan is 
outlined in the figure below. 
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Figure 11. Summary of management plan following 36wkGA scan. 
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Chapter 11. Economic analysis of universal versus selective ultrasound screening in late stage 
pregnancy: cost-effectiveness and value of information analyses. 
 
Introduction 
This study was commissioned to evaluate the current evidence base as to the costs and effectiveness 
of performing a routine ultrasound scan in late pregnancy in all nulliparous women combined with 
appropriate management plans, to identify evidence gaps, and to predict whether future research to 
plug those gaps is likely to be a cost-effective use of healthcare resources. In this analysis, we use 
decision modelling to assess the likely outcomes from universal ultrasound screening and determine 
whether its potential benefits can be clinically and economically justified. 
 
We present a cost utility analysis focusing on three of the main conditions detectable by ultrasound 
screening that may warrant intervention: breech presentation, SGA and LGA. The cost-effectiveness 
of universal ultrasound screening for each of these conditions individually has been explored 
previously.10, 150 However, here we evaluate the cost-effectiveness of screening for all of these 
conditions at the same screening session. Furthermore, we use decision uncertainty to predict the 
expected return on further research. We have applied the simplified management plan outlined above 
(Figure 11). In essence, women are first assessed for presentation. Where the baby is in a breech 
presentation ECV is offered. If successful, the woman reverts to expectant management and, if 
unsuccessful, is delivered by planned caesarean. Where the baby is in a cephalic presentation and the 
estimated fetal weight is in the normal range, the woman receives expectant management. If the baby 
is either SGA or LGA, IOL is offered. However, we also compare combined assessment for presentation 
and fetal biometry with a scan simply for presentation. The rationale for this is that a presentation 
scan may be readily implemented and relatively inexpensive, and there is much less uncertainty about 
the utilitǇ of kŶoǁiŶg the ďaďǇ͛s pƌeseŶtatioŶ ǀeƌsus estiŵatiŶg the ďaďǇ͛s size. 
 
The structure of this Đhapteƌ is as folloǁs: uŶdeƌ ͚Methods͛, ǁe fiƌst iŶtƌoduĐe the geŶeƌal 
methodology for our economic evaluation. We then summarise the clinical definitions used, as well 
as the competing strategies evaluated in this study before introducing the structure of the economic 
simulation model underlying the analysis. Once the model structure and mechanics have been 
explained, we discuss how we populated the model with the best available data; complete technical 
details regarding how individual parameters were derived is presented in Appendix 7. Finally, we 
describe the base case analyses, sensitivity analyses and value of information analysis (VOI) to guide 
how future research in this area should be prioritized. 
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UŶdeƌ ͚‘esults͛, ǁe fiƌst pƌeseŶt the ƌesults foƌ the baseline economic evaluation, and sensitivity 
analsyses. The results from the VOI analysis are then presented: these include the results for the 
expected value of perfect information (EVPI), the expected value of partial perfect information 
(EVPPI), and finally the expected value of sample information (EVSI). 
 
UŶdeƌ ͚DisĐussioŶ͛, ǁe suŵŵaƌise keǇ fiŶdiŶgs, eǆplaiŶ the iŶteƌpƌetatioŶ of ouƌ ƌesults, aŶd disĐuss 
what impact our methodological limitations may have had upon the results. 
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Methods 
To compare long-term health and cost outcomes associated with different strategies of screening in 
third-trimester pregnancy, we constructed an economic simulation model. We focused the model 
upon two features for which late-pregnancy ultrasound is amenable to detect: fetal presentation and 
fetal size. We used a decision tree model, consisting of four sub-trees, one each for breech 
presentation, LGA, SGA, and AGA. The model structure is largely based upon previous economic 
analyses of screening for these conditions individually, and the development and key characteristics 
of these sub-models models have previously been described10, 150; a brief summary is provided in 
Appendix 6. The previous chapters dealt with the diagnostic effectiveness of ultrasound in this setting 
and outlined how a positive result on scan could influence subsequent care. This chapter focuses on 
how these sub-models were incorporated into a joint framework, enabling cost-effectiveness analysis 
of simultaneous screening for all of these conditions. 
 
Scope and population 
The analysis relates to nulliparous women in England with singleton pregnancies, excluding those 
opting for elective CS for any reason except following a diagnosis of breech presentation. The 
economic analysis uses a public sector perspective defined as NHS and special educational needs 
costs.  Outcomes are from the perspective of the foetus/infant. 
 
Comparators and interventions 
This analysis evaluated three different strategies for ultrasound screening in late pregnancy, defined 
as a scan between 36+0 weeks aŶd ϯϲ+ϲ ǁeeks. ͚ “eleĐtiǀe U“͛ ;i.e. ǁheƌe ultƌasouŶd is oŶlǇ peƌfoƌŵed 
following clinical indication of its need) is the current standard in England.146 ͚UŶiǀeƌsal U“ foƌ fetal 
size͛ ǁould ŵeaŶ ƌoutiŶelǇ offeƌiŶg a thiƌd-trimester ultrasonic assessment of fetal weight in every 
pregnancy. Given the simplicity of detecting fetal presentation during an ultrasound scan, such a 
sĐƌeeŶiŶg stƌategǇ ǁould also ideŶtifǇ ďƌeeĐh pƌeseŶtatioŶ. A thiƌd optioŶ ǁould ďe to offeƌ ͚UŶiǀeƌsal 
U“ foƌ pƌeseŶtatioŶ oŶlǇ͛, i.e. a siŵpleƌ U“ sĐaŶ ǁith the sole puƌpose of deteĐtiŶg pƌegŶaŶĐies ǁith 
breech presentation. Compared to a standard antenatal ultrasound for which, typically, multiple 
measurements are made, an ultrasound scan for fetal presentation alone is technically simple. We 
theorised that such a scan could be provided by an attending midwife in conjunction with a standard 
antenatal visit in primary care, using basic ultrasound equipment. 
 
We assumed that all identified cases of breech presentation would be offered an ECV unless 
contraindicated, in line with RCOG guidelines.151 We further assumed that pregnancies identified as 
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SGA (whether correctly diagnosed or not) would be given early IOL. However, for pregnancies 
diagnosed as LGA, there is uncertainty as to whether intervention (IOL) is beneficial. For this reason, 
expectant management of suspected LGA pregnancies was also an option. We had previously 
considered also including elective CS for management of macrosomia, however ruled this out because 
it was inferior to IOL in our cost-effectiveness analysis of ultrasound assessment for macrosomia 
alone.150 This conclusion was consistent with a previous decision model analysis.152 We therefore 
compare six discrete strategies in the analysis (Table 9). 
 
We assume that selective scanning (i.e. only where clinically indicated) with a policy of offering ECV 
for suspicion of breech, and IOL for suspicion of SGA or LGA (strategy 2, Table 9) represents an 
approximation of the status quo from which estimates of incremental net benefit are calculated. 
 
Table 9. Comparator strategies for economic simulation model  
Strategy Screen Offered management if diagnosed: 
  Breech+ Macrosomia+ SGA+ 
1 Selective ECV IoL IoL 
2 Selective ECV Exp IoL 
3 Breech only ECV IoL IoL 
4 Breech only ECV Exp IoL 
5 Universal ECV IoL IoL 
6 Universal ECV Exp IoL 
ECV = External cephalic version; Exp = Expectant management; IoL = Induction of labour; LGA = Large 
for gestational age; SGA = Small for gestational age 
 
As discussed in the preceding chapters there is more uncertainty in relation to the management of 
LGA than SGA. However, performing fetal biometry will yield a percentile of EFW hence a scan 
involving fetal biometry can yield three possible outcomes: AGA, SGA or LGA. Consequently, we 
considered two possible approaches to screening involving fetal biometry. Both included IOL for SGA. 
However, one also included induction for LGA whereas the other dictated expectant management, 
given the uncertainty. 
 
 
 
Outcomes 
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In the absence of any trials on third-trimester screening strategies with long enough follow-up, we 
could not directly estimate long-term health outcomes as a function of screening strategies alone 
(hence the need for this modelling study). Instead, we simulated outcomes at delivery (survival and 
different levels of neonatal complications/morbidity), and then simulated long-term health outcomes 
as a function of these short-term outcomes. Overall health gain was captured as QALYs153 accrued to 
the infant. Overall costs for each screening strategy included the cost of the ultrasound scanning, 
possible intervention, delivery episode, neonatal care and mortality, and long-term care.  
 
Model structure 
As stated, the model structure is a decision tree. It was coded in R154(R Core Team, 2017), using 
packages: 'BCEA', 'FinCal', 'ggplot2', 'gtools', 'readxl', 'tidyr', and 'SAVI'.155-161 The code for the model is 
available from the corresponding author upon request. 
 
Figure 12 shows the structure of the first stages of the decision model. The [ + ] indicates branches 
which are collapsed for clarity. Nodes are named to show their relationship to one another: nodes 
with the same letter have identical structures to the branches of the tree beyond, whilst a different 
number and/or lower case letter indicates a different set of probabilities. The prefixes B_, L_ and S_ 
denote nodes with probability sets specific to either breech, large or small for gestational age babies 
respectively.  
 
At commencement, the scan policy can be set to either selective (i.e. status quo), a universal scan for 
presentation only, or universal scan for fetal biometry and presentation. The model structure is 
identical for each case. The difference is the sensitivity and specificity of the scanning policies, and 
their cost. 
 
A pregnancy will be either in a breech or cephalic presentation (node A1), or be either LGA, SGA, or 
AGA (node A2). For ease of modelling we assume all four possibilities are mutually exclusive and 
structure hierarchically, beginning with presentation (breech or cephalic), and then fetal size (LGA, 
SGA, AGA). The implications of this are considered in the discussion. The probability of being in breech 
is the prevalence of breech at the time of screening (approximately 4.6%).10 If the scan policy is 
universal ultrasound (whether for fetal biometry or presentation only), then, given the ease of 
interpretation of such a scan, we assume all breeches are detected (i.e. 100% sensitivity and 
specificity, node B_B). However, under the selective scan policy, approximately 45% of breeches will 
be undetected10 due to the mother not having undergone a scan at all (for consistency with the rest 
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of the ŵodel ǁe laďel these ͚false Ŷegatiǀes͛Ϳ. Further outcomes relating to breech presentation are 
desĐƌiďed ďeloǁ ;seĐtioŶ ͚outĐoŵes ƌelatiŶg to ďƌeeĐh͛Ϳ. 
 
If the baby has cephalic presentation, it may be LGA, SGA or AGA. The probabilities of each are the 
prevalence of the conditions (node A2, by definition 10% for each). If a baby is LGA or SGA, the 
probability of detection is a function of the sensitivity of the scanning policy (nodes L_B and S_B, LGA: 
26.55% under selective and presentation only scan policies, 37.85% under universal scan for fetal 
size.135 SGA: 19.6% under selective and presentation only scan, 56.53% under universal scan for fetal 
size7). The sensitivity and specificity of ultrasound to detect SGA and LGA were derived from the POP 
study7, 135. The rationale for using the POP study values is that it was conducted in the English NHS, it 
involved nulliparous women being scanned at 36 weeks, it is the only level 1 study of the diagnostic 
effectiveness of ultrasound to predict SGA and LGA (i.e. where the test result was blinded) and the 
values of sensitivity and specificity for SGA were similar to a 2019 Cochrane review of diagnostic test 
accuracy22 and the DOR from the POP study for macrosomia was identical to the DOR in the meta-
analysis presented in Chapter 8 of this report. 
 
If an LGA baby is correctly diagnosed positive for LGA, the pregnancy is managed according to the 
defined LGA policy; either IOL oƌ eǆpeĐtaŶt ŵaŶageŵeŶt ;Ŷode ͚ MGT_LGA_TP͛Ϳ, iŶ eitheƌ Đase leadiŶg 
to either vaginal delivery or emergency CS (nodes L_C3 and L_C2a, odds ratio of EmCS, compared with 
otherwise healthy baby, 1.79141. If an LGA baby is misdiagnosed as AGA (i.e. false negative scan), 
delivery can be either vaginal or emergency CS. Further outcomes relating to LGA pregnancies are 
desĐƌiďed ďeloǁ ;seĐtioŶ ͚outĐoŵes ƌelatiŶg to LGA͛Ϳ. 
 
If the baby is SGA and is correctly diagnosed, the pregnancy is induced, leading to either vaginal 
delivery or emergency CS (node S_C3). False negatives may lead to vaginal delivery or emergency CS 
;Ŷode “_CϮͿ. Fuƌtheƌ outĐoŵes ƌelatiŶg to “GA pƌegŶaŶĐies aƌe desĐƌiďed ďeloǁ ;seĐtioŶ ͚outĐoŵes 
ƌelatiŶg to “GA͛Ϳ. 
 
An AGA baby may be misdiagnosed as SGA or LGA (false positive SGA and LGA respectively), or 
correctly diagnosed as AGA (node B). A false positive SGA baby will be induced unnecessarily, leading 
to either vaginal delivery or emergency CS (node S_C4). A false positive LGA baby will be managed 
according to the defined LGA policy; either IOL oƌ eǆpeĐtaŶt ŵaŶageŵeŶt ;Ŷode ͚MGT_LGA_FP͛Ϳ. IOL 
and expectant management can either lead to spontaneous vaginal or emergency CS deliveries (nodes 
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L_C4 and L_C1 respectively). Finally, a correctly diagnosed AGA baby (true negative) can undergo 
vaginal delivery or emergency CS (node C1). 
 
Short- and long-term outcomes 
For all parts of the model, different levels of neonatal morbidity and mortality are possible, although 
these outĐoŵes aƌe stƌuĐtuƌed slightlǇ diffeƌeŶtlǇ ďetǁeeŶ the ŵodel͛s suď-trees. For the breech, SGA 
and AGA models, delivery outcomes include no, moderate, and severe neonatal morbidity, as well as 
perinatal death. The risks of each level of adverse outcome differ between specific branches, i.e. is 
affected by the true status of the baby, the mode of delivery, and whether labour was induced early. 
Long-term outcomes are then modelled as a function of the level of neonatal morbidity at delivery. 
For the LGA model, delivery and long-term outcomes are modelled differently. This is explained in 
detail ďeloǁ ;seĐtioŶ ͚outĐoŵes ƌelatiŶg to LGA͛Ϳ. 
 
Long-teƌŵ outĐoŵes iŶĐlude ͚No loŶg-teƌŵ ĐoŵpliĐatioŶs͛, ͚“peĐial eduĐatioŶal Ŷeeds͛, ͚“eǀeƌe 
neurological ŵoƌďiditǇ͛, aŶd ͚ ŶeoŶatal/iŶfaŶt ŵoƌtalitǇ͛. The ƌisk of loŶg-term complications increases 
with the level of neonatal morbidity (nodes E1, E2, and E3). Unlike delivery outcomes, long-term 
outcomes are not affected by the actual status of the baby prior to delivery, only by the level of 
neonatal morbidity at delivery. Importantly, this means that all screening and management options 
only affect long-term outcomes indirectly, through their impact upon the outcomes at delivery. 
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Figure 12. Model overview. 
 
[+] = sub-branches of model collapsed for clarity. 
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Outcomes relating to breech 
Figure 13 shows the decision tree with outcomes relevant to breech expanded and remaining 
branches collapsed. The prevalence of breech refers to the fetal presentation at the time of screening. 
We assume that sensitivity and specificity for universal ultrasound is perfect at detecting fetal 
presentation, whether for size or breech presentation only. For selective ultrasound, the sensitivity is 
lower since not all women receive US screening, however, we assume that all cases of suspected 
breech presentation would be either confirmed or rejected through US, so that false positive diagnosis 
is not an option (i.e. perfect specificity).  
 
On diagnosis of a breech, ECV is offered (node B_ECV). If the ECV is successful (node B_ECVs) and the 
infant remains cephalic (node B_ECVs_rb), no further intervention will be offered (i.e. expectant 
management). However, the baby may spontaneously revert back to breech (node B_ECVs_rb). In 
either case, there is a probability of emergency CS, which is increased if the baby has reverted to 
breech presentation (nodes B_C3b and B_C3a respectively). If a breech presentation is not diagnosed 
prior to labour, delivery options include breech vaginal delivery or emergency CS (node B_C2). 
 
Following labour and delivery there is a risk of either no, moderate or severe neonatal complications 
or perinatal death (node D1), subsequently leading to no long-term complications, special educational 
needs, severe neurological morbidity or perinatal mortality (node E1). Note we assume no raised risk 
of neonatal morbidity associated with cephalic emergency CS versus cephalic vaginal delivery per se. 
We do however allow for a raised risk of complications with an emergency CS following breech 
compared with a vaginal breech delivery (nodes B_D2a and B_D2c). If ECV is not accepted, or fails, 
then elective CS may be offered.
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Figure 13. Outcomes associated with breech. 
 
[+] indicates collapsed sections of the decision tree 
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Outcomes relating to LGA 
Figure 14. Outcomes associated with LGA. shows the decision tree with outcomes relevant to LGA 
expanded and remaining branches collapsed. Where LGA is suspected, intervention will be given 
according to the pre-determined management strategy (IOL or expectant management), both for true 
positive and false positive LGA diagnosis. The management option will affect the likelihood of both 
the delivery outcome, as well as the mode of delivery, which can be either vaginal or through 
emergency CS. Where LGA is not suspected, delivery can be either vaginal or through emergency CS.  
 
DeliǀeƌǇ outĐoŵes iŶĐlude ͚No ĐoŵpliĐatioŶs͛, ͚‘espiƌatoƌǇ ŵoƌďiditǇ͛, ͚“houldeƌ dǇstoĐia͛, ͚Otheƌ 
aĐidosis͛ ;i.e. aĐidosis Ŷot Đaused ďǇ shouldeƌ dǇstoĐiaͿ, aŶd ͚peƌiŶatal death͛. The ƌisk of eaĐh adǀeƌse 
outcome depends on the baseline risk, as well as on the mode of delivery, and whether labour was 
induced early. 
 
Long-teƌŵ outĐoŵes depeŶd oŶ the outĐoŵe at deliǀeƌǇ. Foƌ ͚No ĐoŵpliĐatioŶs͛, ͚‘espiƌatoƌǇ 
morbiditǇ͛, aŶd ͚Otheƌ aĐidosis͛, loŶg-teƌŵ outĐoŵes iŶĐluded ͚No loŶg-teƌŵ ĐoŵpliĐatioŶs͛, ͚“peĐial 
eduĐatioŶal Ŷeeds͛ ;“ENͿ, ͚“eǀeƌe ŶeuƌologiĐal ŵoƌďiditǇ͛, aŶd ͚ŶeoŶatal/iŶfaŶt ŵoƌtalitǇ͛. Foƌ ͚No 
long-teƌŵ ĐoŵpliĐatioŶs͛ the ƌisk ǁas eƋuiǀaleŶt to ͚No ŶeoŶatal ŵoƌďiditǇ͛ ;Ŷode EϭͿ, ǁheƌeas foƌ 
͚‘espiƌatoƌǇ ŵoƌďiditǇ͛, aŶd ͚Otheƌ aĐidosis͛, the ƌisk of loŶg-term complications were equivalent to 
͚“eǀeƌe ŶeoŶatal ŵoƌďiditǇ ;Ŷode EϯͿ. “houldeƌ dǇstoĐia ;Ŷode L_EϭͿ Đould ƌesult iŶ eitheƌ Ŷo 
complications, brachial plexus injury (BPI, node L_F1), or acidosis. BPI could be either transient or 
permanent (node L_G), where the latter had the same risk of long-term outcomes as for no neonatal 
morbidity (node E1), but with a penalty for quality of life. Permanent BPI, special education needs, 
and severe neurological morbidity were long-term events; any other morbidity was expected to be 
resolved within the first year of life. 
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Figure 14. Outcomes associated with LGA. 
 
[+] indicates collapsed sections of the decision tree
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Outcomes relating to SGA 
Figure 15 shows the decision tree with outcomes relevant to SGA expanded and remaining branches 
collapsed. Labour will be induced early for suspected cases of SGA, whether based upon a true or false 
SGA diagnosis. Deliveries can either be vaginal or through emergency CS. The probability of each mode 
of delivery is affected by whether or not labour was induced early. However, in order to avoid double 
counting the health effects of early labour induction, the mode of delivery affects only costs and not 
health outcomes. 
 
Delivery outcomes include no, moderate, and severe neonatal morbidity, as well as perinatal death. 
The correctly diagnosed SGA pregnancies (true positives) are offered early IOL, which reduces the risk 
of morbidity and mortality. Where SGA is unsuspected (false negatives), pregnancies are managed 
expectantly, with no risk reduction. Note that early labour induction may also increase the risk of 
morbidity if initiated needlessly, i.e. in an AGA pregnancy falsely suspected of being SGA. However, in 
a true SGA pregnancy, early labour induction is expected to reduce the risk of morbidity. The scenario 
ǁith a false positiǀe diagŶosis is disĐussed fuƌtheƌ ďeloǁ ;seĐtioŶ ͚outĐoŵes ƌelatiŶg to AGA͛Ϳ. 
 
Long-teƌŵ outĐoŵes iŶĐlude ͚No loŶg-teƌŵ outĐoŵes͛, ͚“peĐial eduĐatioŶal Ŷeeds͛ ;“ENͿ, ͚“eǀeƌe 
ŶeuƌologiĐal ŵoƌďiditǇ͛ ;“NMͿ, aŶd ͚ŶeoŶatal/iŶfaŶt ŵoƌtalitǇ͛. EaĐh outĐoŵe is possiďle foƌ all leǀels 
of neonatal morbidity. However, the risk of long-term complications increases for moderate and 
severe neonatal morbidity (nodes E2 and E3).
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Figure 15. Outcomes associated with SGA. 
 
[+] indicates collapsed sections of the decision tree
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Outcomes relating to AGA 
Figure 16 shows the decision tree with outcomes relevant to AGA expanded and remaining branches 
collapsed. An AGA pregnancy may either be correctly diagnosed, or incorrectly diagnosed as either 
SGA or LGA (node B). If correctly diagnosed, the mode of delivery can either be vaginal or emergency 
CS (node C1), after which short-and long-teƌŵ outĐoŵes ǁill folloǁ as desĐƌiďed aďoǀe ;seĐtioŶ ͚ “hoƌt- 
and long-teƌŵ outĐoŵes͛Ϳ. 
 
If an AGA pregnancy is falsely diagnosed as SGA, early IOL is offered. Unlike for true SGA, early labour 
induction of AGA pregnancies increases the risk of morbidity; however, the risk of perinatal death is 
still reduced.162 Short- and long-teƌŵ outĐoŵes ǁill theŶ folloǁ as desĐƌiďed aďoǀe ;seĐtioŶ ͚“hoƌt- 
and long-teƌŵ outĐoŵes͛Ϳ. If iŶstead, aŶ AGA pƌegŶaŶĐǇ is ŵisdiagŶosed as LGA, the shoƌt-and long-
term outcomes depend on the management strategy. Compared to expectant management, early IOL 
decreases the risk of emergency CS and perinatal death, but increases the risk of neonatal morbidity. 
 
Just as for other branches of the model, long-teƌŵ outĐoŵes iŶĐlude ͚No loŶg-term outĐoŵes͛, ͚SEN͛, 
͚SNM͛, aŶd ͚NeoŶatal ŵoƌtalitǇ͛. EaĐh outĐoŵe is possiďle foƌ all leǀels of ŶeoŶatal ŵoƌďiditǇ, 
however, the risk of long-term complications increases for moderate and severe neonatal morbidity 
(nodes E2 and E3).
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Figure 16. Outcomes associated with AGA. 
 
[+] indicates collapsed sections of the decision tree
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Data 
We populated the model with data from multiple sources from the literature. Where possible, we 
prioritised inclusion of good quality systematic reviews and meta-analyses, followed by large, good 
quality clinical trials or cohort studies as appropriate. Where there was no objective evidence for a 
parameter we relied on expert opinion either to judge whether a study in a related area provided a 
sufficient proxy, or to provide a central estimate and credible interval representing beliefs about 
plausible values for the parameter. Data sources were subjectively graded as high, moderate or low, 
where high represented directly relevant data (i.e. providing the required parameter) from a good 
quality source (e.g. RCT for relative effects and high quality epidemiological study for baseline risks). 
A low grade represents situations where evidence on the required parameter was absent from the 
literature and so are sourced from a related parameter, used as indirect evidence and revised 
reflecting expert opinion as to the plausible values. Full details of the derivation of model inputs is in 
Appendix 7 (Tables 25-30), and all parameters are listed in Table 10, Table 11 and Table 12.
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Table 10. Model inputs for diagnostic performance. 
Parameter Mean 95%CI 
Distribution 
summary 
Node Source 
Quality of 
evidence 
Prevalence of breech 4.60% 3.98%, 5.30% ~B(179, 3700) A1 Wastlund et al.
10 H 
Prevalence of LGA 10.00% 10%, 10% N/A A2 By definition H 
Prevalence of SGA 10.00% 10%, 10% N/A A2 By definition H 
Selective US             
Specificity SGA - Selective US 98.10% 97.63%, 98.52% ~B(3556, 69) B Sovio et al. (2015)
7 H 
Specificity LGA – Selective US 98.67% 98.28%, 99.02% ~B(3640, 49) B Sovio et al. (2018)135 H 
Sensitivity SGA - Selective US 19.60% 15.63%, 23.90% ~B(69, 283) S_B Sovio et al. (2015)
7 H 
Sensitivity LGA - Selective US 26.55% 20.33%, 33.28% ~B(47, 130) L_B Sovio et al. (2018)
135 H 
Sensitivity breech – selective US 45.10% 37.85%, 52.54% ~B(79, 96) B_B Wastlund et al.10 H 
Universal US for fetal size and presentation       
Specificity SGA - Universal US 89.99% 88.99%, 90.94% ~B(3262, 363) B Sovio et al. (2015)
7 H 
Specificity LGA – Universal US 96.56% 95.95%, 97.12% ~B(3562, 127) B Sovio et al. (2018)135 H 
Sensitivity SGA - Universal US 56.53% 52.33%, 61.67% ~B(199, 153) S_B Sovio et al. (2015)
7 H 
Sensitivity LGA - Universal US 37.85% 30.87%, 45.10% ~B(67, 110) L_B Sovio et al. (2018)
135 H 
Sensitivity breech – Universal US 100% 100%, 100% N/A B_B Assumption N/A 
Universal US for fetal presentation only             
Specificity SGA - Positioning scan 98.10% 97.63%, 98.52% ~B(3556, 69) B Sovio et al. (2015)
7 H 
Specificity LGA – Positioning scan 98.67% 98.28%, 99.02% ~B(3640, 49) B Sovio et al. (2018)135 H 
Sensitivity SGA - Positioning scan 19.60% 15.63%, 23.90% ~B(69, 283) S_B Sovio et al. (2015)
7 H 
Sensitivity LGA - Positioning scan 26.55% 20.33%, 33.28% ~B(47, 130) L_B Sovio et al. (2018)
135 H 
Sensitivity breech – Positioning scan 100% 100%, 100% N/A B_B Assumption N/A 
 
a B = Beta distribution 
b Quality assessment: High – good quality directly relevant evidence (e.g. directly relevant population, well conducted RCT for relative effects, or cohort for 
baseline effects). Med – directly relevant evidence but poorer quality source (e.g. retrospective cohort for relative treatment effect) Low – lack of direct evidence 
  
101 
 
/ informed by expert opinion. Direct = source provides required parameter. Indirect = source provides related parameter used as background evidence to inform 
expert opinion. Note the same source may be used in different contexts, therefore resulting in a different relevance rating to inform different parameters. 
LGA = Large for gestational age; SGA = Small for gestational age; US = Ultrasound 
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Probabilities 
Where possible probabilities were expressed as a baseline (beta or Dirichlet) for an otherwise healthy 
baby (i.e. neither breech nor LGA nor SGA), which were then modified by odds ratios or relative risks, 
depending on the statistic either reported in, or calculable from, the literature. Odds ratios were 
selected in preference to risk ratios, as these are independent of the baseline risk. Where no relative 
quantities were identified in the literature, probabilities are reported as independent beta 
distributions. Sampled values for probabilities were inspected to ensure they were bounded between 
[0,1]. Where out of range values were sampled, resampling was repeated until within-bounds values 
were generated. 
 
Where relative effects were expressed as means and 95% CI, standard error of the log of the mean 
was estimated by dividing the absolute difference between the log mean and log lower or upper 95% 
confidence interval by 1.96.
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Table 11. Model inputs for probabilities.  
Parameter Mean 95%CI 
Distribution 
summary 
Node Source 
Quality of 
evidence 
Mode of delivery       
EmCS delivery | AGA and Exp Mgt 20.70% 19.4%, 22.06% ~B(735, 2813) C1 Wastlund et al.10 H 
RR EmCS delivery | SGA and Exp Mgt [FN] vs. C1 1.9 1.4, 2.5 ~LN(0.642, 0.14) S_C2 Monier et al.21 M 
RR EMCS | induced, SGA [TP] vs. C1 2.9 1.8, 4.7 ~LN(1.065, 0.246) S_C3 Monier et al.21 L 
RR EMCS | induced, AGA, [FP SGA] vs. C1 0.84 0.76, 0.93 ~LN(-0.174, 0.052) C4 Grobman et al.148 H 
OR of EmCS delivery | LGA and Exp Mgt [FN] vs. C1 1.792 0.718, 4.471 ~LN(0.583, 0.466) L_C2 Blackwell et al.141 M 
OR of EmCS delivery | LGA and Induce [TP] vs. L_C2 0.92 0.85, 0.99 ~LN(-0.083, 0.037) L_C3 Middleton et al.15 L 
EmCS delivery | Breech and Exp Mgt [FN] 57.69% 
38.67%, 
75.62% 
~B(15, 11) B_C2 Leung et al.163 M 
EmCS delivery | breech, ECV success, remain cephalic 27.27% 6.69%, 55.64% ~B(3, 8) B_C3a Wastlund et al.10 H 
EmCS delivery | breech, ECV success, revert breech 57.69% 
38.67%, 
75.62% 
~B(15, 11) B_C3b Leung et al.163 M 
Vaginal delivery | breech, ECV fail, revert cephalic 52.38% 
31.51%, 
72.80% 
~D(11, 1, 9) B_C3c Wastlund et al.10 H 
ELCS delivery | breech, ECV fail, revert cephalic 4.76% 0.13%, 16.84% - B_C3c Wastlund et al.10  
EmCS delivery | breech, ECV fail, revert cephalic 42.86% 
23.07%, 
63.97% 
- B_C3c Wastlund et al.10  
Vaginal delivery | breech, ECV fail, remain breech 0% 0%, 0% ~D(0, 54, 18) B_C3d Wastlund et al.10 H 
ELCS delivery | breech, ECV fail, remain breech 75% 
64.47%, 
84.22% 
- B_C3d Wastlund et al.10  
EmCS delivery | breech, ECV fail, remain breech 25% 
15.78%, 
35.53% 
- B_C3d Wastlund et al.10  
Vaginal delivery | breech, no ECV, revert cephalic 52.38% 
31.51%, 
72.80% 
~D(11, 1, 9) B_C3e Wastlund et al.10 H 
ELCS delivery | breech, no ECV, revert cephalic 4.76% 0.13%, 16.84% - B_C3e Wastlund et al.10  
EmCS delivery | breech, no ECV, revert cephalic 42.86% 
23.07%, 
63.97% 
- B_C3e Wastlund et al.10  
Vaginal delivery | breech, no ECV, remain breech 0% 0%, 0% ~D(0, 52, 20) B_C3f Wastlund et al.10 H 
ELCS delivery | breech, no ECV, remain breech 72.22% 
61.38%, 
81.88% 
- B_C3f Wastlund et al.10  
EmCS delivery | breech, no ECV, remain breech 27.77% 
18.12%, 
38.62% 
- B_C3f Wastlund et al.10  
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External cephalic version       
ECV attempted 47.46% 
40.16%, 
54.81% 
~B(84, 93) B_ECV Wastlund et al.10 H 
ECV not attempted, spontaneous reversion to cephalic 22.58% 
14.72%, 
31.56% 
~B(21, 72) B_noECV_rc Wastlund et al.10 H 
Probability ECV successful 14.29% 7.70%, 22.48% ~B(12, 72) B_ECVs Wastlund et al.10 H 
Probability of reverting to breech post successful ECV 8.33% 0.23%, 28.49% ~B(1, 11) B_ECVs_rb Wastlund et al.10 H 
Probability of spontaneous revesion to cephalic post ECV failure 2.31% 0.48%, 5.49% ~B(3, 127) B_ECVf_rc Ben-Meir et al.164 H 
Outcomes for LGA model       
Respiratory morbidity, baseline 0.32% 0.20%, 0.46% ~B(22, 6933) - Morrison et al.165 H 
Shoulder dystocia, baseline 0.63% 0.60%, 0.66% ~B(1686, 265542) - Ouzounian et al.166 M 
Other acidosis, baseline 0.68% 0.22%, 1.40% ~B(5, 726) - Middleton et al.15 H 
Perinatal mortality, baseline 0.155% 
0.145%, 
0.165% 
~B(984, 634412) - Moraitis et al.51 M 
RR respiratory morbidity, LGA vs. AGA [FN & ExpMan LGA policy] 0.75 0.5125, 0.9875 ~U(0.5, 1) L_D2a Expert opinion L 
OR shoulder dystocia, LGA vs. AGA [FN & ExpMan LGA policy] 7.18 2.06, 25.00 ~LN(1.971, 0.637) L_D2a Rossi et al.167 H 
OR other acidosis, LGA vs. AGA [FN & ExpMan LGA policy] 2.88 1.34, 6.22 ~LN(1.058, 0.393) L_D2a Rossi et al.167 M 
OR perinatal mortality, LGA vs. AGA [FN & ExpMan LGA policy] 1.77 0.30, 10.34 ~LN(0.571, 0.901) L_D2a Rossi et al.167 M 
OR respiratory morbidity, LGA vs. AGA, EMCS [FN & ExpMan LGA policy] 5.33 3.50, 7.40 ~LN(1.674, 0.167) L_D2c Morrison et al.165 H 
P shoulder dystocia, LGA, EMCS [FN & ExpMan LGA policy] 0 0, 0 N/A L_D2c Assumption H 
OR other acidosis, LGA, EMCS [FN & ExpMan LGA policy] 1.867 1.217, 2.865 ~LN(0.625, 0.218) L_D2c Chongsuvivatwong et al.168 M 
OR perinatal mortality, LGA, EMCS [FN & ExpMan LGA policy] 1.781 1.266, 2.505 ~LN(0.577, 0.174) L_D2c Chongsuvivatwong et al.168 M 
OR respiratory morbidity, LGA, Induction of labour, vaginal delivery [TP] 0.54 0.373, 0.783 ~LN(-0.616, 0.19) L_D3a Gibson et al.169 M 
RR shoulder dystocia, LGA, Induction of labour, vaginal delivery [TP] 0.6 0.37, 0.98 ~LN(-0.511, 0.25) L_D3a Boulvain et al.98 M 
RR acidosis, LGA, Induction of labour, vaginal delivery [TP] 1.66 0.61, 4.55 ~LN(0.507, 0.514) L_D3a Middleton et al.15 M 
RR perinatal mortality, LGA, Induction of labour, vaginal delivery [TP] 0.33 0.14, 0.78 ~LN(-1.109, 0.439) L_D3a Middleton et al.15 M 
OR respiratory morbidity, LGA, Induction of labour, EmCS [TP] 0.54 0.373, 0.783 ~LN(-0.616, 0.19) L_D3c Gibson et al.169 M 
P shoulder dystocia, LGA, Induction of labour, EmCS [TP] 0 0, 0 N/A L_D3c Assumption H 
RR acidosis, LGA, Induction of labour, EmCS [TP] 1.66 0.61, 4.55 ~LN(0.507, 0.514) L_D3c Middleton et al.15 M 
RR perinatal mortality, LGA, Induction of labour, EmCS [TP] 0.33 0.14, 0.78 ~LN(-1.109, 0.439) L_D3c Middleton et al.15 M 
Risk of acidosis | shoulder dystocia 0.07 0.0630, 0.1112 ~B(36, 478) L_E1 MacKenzie et al.170 L 
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Risk of BPI | shoulder dystocia 0.0856 0.0496, 0.0936 ~B(44, 470) L_E1 MacKenzie et al.170 c L 
Risk of permanent BPI 0.055 0.024, 0.098 ~B(8, 137) L_F1 Sandmire et al.171 c M 
Neonatal morbidity       
Risk of moderate neonatal morbidity (AGA) [FP] 5.62% 0.0488, 0.0641 ~B(198, 3325) D1 The POP study c H 
Risk of severe neonatal morbidity (AGA) [FP] 0.62% 0.0039, 0.0091 ~B(22, 3501) D1 The POP study c H 
Risk of perinatal death (AGA) [FP] 0.155% 
0.145%, 
0.165% 
~B(984, 634412) D1 Moraitis et al.51 M 
OR moderate neonatal morbidity (SGA vs. AGA, ExpMan) 2.48 1.75, 3.51 ~LN(0.91, 0.18) S_D2 The POP Study c H 
OR severe neonatal morbidity (SGA vs. AGA, ExpMan) 1.88 0.65, 5.50 ~LN(0.63, 0.55) S_D2 The POP Study c H 
OR perinatal death (SGA vs. AGA, ExpMan) 4.39 3.84, 5.03 ~LN(1.48, 0.07) S_D2 Moraitis et al.51 H 
RR moderate morbidity | induce SGA vs. not inducing SGA [TP] 0.7 0.50, 0.98 ~LN(-0.357, 0.172) S_D3 Middleton et al.15 L 
RR severe morbidity | induce SGA vs. not inducing SGA [TP] 0.7 0.50, 0.98 ~LN(-0.357, 0.172) S_D3 Middleton et al.15 L 
RR perinatal death | induce SGA vs. not inducing SGA [TP] 0.33 0.11, 0.96 ~LN(-1.109, 0.553) S_D3 Middleton et al.15 L 
OR of moderate neonatal morbidity if induce | AGA [FP SGA or LGA] 1.92 1.71, 2.15 ~LN(0.652, 0.058) D4 Stock et al.162 H 
OR of severe neonatal morbidity if induce | AGA [FP SGA or LGA] 1.92 1.71, 2.15 ~LN(0.652, 0.058) D4 Stock et al.162 H 
OR of perinatal death if induce | AGA [FP SGA or LGA] 0.15 0.03, 0.68 ~LN(-1.897, 0.771) D4 Stock et al.162 H 
OR of moderate neonatal morbidity | 
vaginal breech vs. vaginal cephalic delivery 
6.70 5.9, 7.6 ~LN(1.902, 0.064) B_D2a Thorngren-Jerneck et al.172 H 
OR of severe neonatal morbidity | 
vaginal breech vs. vaginal cephalic delivery 
6.70 5.9, 7.6 ~LN(1.902, 0.064) B_D2a Thorngren-Jerneck et al.172 H 
OR of perinatal death | 
vaginal breech vs. vaginal cephalic delivery 
6.68 2.75, 16.22 ~LN(1.899, 0.453) B_D2a Moraitis et al.51 H 
RR of moderate morbidity | ELCS vs. vaginal breech delivery 0.43 0.12, 1.47 ~LN(-0.844, 0.627) B_D2b Hofmeyr et al.13 H 
RR of severe morbidity | ELCS vs. vaginal breech delivery 0.11 0.01, 0.87 ~LN(-2.207, 1.055) B_D2b Hofmeyr et al.13 H 
RR of perinatal death | ELCS vs. vaginal breech delivery  0.29 0.1, 0.86 ~LN(-1.238, 0.555) B_D2b Hofmeyr et al.13 H 
OR of moderate morbidity | EmCS vs. vaginal breech delivery 0.533 0.192, 1.482 ~LN(-0.629, 0.522) B_D2c Pasupathy et al.173 c M 
OR of severe morbidity | EmCS vs. vaginal breech delivery 0.533 0.192, 1.482 ~LN(-0.629, 0.522) B_D2c Pasupathy et al.173 c M 
OR of perinatal death | EmCS vs. vaginal breech delivery  0.533 0.192, 1.482 ~LN(-0.629, 0.522) B_D2c Pasupathy et al.173 c M 
Risk of long-term outcomes from neonatal morbidity       
Risk of SEN | no neonatal morbidity 0.0474 0.0467, 0.0480 ~B(18736, 376891) E1 MacKay et al.174 H 
Risk of neurological morbidity | no neonatal morbidity 0.0008 0.0007, 0.0008 ~B(906, 1193647) E1 Persson et al.175 H 
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Risk of neonatal/infant mortality | no neonatal morbidity 0.002 0.0020, 0.0021 ~B(2074, 1011289) E1 Iliodromiti et al.176 H 
OR of SEN | moderate neonatal morbidity 1.55 1.43, 1.67 ~LN(0.438, 0.038) E2 MacKay et al.174 H 
RR of neurological morbidity | moderate neonatal morbidity 10.4 7.8, 13.9 ~LN(2.34, 0.149) E2 Persson et al.175 H 
RR of neonatal/infant mortality | moderate morbidity 12.82 9.33, 17.61 ~LN(2.551, 0.162) E2 Iliodromiti et al.176 H 
OR of SEN | severe neonatal morbidity 1.66 1.46, 1.88 ~LN(0.507, 0.063) E3 MacKay et al.174 H 
RR of neurological morbidity | severe morbidity 145.5 104.0, 204.1 ~LN(4.98, 0.173) E3 Persson et al.175 H 
RR of neonatal/infant mortality | severe morbidity 60.61 48.17, 76.26 ~LN(4.104, 0.117) E3 Iliodromiti et al.176 H 
 
a Distributions: B = Beta, D = Dirichlet; LN = Log-normal, U = Uniform 
b Quality assessment: High – good quality directly relevant evidence (e.g. directly relevant population, well conducted RCT for relative effects, or cohort for 
baseline effects). Med – directly relevant evidence but poorer quality source (e.g. retrospective cohort for relative treatment effect) Low – lack of direct evidence 
/ informed by expert opinion. Direct = source provides required parameter. Indirect = source provides related parameter used as background evidence to inform 
expert opinion. Note the same source may be used in different contexts, therefore resulting in a different relevance rating to inform different parameters. 
c Parameter estimated based upon data from the source, rather than directly from the source. Details are provided in Appendix 7 (Tables 25-30). 
BPI = Brachial plexus injury, ECV = External cephalic version, ELCS = Elective Caesarean section, EmCS = Emergency Caesarean section, ExpMan = Expectant 
management, FN = False negative, FP = False positive, LGA = Large for gestational age, OR = odds ratio, RR = relative risk, SEN = Special educational needs, 
SGA = Small for gestational age, TP = True positive. 
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Costs 
The price year of the analysis is 2016/17. The majority of costs were sourced from the English national 
schedule of reference costs177. The national schedule of reference costs report different costs 
depending on how the service was delivered (e.g. elective inpatient, non-elective inpatient, outpatient 
procedures etc.). We used costs fƌoŵ total H‘G͛s ;i.e. ǁeighted ďǇ eaĐh ĐategoƌǇ ďǇ the Ŷuŵďeƌ of 
yearly activities), except for cases where only one or a few categories made logical sense. All 
categories in the schedule reports costs as mean and inter-quartile range. To obtain parameter 
estimates of costs, we fitted a gamma distribution using these data points. Where multiple cost 
categories were used, we first calculated a weighted average of the mean and inter-quartile range by 
the number of yearly activities in each category before fitting the gamma distribution. 
 
Where no directly applicable cost could be identified in the reference schedule, we first attempted to 
obtain resource usage from literature, and assign costs to these using the reference costs. Where 
insufficient data on resource usage were available, we adopted the costs directly from literature. Costs 
reported in currencies other than GBP or 2016/17 costs were converted to GBP at the exchange rate 
of the year that the source was published and inflated to 2016/17 prices using the hospital & 
community health services (HCHS) index.178 Where no credible estimates could be identified from 
literature, we estimated the costs ourselves assigning a wide credibility interval to represent the 
uncertainty. Full details on the derivation of all cost parameters is presented in Appendix 7.
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Table 12. Model inputs for costs and related probabilities. 
Parameter Mean 95%CI Distribution summary Node Source 
Quality of 
evidence 
Ultrasound scan £107.06 £70.98, 134.92 ~G(4.9604, 22.8062) A NHS reference costs 2016-17177 c H 
Positioning scan only £48.71 £8.96, 88.46 ~U(6.87, 90.55) A Expert opinion N/A 
Proportion scanned with US (selective screening) 0.3499 0.3349, 0.3650 ~B(1351, 2510) A Sovio et al.7 H 
Induction of labour (difference vs. normal delivery) £125 -£1343, 1594 ~N(125.3, 749.2) B1, B2 Vijgen et al.179 M 
Cost of vaginal (cephalic) delivery £1,834 £1750, 2236 ~G(7.2606, 252.5824) C1 – C4 NHS reference costs 2016-17177 c H 
Relative cost difference (vaginal breech vs. cephalic 
delivery) 
1.1633 1.0982, 1.2284 ~N(1.1633, 0.0332) 
B_C3b, 
B_C3d, B_C3f, 
B_C2,  
Palencia et al.180 M 
Cost of ECV £292.30 £287.5, 297.1 ~U(287.22, 297.38) B_ECV James et al.181 c M 
Cost of emergency Caesarean section £4,688 £3816, 5443 ~G(14.7329, 318.1354) C1 – C4 NHS reference costs 2016-17177 c H 
Cost of elective Caesarean section £3,412 £2680, 4038 ~G(11.1212, 307.0169) C1 - C4 NHS reference costs 2016-17177 c H 
Cost of Special Care Baby Unit admission £1,064 £487, 1862 ~G(9.0371, 117.7307) D1 - D4 NHS reference costs 2016-17177 c H 
Cost of Neonatal High Dependency Unit admission £1,346 £807, 2020 ~G(18.7696, 71.7047) D1 - D4 NHS reference costs 2016-17177 c H 
Cost of Neonatal Intensive Care Unit admission £2,590 £1280, 4352 ~G(10.7403, 241.0768) D1 - D4 NHS reference costs 2016-17177 c H 
Proportion of neonates admitted to SCBU 74% 65%, 82% ~D(74, 7, 19) D1 - D4 Alfirevic et al.182 M 
Proportion of neonates admitted to NHDU 7% 3%, 13% - D1 - D4 Alfirevic et al.182  
Proportion of neonates admitted to NICU 19% 12%, 27% - D1 - D4 Alfirevic et al.182  
Probability of admission to care | 
no neonatal morbidity 
0.074 0.066, 0.082 ~B(292, 3659) D1 - D4 Sovio et al.7 H 
Odds ratio of admission to care | 
Moderate neonatal morbidity 
11.29 5.90, 21.60 ~LN(2.424, 0.331) D1 - D4 Sovio et al.7 H 
Probability of admission to care | 
Severe neonatal morbidity 
1 1, 1 N/A D1 - D4 Assumption N/A 
Short-term cost of acidosis / anoxia £3,240 £806, 7328 ~G(3.6143, 895.6169) L_E1, L_D2a Own estimation c L 
Short-term cost of respiratory morbidity £2,011 £993, 3381 ~G(10.7125, 187.6316) L_D2a, L_D3a Own estimation c L 
Cost of transient BPI £2,066 £1033, 4132 ~LN(7.6334, 0.3536) L_F1 Culligan et al.183 M 
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Cost of permanent BPI £14,134 £7068, 28264 ~LN(9.5563, 0.03536) L_F1 Culligan et a.183 c M 
Cost of perinatal or infant mortality £1,664 £1372, 1956 ~U(1357, 1971) D1 & E1 – 3 Mistry et al.184 M 
Special educational needs (per annum) £7,428 £4467, 10389 ~N(7428.1, 1511) E1 – E3 Barrett et al.185 M 
Severe neurological morbidity (per annum) £2,930 £1465, 5859 ~LN(7.9826, 0.3536) E1 – E3 Access economics186 c M 
 
a Distributions: B = Beta, D = Dirichlet; G = Gamma, LN = Log-normal, N = Normal, U = Uniform 
b Quality assessment: High – good quality directly relevant evidence (e.g. directly relevant population, well conducted RCT for relative effects, or cohort for 
baseline effects). Med – directly relevant evidence but poorer quality source (e.g. retrospective cohort for relative treatment effect) Low – lack of direct evidence 
or informed by expert opinion. Direct = source provides required parameter. Indirect = source provides related parameter used as background evidence to 
inform expert opinion. Note the same source may be used in different contexts, therefore resulting in a different relevance rating to inform different 
parameters. 
c Parameter estimated based upon data from the source, rather than directly from the source. Details are provided in 7. 
BPI = Brachial plexus injury, ECV = External cephalic version, NHDU = Neonatal high-dependency unit, NICU = Neonatal intensive care unit, SCBU = Special care 
baby unit, US = Ultrasound 
All costs presented in pound sterling (£) and updated to the cost-year of 2016-17 using the HCHS Index178.
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Quality of life 
We estimated age-specific quality of life for healthy neonates using EuroQol data for a general UK 
population.187 Age specific health state utilities were multiplied by age specific survival188, the 
discounted sum over the time horizon of the model yielding the expected QALYs gained for an 
otherwise healthy neonate. Per definition, the quality of life following mortality is zero, and we made 
the simplifying assumption that all deaths during a particular year of life occurred on the first day of 
the year. In the absence on suitable evidence of how SEN affect quality of life, we assumed for our 
base-case scenario that SEN would affect costs only. In the case of severe neurological morbidity, we 
adjusted the baseline quality of life with a relative decrease following the methodology of Leigh et 
al.189, using CP as a proxy for severe neurological morbidity. Full details on the derivation of quality of 
life parameters is presented in Appendix 7. 
 
Analysis 
The model was analysed via Monte Carlo simulation, capturing the overall uncertainty in cost-
effectiveness as a function of the uncertainty of the input parameters. Health outcomes were from 
the fetal perspective only and ultimately presented as QALYs. Cost-effectiveness was explored 
through ICERs and net monetary benefits (NMB), using a willingness-to-pay (WTP) threshold of 
£20,000 per QALY. All costs and QALYs were discounted by 3.5% per annum.190 All costs were from a 
third-party (payer) perspective, i.e. the English NHS plus special educational needs costs, and the 
reference case time horizon was 20 years (varied in sensitivity analysis). 
 
Stability testing was conducted to quantify (and thence minimise) Monte Carlo error as a function of 
the number of simulations. The model was run 30 times with a given number of simulations. The 
coefficient of variation of the estimates of mean and standard error of mean cost and QALYs for each 
comparator were calculated. The mean of all of these was used as a summary measure of the Monte 
Carlo error. We used an arbitrary 2% cut-off to declare the results stable. 
 
Cost-effectiveness: reference case 
For each of the six discrete strategies, we present mean and 95% credibility intervals for cost and 
QALYs gained, net benefit at a willingness to pay of £20,000 per QALY, and INMB relative to the 
assumed status quo (selective scanning with IOL for macrosomia or SGA, offer of ECV for breech). The 
option with the highest expected net benefit was identified as the most cost-effective. Decision 
uncertainty was expressed as the probability of each decision being cost-effective at the reference 
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case threshold (£20,000/QALY). The cost-effectiveness acceptability curve plots decision uncertainty 
as a function of willingness to pay per QALY. 
 
Cost-effectiveness: sensitivity and scenario analyses 
In addition to the primary analysis, we report a number of scenario analyses and one-way sensitivity 
analyses to explore specific uncertainties in more detail.  Specifically:  • Time horizon 
o The base case analysis assumes a 20 year time horizon.  We vary this from 1 to 100 
years. • Cost of scan to assess fetal presentation only 
o The cost of a presentation-only scan is dependent on whether it is feasible to 
incorporate it into a routine antenatal visit with the scan conducted by a midwife 
using a hand-held unit, or whether it can only be done at a dedicated visit by an 
ultrasonographer in a secondary care setting. • The baseline risks of perinatal death, moderate and severe neonatal morbidity. 
o Baseline risks of each of these were estimated from different sources, yet they are 
mutually exclusive events.  Ideally, these should be modelled as a Dirichlet 
distribution, but as the data were from different sources we modelled them as 
independent betas.  We thus explore these further in one-way sensitivity analysis. 
In addition, due to concerns over the validity of input data, we also explore the difference in risk of 
acidosis and respiratory morbidity associated with vaginal delivery of an LGA infant (versus AGA), the 
odds ratio of perinatal death from an emergency caesarean section from a breech baby (versus vaginal 
delivery), the relative risk of an emergency CS from IOL for an SGA infant (versus expectant 
management of an AGA infant), the relative risk of SEN as a result of inducing labour (versus expectant 
management), and its impact on health related quality of life, and the sensitivity of ultrasound 
scanning at detecting SGA. 
 
Value of information analysis 
Uncertainty in cost-effectiveness results (i.e. decision uncertainty) was used to conduct a value of 
information analysis. Decision uncertainty arises from parameter uncertainty. The expected value of 
perfect information (EVPI) is the expected value of eliminating all decision uncertainty, which by 
definition implies eliminating all parameter uncertainty. This therefore provides an upper bound for 
the value of all research into the decision question. The expected value of perfect parameter 
information (EVPPI) is the expected value of eliminating uncertainty in a single parameter or group of 
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parameters. The expected value of sample information (EVSI) is the expected value of a study of 
sample size n. The EVSI of a study of size n less the cost of conducting it provides a measure of the 
expected return on investment in that research project (expected net gain of sampling, ENGS).191-193 
An EVPPI above the plausible cost of a research project is a necessary condition for future research to 
be economically viable. A positive ENGS is the sufficient condition. The efficient sample size of a study 
is that which maximises the ENGS. 
 
We estimated that theƌe aƌe appƌoǆiŵatelǇ ϭϵϲ,Ϯϵϳ siŶgletoŶ ďiƌths at шϯϳ ǁeeks͛ gestatioŶ to 
nulliparous women not delivered by elective CS each year. Assuming a time horizon for which the 
decision question remains valid of 10 years yields a (discounted) beneficial population of 1,689,663. If 
it is reasonable to assume our analyses are generalisable to all births in England, the beneficial 
population is 5,477,940. 
 
We report the per-patient (i.e. per mother/infant dyad) and population expected value of perfect 
information at a willingness to pay of £20,000/QALY. We then report the per patient and population 
EVPPI for each parameter individually, calculated using the Sheffield Accelerated Value of Information 
(SAVI) tool.161 Parameters with a positive EVPPI were grouped into those which could logically be 
collected within one research study and the EVPPI for that group of parameters calculated (also with 
the SAVI tool161). The expected value of sample information (EVSI) for any parameters or groups of 
parameters is then calculated using the method of Heath et al.194 Population values are presented as 
a ͚ĐoŶseƌǀatiǀe͛ estiŵate, assuŵiŶg the iŶfoƌŵatioŶ is only of value to singleton nulliparous 
pregnancies (i.e. using the 1,689,663 beneficial population), and a broader estimate which assumes 
the information is of value to all pregnancies in England (5,477,940 population). 
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Results 
Stability testing 
Our analyses showed that we were able to achieve extremely stable results (coefficient of variation of 
<Ϭ.Ϭϭ%Ϳ ǁith ϭϬϬ,ϬϬϬ siŵulatioŶs, at a ͚ƌeasoŶaďle͛ ƌuŶ tiŵe of aƌouŶd ϯϬ seĐoŶds (Table 13). We 
therefore ran our cost-effectiveness analyses with 100,000 simulations. However, due to the need for 
repeated loops, the EVSI calculations are based on 10,000 simulations. 
 
Table 13. Results from stability testing. 
Simulations Computation time 
(seconds) 
Mean Coefficient of Variation 
(%) 
10 0.10 24.68 
100 0.09 7.73 
1000 0.33 2.53 
10000 2.75 0.56 
100000 29.56 <0.01 
 
 
Cost-effectiveness results 
Table 14 shows the overall costs, QALYs, net benefit and incremental net benefit for each of the six 
screening-management strategies. Net benefit is calculated assuming a willingness to pay of £20,000 
per QALY gained. Incremental net benefit is shown relative to the status quo (assumed selective 
ultrasound scanning and IOL foƌ ďoth suspeĐted “GA aŶd LGA͟Ϳ. “tƌategies aƌe oƌdeƌed iŶ teƌŵs of 
increasing cost. 
 
Given current evidence and assuming a willingness to pay of £20,000 per QALY, the strategy associated 
with the highest net benefit is a presentation only scan for all women (where women with relevant 
iŶdiĐatioŶs also get a full sĐaŶ͟Ϳ. Wheƌe LGA is suspeĐted, the ƌeĐoŵŵeŶded ŵaŶageŵeŶt is IOL: on 
average IOL is associated with a small improvement in QALYs compared with expectant management 
(SGA is assumed managed with IOL). Universal ultrasound screening for fetal size is not recommended 
as its added benefits do not justify its added cost. Decision uncertainty suggests there is a 44.19% 
probability that this is the most cost-effective strategy (Table 14 and Figure 17). 
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Table 14. Cost effectiveness results (per mother scanned, mean and 95% Credibility Interval). 
 
 
 
 
 
 
 
 
 
 
 
Management refer to management strategy when LGA is suspected, all cases of suspected SGA are assumed induced. 
* Strategy with highest expected net benefit. 
INB = Incremental net benefit relative to current practice (selective US + induction of labour); NB = Net benefit ; P_CE = Probability of being the most cost-
effective strategy 
Screening + management Cost QALYs NB|£20k INB|£20k P_CE|£20k 
Selective US + Induction 6090  
(4420, 7890) 
13.640  
(13.441, 13.841) 
266719  
(262333, 271079) 
0  
(0, 0) 
0.65% 
Selective US + Expectant 6091  
(4424, 7889) 
13.639  
(13.439, 13.839) 
266682  
(262297, 271040) 
-37.09  
(-124.7, 35.24) 
0.22% 
Universal US for presentation + induction * 6101.  
(4443, 7887) 
13.645  
(13.446, 13.846) 
266806  
(262426, 271154) 
87.36  
(4.88, 205.68) 
44.19% 
Universal US for size + Expectant 6102  
(4446, 7887) 
13.644  
(13.444, 13.844) 
266769  
(262389, 271120) 
50.29  
(-68.06, 186.43) 
15.63% 
Universal US for size + Expectant 6178  
(4508, 7972) 
13.646  
(13.446, 13.846) 
266734  
(262351, 271099) 
14.47  
(-133.98, 173.31) 
0.51% 
Universal US + Induction 6180  
(4498, 7983) 
13.648  
(13.448, 13.849) 
266779  
(262386, 271147) 
60.24  
(-151.43, 281.7) 
38.81% 
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Figure 17. Cost-effectiveness acceptability curve for the chance of each strategy being the most cost-
effective as a function of willingness-to-pay for an additional quality-adjusted life year. 
 
MExp = Expectant management, MIOL = Induction of labour, Sbre = Universal ultrasound for fetal 
presentation only, Ssel = Selective ultrasound, Suni = Universal ultrasound for fetal biometry plus 
presentation. 
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One-way and scenario analyses  
Cost-effectiveness conclusions were sensitive only to the time horizon, the cost of an ultrasound scan 
for fetal presentation only, the background risk of stillbirth, moderate and severe perinatal 
complications, and the risk of special educational needs associated with IOL. 
 
With respect to the time horizon, universal ultrasound for fetal presentation only is the most cost-
effective option as long as the time horizon of the analysis is below 45 years (Figure 18 below). Above 
this time horizon, universal ultrasound for size and presentation becomes the most cost-effective 
option. With respect to the cost of a presentation scan, a presentation-only scan remains the most 
cost-effective option provided it costs no more than £90. Above this cost, status quo is the most cost-
effective (Figure 19 below). 
 
As the background risks of perinatal mortality, moderate and severe perinatal complications rise, the 
net benefit of a detailed universal scan rises (Figure 20 below). This is because the risks of 
complications from SGA and LGA infants are modelled relative to the baseline risks: as the baseline 
risk rises, the risks for SGA and LGA infants rises more than proportionately, thus the benefit from 
detecting and intervening rises. A breech-only scan remains the most cost-effective option so long as 
the baseline risk of perinatal death remains below 0.28%, and for moderate and severe complications 
below 4.8% and 1.12% respectively. Above these values, universal screening becomes the cost-
effective option. 
 
Our base case analysis assumed a linear progression through the model whereby long term outcomes 
were dependent on perinatal outcomes, which were dependent on mode of delivery alone (vaginal 
versus (emergency or elective) CS).  However, there is evidence to suggest that IOL may of itself 
increase the risk of special educational needs in later life.174  We therefore explored the impact on the 
results via a one-way sensitivity analysis. We find that our results remain the same as long as the 
relative risk of SEN as a result of IOL is between approximately 0.95 and 1.3; and the estimated risk at 
38 wkGA lies within this range174. Below this risk, the most cost-effective strategy is to perform 
universal screening for both presentation and estimated fetal weight, and to induce labour where SGA 
or LGA is suspected.  Above this risk, then whilst the recommended scan remains a presentation-only 
scan, the most cost-effective intervention for suspected SGA or LGA is expectant management (i.e. 
IOL ceases to be the appropriate intervention, Figure 21).  Given this, whilst not captured in our formal 
value of information analysis (due to structural assumptions), it may be worthwhile exploring the 
impact of inducing labour on long term risk of special educational needs in future research. 
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Figure 18. One-way sensitivity analysis on model time horizon. 
 
MExp = Expectant management, MIOL = Induction of labour, Sbre = Universal ultrasound for fetal 
presentation only, Ssel = Selective ultrasound, Suni = Universal ultrasound for fetal biometry plus 
presentation. 
The figure shows the expected incremental net monetary benefit for different strategies compared to 
current practice (selective ultrasound with induction of labour for suspected LGA) as a function of the 
ŵodel’s tiŵe horizon (years). Calculations are based upon a willingness-to-pay (i.e. valuation of one 
additional quality-adjusted life year) of £20,000.  
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Figure 19. One-way sensitivity analysis on the cost of a scan for fetal presentation only. 
 
MExp = Expectant management, MIOL = Induction of labour, Sbre = Universal ultrasound for fetal 
presentation only, Ssel = Selective ultrasound, Suni = Universal ultrasound for fetal biometry plus 
presentation. 
The figure shows the expected incremental net monetary benefit for different strategies compared to 
current practice (selective ultrasound with induction of labour for suspected LGA) as a function of the 
cost of an ultrasound for fetal presentation only. Calculations are based upon a willingness-to-pay (i.e. 
valuation of one additional quality-adjusted life year) of £20,000.
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Figure 20. One-way sensitivity analysis on baseline risk of perinatal mortality, moderate and severe morbidity respectively. 
 
 
MExp = Expectant management, MIOL = Induction of labour, Sbre = Universal ultrasound for fetal presentation only, Ssel = Selective ultrasound, Suni = Universal 
ultrasound for fetal biometry plus presentation. 
The figure shows the expected incremental net monetary benefit for different strategies compared to current practice (selective ultrasound with induction of 
labour for suspected LGA) as a function of the baseline risk of perinatal mortality (left), moderate neonatal morbidity (middle), and severe neonatal morbidity 
(right). Calculations are based upon a willingness-to-pay (i.e. valuation of one additional quality-adjusted life year) of £20,000.
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Figure 21. One-way sensitivity analysis on relative risk of special educational needs from induction 
of labour. 
 
MExp = Expectant management, MIOL = Induction of labour, Sbre = Universal ultrasound for fetal 
presentation only, Ssel = Selective ultrasound, Suni = Universal ultrasound for fetal biometry plus 
presentation. 
The figure shows the expected incremental net monetary benefit for different strategies compared to 
current practice (selective ultrasound with induction of labour for suspected LGA) as a function of the 
relative risk of special education needs if labour is induced early (compared to expectant 
management). Calculations are based upon a willingness-to-pay (i.e. valuation of one additional 
quality-adjusted life year) of £20,000.  
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Value of information analysis 
Expected Value of Perfect Information 
At a willingness to pay of £20,000 / QALY, the per patient EVPI is £31.56. Given a beneficial population 
of 1,689,663, the population EVPI to England is £53.3m. If the results of the analysis are assumed 
generalizable to all pregnancies in England, then the population EVPI is £172.9m. Figure 22 shows the 
per patient EVPI as a function of the willingness to pay threshold. The two local peaks are where the 
decision (i.e. which screening strategy is preferred) changes and thus the impact of decision 
uncertainty is greatest around these thresholds. 
 
Figure 22. Per patient expected value of perfect information (EVPI) as a function of the willingness-
to-pay for an additional quality-adjusted life year (QALY). 
 
EVPI = Expected value of information 
EVPI presented per person. Willingness to pay refers to monetary valuation of an additional quality-
adjusted life year (£). 
 
Expected Value of Perfect Parameter Information and Expected Value of Sample Information 
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Table 15 shows parameters with an EVPPI exceeding £100,000 under the broader assumption that any 
future study will be of value to all births in England, not just low risk singleton pregnancies. The most 
valuable parameter is difference in cost of delivery from induction of labour (c.IOL), accounting for 
84% of the EVPI. Except for this cost, no other parameters individually account for more than 1% of 
the total EVPI. The other parameters with the greatest contribution to EVSI are: the relative risk (LGA 
versus AGA) of acidosis from a vaginal delivery following IOL ; the odds ratio of perinatal death (LGA 
versus AGA) from a baby being delivered vaginally without IOL; the relative risk (SGA versus AGA) of 
Emergency CS following IOL; ´the odds ratio (SGA versus AGA) of severe neonatal morbidity under 
expectant management. 
These five parameters could naturally be collected from three separate studies, namely: 
1. a costing study of the difference in cost of delivery associated with IOL versus expectant 
management 
2. an RCT of delivery outcomes relating to LGA 
3. an RCT of delivery outcomes relating to SGA babies 
The EVPPI of the costing study is either £44.8m or £145.2m, depending on whether the results are 
considered applicable to only singleton nulliparous pregnancies, or all pregnant mothers respectively. 
The two RCTs have EVPPIs of up to £3.9m and £1.4m under the broader applicability criteria. 
 
The EVSI of the costing study suggests scope for it to yield a positive return on investment. For 
example, a study with 1000 patients (in each arm of a two-arm study) has an EVSI to England of £11.3m 
(or £97.2m if this information is of value to all pregnancies in England, not just low risk nulliparous 
singleton pregnancies). If such a study was to cost £1m, then it would yield a net return on investment 
of at least £10.3m (  
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Figure 23).  
 
We were not able to calculate non-zero EVSI estimates for studies on macrosomia or SGA outcomes 
as the per-patient EVPPI is too low. 
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Table 15. EVPPI for individual parameters and groups of parameters. 
 
Per Person 
EVPPI (£) SE 
% of 
EVPI pEVPPI (£) pEVPPI (£)* 
c.IOL 26.51 0.07 84 44,790,000 145,200,000 
      
RR.acidosis.macro.IoL.vag 0.27 0.04 1% 456,000 1,478,000 
OR.mort.macro.vag 0.26 0.03 1% 438,900 1,423,000 
Group 0.72 0.07 2% 1,215,199 3,939,513 
 
     
RR.EMCS.SGA.IoL 0.06 0.01 0% 99,290 321,900 
OR.sev.SGA 0.03 0.01 0% 48,740 158,000 
Group 0.26 0.04 1% 443,104 1,436,484 
* Assuming study results are applicable to all births in England. 
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Figure 23. Population Expected Value of Sample Information for a study on the cost of induction of 
labour. 
 
EVSI = Estimated value of perfect information 
 
Expected Value of Perfect Parameter Information under alternative scenarios 
EVPPI provides the value of obtaining perfect information for a parameter based upon the magnitude 
for which perfect information would affect the decision outcome. This mean that even parameters 
with great impact upon overall cost and QALYs, and for which the value is highly uncertain, may have 
low EVPPI if perfect information would not change the decision; i.e. which screening strategy is most 
cost-effective. However, whether the exact value of a parameter affect the decision outcome is highly 
dependent on context. Through simulating alternative scenarios, we analysed how the EVPPI of key 
parameters were affected by model assumptions. 
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Given the uncertainty over which setting an ultrasound scan for fetal presentation only could be 
provided in, there were some concerns that the cost was not correctly specified in the base-case 
scenario. We therefore simulated three alternative scenarios where we varied the assumptions 
underlying the cost calculations: 1) where fetal presentation could be assessed through directly 
accessed diagnostic services (£52 [95% CI: £24, 91]), 2) where an antenatal standard routine 
ultrasound scan was required (£108 [95% CI: £97, 118]), and 3) where costs could range between 
either of these scenarios (£24-118). Results showed that EVPPI was highest where the cost was 
highest. For this scenario, the EVPPI was £6.07 per person. Depending on the beneficial population, 
the overall EVPPI was £10.3m (nulliparous women only), or £33.3m (all mothers). It is worth noting 
that the ŵodel͛s assessŵeŶt of the ǀalue of fuƌtheƌ studies is iŶ this Đase at odds ǁith Đost-
effectiveness. A greater cost for scanning means a lower chance of ultrasound for fetal presentation 
being cost-effective, but the value of researching this parameter further increases. 
 
The cost of IOL (specifically, the net difference in total cost between pregnancies that were induced 
early versus expectant management) had the greatest EVPPI in our base-case scenario, and hence the 
greatest expected benefit from future research. In the base-case scenario, the cost was £125 (95% CI: 
-£1343, £1594); more details are presented in appendix 7. To test how sensitive the EVPPI was to the 
exact input values used, we simulated two alternative scenarios: 1) where the standard error of the 
mean was reduced by 50%, and 2) where costs were instead obtained from the 35/39 trial, where the 
cost difference was -£236 (95% CI: -£646, £174)195; see appendix 7 for details. When the standard 
error was reduced by 50%, the EVPPI fell by ~80%. When costs were obtained from the 35/39 trial, 
the EVPPI was £6.3m for the beneficial population (nulliparous women). 
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Discussion 
Main findings 
This study has evaluated the cost-effectiveness of alternative screening strategies for ultrasound in 
the third-trimester in a population of low-risk nulliparous women. Based on current information, and 
assuming a willingness to pay of £20,000 per QALY, offering a universal ultrasound (US) presentation-
only scan is on average the most cost-effective strategy. This is associated with an incremental net 
monetary benefit of £87.36 (95% CI: 4.88, 205.68) per pregnancy compared to current practice. Scaled 
up to the English population, this equates to an added net benefit of £17.1m or 857 QALYs per annual 
birth cohort. This is the present value of the future flows of expected costs and benefits over a time 
horizon of 20 years.  
 
Third-trimester scans for fetal size should take place only where clinically indicated. We estimate that 
the added benefits of including estimation of fetal weight in the scan are too small to justify the added 
cost: more health would be lost elsewhere than would be gained from the added knowledge and 
subsequent management from these scans. Where LGA is suspected following ultrasound, early IOL is 
the preferred management, irrespective of whether screening was offered routinely or following 
clinical indication. 
 
It should be noted that the presentation-only scan policy implies an increased burden on those 
performing the scan, but that this is partially offset by reductions in the cost of complications from 
delivery.  Implementation would therefore require a reallocation of resources away from delivery and 
towards antenatal care or ultrasonography. 
 
Due to uncertainties in the evidence base (parameter uncertainty), there is a only a 44% probability 
that this screening strategy really is the most cost-effective, i.e. there is a 56% probability that this 
conclusion is incorrect in which case a loss will be incurred. The expected loss associated with this 
decision uncertainty is £31.56 per pregnancy. Equivalently, this is the expected gain if uncertainty 
were to be eliminated (expected value of perfect information, EVPI). Scaled up to the population of 
England who could benefit from the information from any future studies, this equates to an EVPI of 
£53.3m. If it is assumed the results of any future study are generalizable to all pregnancies in England, 
the EVPI is £172.9m. 
 
The net difference in cost between an induced delivery and expectant management was the 
parameter with the biggest impact on decision uncertainty in the base-case scenario, and hence is the 
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parameter that should be prioritised for future research.  It should be noted that this does not simply 
relate to the cost of a procedure to induce delivery; included within this definition is uncertainty as to 
the timing of induction, and the impact on for example, antenatal appointments, as well as the cost 
of the deliǀeƌǇ itself. A studǇ of ͚ƌeasoŶaďle size͛ to ƌeduĐe uŶĐeƌtaiŶtǇ iŶ this paƌaŵeteƌ is likelǇ to 
yield a positive return on investment. For example, the EVSI of a study of 1000 mothers in each arm is 
worth in excess of £11m. If this was to be delivered for a cost of £1m, it would yield a greater than 10-
fold return on investment. Alternative scenarios found that the value of future research may be less 
than for the base-case scenario. Nonetheless, although the exact value of future research is hard to 
determine, the net cost of labour induction appears influential for which screening strategy is the 
most cost-effective. Of note is that studies on the outcomes from SGA or LGA fetuses are unlikely to 
yield a positive return on investment based upon the model. 
 
Our base-case scenario showed very limited value in further researching the cost for which an 
ultrasound scan for fetal presentation only could be provided. However, this was because the model 
deemed a policy of universal ultrasound for fetal presentation so cost-effective that the cost of the 
scan was unlikely to change which policy is preferred; one-way sensitivity analysis showed that, all 
else equal, the cost of a presentation scan would need to exceed £90 before another screening 
strategy was likely to be more cost-effective. In practice, the cost for which universal ultrasound for 
fetal presentation only could be provided is uncertain, mainly because it is unclear which type of 
clinical setting would be required for the scan.  Therefore, prior to any roll-out, it is essential to 
establish whether, for example, midwifes can be trained to perform the presentation scans and find 
it feasible to incorporate them into routine antenatal visits, or whether this can only be done in a 
secondary care setting. 
 
The results described above relate to a willingness to pay threshold of £20,000 per QALY. At a 
thƌeshold of £ϯϬ,ϲϬϬ peƌ QALY ;just aďoǀe the uppeƌ eŶd of NICE͛s stated aĐĐeptaďle ƌaŶge of £ϮϬ,ϬϬϬ 
to £30,000190, universal scanning becomes the most cost-effective option. Furthermore, our one-way 
sensitivity analyses suggest there is scope for universal scanning to be cost effective under other 
assumptions. For example, the most cost-effective option remains a breech-only scan only so long as 
the time horizon of the analysis is below 45 years. The ideal time horizon for an economic evaluation 
should be sufficient to capture all relevant differences in cost and outcomes.190 In many cases this 
implies a life-time horizon.196 However, our base case analysis was limited to 20 years. This represents 
a compromise between the desire for a long time horizon and the inherent uncertainties in 
extrapolating relatively short-term data into long term outcomes. We therefore acknowledge the 
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possibility that universal ultrasound scanning may be cost-effective in the long run, but would urge 
caution in any recommendation of such. 
 
Finally, all else being equal, a presentation-only scan is the most cost-effective option provided it can 
be accomplished for below £90 a scan. This is higher than we estimated in our previous work, which 
estimated a maximum cost-effective price of a presentation scan of approximately £2010(Wastlund et 
al., 2019a). This difference is due to the more detailed modelling in this analysis; where the previous 
analysis based QALY gains upon mortalities averted and a set life-expectancy, this analysis included 
the impact of morbidity on costs and quality of life, and incorporation of explicit survival functions. 
 
Strength and weaknesses 
Through incorporating several conditions detectable by US screening into one decision model, this 
study was able to assess the overall effect that the introduction of universal US may have upon a 
population of nulliparous women. It also enables assessing the impact that introducing such a 
programme would have upon NHS budget and whether it is likely to represent good value for money. 
Further, by incorporating a value of information analysis, this study has the potential to assess, not 
only where the current gaps are in the evidence base for evaluating the use of universal US screening, 
but also for which of these gaps future research would have the greatest potential of resulting in 
meaningful findings. 
 
A key limitation of this study is that only foetal outcomes were considered, excluding those of the 
mother. Maternal outcomes may be as significant as fetal outcomes, or more so. Further, the well-
being of mother and child are sometimes at odds with each other, and clinical decisions frequently 
trade-off between the two.  Incorporating maternal outcomes into the analysis therefore could have 
an impact upon both the cost-effectiveness of the different strategies (in either direction), and our 
value of information analyses guiding where future research should be prioritized. However, as per 
our original protocol, maternal health consequences were not incorporated in this study.  The primary 
justification for this is the lack of sufficiently reliable evidence of how screening outcomes may affect 
maternal quality of life. We have previously emphasised the need for further such research in this 
area, particularly surrounding long-term maternal consequences from mode of delivery,10, 150 and 
repeat that call here. 
 
Throughout the development of the simulation model, we have attempted to capture clinical 
probabilities and their respective uncertainties as accurately as possible. However, uncertainty 
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persists for many parameters, not only over their exact value, but also about how well suited these 
are for the new decision context. Essentially, this creates two separate types of uncertainties. The 
internal validity is well captured in the model through the incorporation of parameter uncertainty as 
quantified by the authors of the respective source. However, there is also the question of external 
validity, i.e. to which extent that parameter is suitable for our model, which is uncaptured by the 
model. This means that the true uncertainty of our results are likely to be greater than what is 
expressed in the confidence intervals of the outputs. While this does not invalidate the model as a 
tool for decision-making, it means that thoughtful interpretation of the results is needed, and that 
such interpretation should always acknowledge the inherent uncertainty of combining data from 
different sources. 
 
Through its focus on breech presentation, SGA and LGA only, this analysis may have underestimated 
the merits of universal US. Such a screening program would also raise the chance of detecting 
otherwise unknown complications, e.g. previously undetected congenital anomalies or placenta 
praevia. Although less prevalent than the conditions included in this analysis, the potential of 
detecting such complications could be an added benefit of introducing a universal US programme. 
However, it is important that subsequent management of other such complications follow protocols 
which have taken the diagnostic performance of US into account. If the risk of false positive diagnoses 
are high, and the consequences severe, introduction of universal US risks putting patients in a worse 
position than they would have been in without screening. 
 
The outcomes of economic modelling and especially value of information (VOI) analysis are highly 
sensitive to the structural assumptions that underlie the simulation model. Throughout this analysis, 
we have attempted to model the potential outcomes of screening using parameters for which credible 
data are available. Where parameter uncertainty has been wider, the expected value of future 
research is generally greater. However, this approach has required us to be able to incorporate a 
parameter into the model structure. The problem has been capturing effects that we suspect exist, 
but for which no evidence has been available.  
 
In this analysis, we modelled the risk of long-term outcomes such as SEN as a function of neonatal 
morbidity. This means that clinical interventions that can alleviate neonatal morbidity are also 
expected to alleviate the risk of SEN. Similarly, interventions that do not affect neonatal morbidity will 
have no impact upon the risk of SEN. However, this may not accurately capture how interventions 
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affect SEN. This model structure has been adopted due to data limitations, and to avoid 
overestimating the effect of intervention. 
 
There is some evidence that the risk of SEN increases with early IOL, and the perceived risk of this is 
often influential in the clinical decision of whether or not to induce labour early. Our model structure 
captures long-term effects on SEN from early labour induction if it is mediated through neonatal 
morbidity. However, if there is a direct link between gestational age at delivery and the risk of SEN 
that is not mediated through neonatal morbidity, this is uncaptured in the model. One-way sensitivity 
analyses exploring this suggest that our results hold so long as the risk of SEN associated with IOL 
(versus expectant management) is below approximately 1.34.  Above this, the recommendation for a 
presentation-only scan holds, but inducing labour for LGA is no longer recommended. If it is plausible 
that the increased risk of SEN associated with IOL exceeds 34%, then it may be worthwhile exploring 
this in future research. However, observational data indicate that delivery at 38 wkGA is associated 
with less than 34% increase in risk174. 
 
Whilst macrosomia and SGA are mutually exclusive by definition, we assumed breech was also 
mutually exclusive with SGA and LGA. This simplification was used because data constraints would not 
allow a credible estimation of risk adjustments for fetuses that were both breech and SGA/LGA, and 
for structural simplicity of an already complex model. It was also considered likely that breech 
presentation would be a stronger determinant of possible clinical interventions than fetal size. 
Relaxing this assumption would in practice have the same effect in the model as a slight increase of 
the prevalence of SGA and LGA, however, the effect of this would be limited given the low prevalence 
of fetuses with a breech presentation and SGA/LGA. 
 
The conclusions for our economic analysis, and especially for the VOI analysis, depend heavily on the 
exact data used to capture parameter uncertainty in the economic model. However, accurately 
capturing the uncertainty of a parameter in line of all current evidence is far from straightforward. For 
many parameters, alternative sources were available, and the combined parameter uncertainty for 
multiple studies is theoretically smaller than for just the one. Ideally, every input parameter in the 
model should be subject to a meta-analysis. However, due to the high number of parameters in the 
model, this was not feasible. Further, in many cases, we suspected that the difference in parameter 
values between studies were the result of different clinical definitions rather than reflective of the 
true parameter uncertainty. To address this issue, we conducted extensive one-way sensitivity 
analyses. 
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We modelled aĐidosis ƌisk as that seĐoŶdaƌǇ to shouldeƌ dǇstoĐia as ǁell as ͚ otheƌ aĐidosis͛. No souƌĐes 
disaggregated that attributable to shoulder dystocia and other causes. We may therefore have 
overestimated the risk of acidosis via double counting. However, our sensitivity analyses suggested 
the base case results were insensitive to this parameter. 
 
Comparison with other studies 
A previous review of studies of universal ultrasound assessment during the late pregnancy found no 
clear benefit of universal ultrasound.20 In this study, we have found that universal ultrasound may be 
associated with better clinical outcomes. Whether universal screening is cost-effective, however, 
depends on the features included in such a scan. Our analysis show that universal ultrasound for fetal 
size is unlikely to be cost-effective, unless the valuation of additional health is higher than those 
recommended by current UK guidelines.190 By contrast, universal ultrasound for fetal presentation 
alone is likely to be cost-effective, although uncertainty persist over whether fetal presentation could 
be assessed sufficiently cheaply using ultrasound to make such a screening policy feasible. 
 
Further, the findings also align with our cost-effectiveness analyses of universal ultrasound for 
individual complications only. When exploring the cost-effectiveness of universal ultrasound for 
breech presentation only, we found that whether such a screening program could be cost-effective 
largely depended on the price for which fetal presentation could be detected.10 It seemed unlikely 
that screening for SGA or LGA only would be cost-effective, however we highlighted that the 
effectiveness of labour induction was uncertain and may warrant further research. This joint analysis 
confirms these findings, and has allowed us to point more specifically towards those parameters for 
which further research may have a meaningful impact upon the decision problem. 
 
Implementation considerations 
The purpose of this stream has been to make recommendations on screening policy based upon our 
current understanding of the evidence base, to identify the current gaps in the evidence, and provide 
recommendations about which of these gaps should be addressed to allow future policy-making about 
late-pregnancy ultrasound in the relevant population. We speculate that late-pregnancy ultrasound 
screening for fetal presentation only could be provided by midwives as part of a routine antenatal 
assessment. Such a screening setting has obvious benefits for the patient, as an extra appointment 
(typically in a secondary care setting) could be avoided, saving time and travel costs for mothers and 
possibly partners as well. However, an US scan in this context would not also assess fetal biometry. It 
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is important that the introduction of such a screening programme into NHS routine care would not 
expand the scope of this scan beyond assessing fetal presentation as this may lead to unnecessary 
intervention. Another potential problem for the NHS would be the implied relocation of budget 
between units. Though universal US in a primary care setting may be cost-effective for NHS as a whole, 
in practice this would put extra financial strain on primary care, while the benefits would mostly arise 
from the avoidance of complications following delivery. To be successful, the implementation of such 
a screening policy would need to be accompanied by a suitable reallocation of budget from the 
benefitting units into primary care. 
 
The consequences of future research likely go beyond the perspective employed in this analysis. First, 
our analysis focused upon nulliparous women with singleton pregnancies, but for many parameters, 
reducing uncertainty would be helpful to women regardless of parity. To address this, we provided 
two population values of information: one based on nulliparous singleton pregnancies, and the other 
on all pregnancies. Second, the scope of our study was limited to England, but many findings are likely 
to be just as applicable to the rest of the UK, and indeed to other high-income countries as well. If the 
value of information analyses are considered applicable to the entire UK, the EVPI, EVPPI and EVSI 
figures should be multiplied by approximately 25% to reflect this (England accounts for approximately 
80% of the UK population). Third, the economic perspective of this study was the English NHS and 
education services only, but many consequences would go beyond this. For instance, it has been 
estimated that the majority of the costs associated with stillbirth and cerebral palsy are indirect, e.g. 
from decreased productivity, extra monitoring for subsequent pregnancies, mourning etc.184, 186, 197 
When considering such perspectives, both the attractiveness of universal ultrasound and the value of 
future research is likely to increase. 
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Conclusions 
The remit of this work was to advise NIHR on the current body of evidence regarding the cost-
effectiveness of late pregnancy ultrasound screening, and specifically whether (a) there was value in 
commissioning further research in the area, and (b) if so what. 
 
Our results suggest that universal ultrasound for fetal presentation only may be both clinically and 
economically justified, but that implementation research is needed before it is adopted into routine 
care. Specifically, this must explore whether a scan can be conducted by a midwife during a routine 
antenatal visit. Universal ultrasound including estimation of fetal weight is of borderline cost-
effectiveness, and sensitive to certain assumptions. Our formal value of information analysis suggests 
that future research should be focused on the net cost of IOL compared to expectant management. 
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Chapter 12. The views of recently delivered and currently pregnant women on universal ultrasound 
screening in late pregnancy. 
 
Aims  
The aims of this section were the following:  
1. To assess the knowledge of pregnant women on the current antenatal care pathway for low 
risk pregnancies.  
2. To assess their understanding of the potential benefits and drawbacks of third trimester 
screening.   
3. To estimate their willingness to participate in a future randomised clinical trial, examine which 
trial design they would prefer to participate in, and calculate the expected recruitment rate.    
 
Methods 
In order to evaluate both the quantitative and qualitative aspects of the above aims we conducted a 
survey and ran focus groups. For both aims we collaborated with the NIHR Cambridge BRC 
Communications and PPI Department of Cambridge University Hospitals NHS Foundation Trust 
(CUHFT). Amanda Stranks, the head of the PPI department of CUHFT, had active role in the writing 
and testing of the survey as well as the design, recruitment and running the focus groups as explained 
below.  
 
The objective of the survey was to meet the requirements of aims 1 and 3 by involving a large and 
representative number of women. We planned to recruit low risk nulliparous women after their 
ultƌasouŶd sĐaŶ at ϭϮ oƌ ϮϬ ǁeeks͛ gestatioŶ, giǀeŶ that the sĐaŶ ĐoŶfiƌŵs a ǀiaďle pƌegŶaŶĐy. We 
excluded any high risk pregnancies with either maternal or fetal pathology.  The questionnaire was 
approved by all the collaborators of the study and tested by the PPI office in CUHFT to ensure it was 
understood by the women. We received feedback from five anonymous individuals and modified our 
form accordingly. We have attached the final version of the questionnaire in Appendix 8. In brief, this 
questionnaire included three parts. The first two questions were about their knowledge of the current 
antenatal care and their willingness to have an additional ultrasound scan in the third trimester. The 
second part included three questions about potential participation in a future randomised trial. We 
discussed two possible trial designs. The first study (study A) would randomize low risk women to have 
a sĐaŶ at ϯϲ ǁeeks͛ gestatioŶ oƌ Ŷot ;ĐuƌƌeŶt staŶdaƌd of ĐaƌeͿ. The ultƌasouŶd ƌesults ǁould ďe 
revealed to their clinical care team and their management would be affected accordingly. In the 
second study (studǇ BͿ all ǁoŵeŶ ǁould haǀe aŶ ultƌasouŶd at ϯϲ ǁeeks͛ gestatioŶ. If theƌe ǁas a 
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major problem (eg breech presentation or very small amount of fluid around the baby) the result 
would be revealed to the care team. In all other cases the result would be blinded to the mothers and 
the clinicians. Finally, we included some questions on womeŶ͛s deŵogƌaphiĐs, such as age, ethnicity, 
and education to ensure that the sample of women was diverse. All the replies were anonymised.   
 
The second part this section was to run focus groups in which we could discuss the qualitative aspects 
of all the above aims. We planned to recruit women that have recently delivered (within the last two 
years), and discuss in detail the benefits and potential risks of third trimester screening. For the 
advertisement we used the mailing list of the PPI office, personal contact by midwives, and social 
media including Facebook, Twitter and WhatsApp to address groups of mothers in the broader area 
of Cambridge. The focus group discussion was designed by AM, GS and Amanda Stranks. 
 
Results 
 
Survey 
We collected 100 replies from pregnant women attending for their routine dating or anomaly scan in 
the Rosie hospital, Cambridge. We present the results in Table 16. The respondents were diverse 
regarding their age group, ethnicity and education level. The majority (85%) was aware that low risk 
pregnancies are not been offered routine ultrasound in the third trimester and 84% would like to have 
a routine third trimester scan. Regarding participation in a future clinical trial, 76% would agree or 
strongly agree to participate in study A and 66% in study B. When asked which study they would prefer 
to participate in, out of the 65 women that replied this question, 10 (15.4%) preferred study A, 23 
(35.4%) study B, and 32 (49.2%) would be happy to participate in either study. 
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Table 16. Results of the survey of low risk pregnant women (n=100). 
Question Answer Number of 
responses 
1)Were you aware that  women whose pregnancies are straight-forward are NOT routinely scanned 
after 20 weeks? 
Yes 85 
 No 15 
ϮͿ ͞I ǁould like to haǀe the optioŶ of a sĐaŶ at aƌouŶd ϯϲ ǁeeks as paƌt of ŵǇ ƌoutiŶe NH“ Đaƌe͟.  Agree/Strongly agree  84 
 Neither agree nor 
disagree 
13 
 Disagree/ Strongly 
disagree 
3 
3) I would be likely to agree to take part in study A Agree/Strongly agree  76 
 Neither agree nor 
disagree 
17 
 Disagree/ Strongly 
disagree 
7 
4) I would be likely to agree to take part in study B Agree/Strongly agree  66 
 Neither agree nor 
disagree 
18 
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 Disagree/ Strongly 
disagree 
16 
5) If you are happy to participate in one of the above research projects which one would you prefer? Study A 10 
 Study B 23 
 Both  32 
 N/A- Missing 35 
Maternal age  <30 38 
 30 60 
 Missing  2 
Ethnicity White British 40 
 Other British 20 
 Other European 17 
 Asian/African  8 
 Missing 15 
Age stopped education <22 53 
 22 39 
 Missing 8 
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Focus group 
Eight women showed an initial interest in participating in our focus groups.  Due to difficulties with 
childcare four of the women could not participate in a focus group in one of multiple suggested dates. 
We managed to run one focus group with  four participants. The focus group was run by Alexandros 
Moraitis and Amanda Stranks (PPI Lead in CUHFT). The participant characteristics are as below:  
 
A: One previous delivery, low risk, she was measuring slightly small on symphysis-fundal height (2cm 
below the appropriate for the gestational age) but had no extra scans. Normal uncomplicated delivery 
of 2.49kg baby at 40wkGA. Her motivation for participation was whether she needed a third scan. She 
also mentioned that her husband is French where they all have a third trimester scan and she wanted 
to know why this is not the policy in the UK.   
 
B: Two previous deliveries (4 and 2 years old), both low risk. The first baby was born in the birth centre, 
for the second she had IOL for postdates. Both deliveries were uncomplicated. Her motivation for 
participation was that four of her friends had stillbirths at term in the last few years which she found 
very stressful as she was planning for a third pregnancy.  
 
C: One previous delivery, initially high risk due to low BMI, had growth scans at 32 and 36 weeks (both 
normal). Then discharged to midwifery care. Delivered in the midwifery unit without complications. 
Her motivation for participating was whether she needed all these scans as it was difficult to attend 
due to work.  
 
D: One previous delivery, initially low risk. Due to low PAPP-A she had close monitoring during 
pregnancy. She had IOL at 37wkGA for suspected FGR. She delivered vaginally a 2.1Kg baby (2nd 
centile) who stayed in NICU for 3 days. Her motivation for participation was whether this could have 
been missed if the PAPP-A was not marginally abnormal in the first trimester.   
 
We initially discussed their opinion on the current screening schedule and whether they would want 
an additional ultrasound scan in the third trimester. Two participants (A and B) thought that this is not 
eŶough aŶd theƌe is loŶg peƌiod afteƌ ϮϬǁkGA that theǇ doŶ͛t kŶoǁ aďout the fetal ǁellďeiŶg. TheǇ 
both believed that an additional scan would make them feel more reassured. One participant (C) 
considered herself low risk (despite her low BMI) and found it difficult to attend the additional scans 
that she was offered. Finally the fourth participant thought that the schedule was about right and she 
wanted to have more evidence that the additional scans would be beneficial before introducing them.   
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We then discussed about potential diagnoses such as breech presentation, SGA and LGA. The 
management in each case was explained and the statistics regarding the risks and benefits. We also 
discussed a large study from France which showed that universal screening could cause harm. In the 
case of breech presentation all participants said that they would definitely want to know and they 
would all opt for external cephalic version in case of diagnosis. In the cases of SGA and LGA one 
participant (B) said that she would definitely want to know and that she would opt for IOL if she was 
diagnosed with either SGA and LGA. Two participants (A and D) said that they would still want to have 
the scan but were not sure about IOL and they would like to have further conversation with the 
doctors. One participant (C) said that she was sceptical about the potential misdiagnosis and hesitant 
about the management.   
 
Finally we discussed about participation in a future trial. All women would be happy to participate in 
a future trial. When we specifically discussed the two potential study designs as above they all 
preferred study B (screening all women and randomizing to blind or not the result). This was because 
they would ďe ƌeassuƌed aďout the ďaďǇ͛s pƌeseŶtatioŶ aŶd that a diagŶosis of a seǀeƌe pƌoďleŵ 
would be revealed. The main suggestions about blinding were that we had to make clear which 
conditions would be revealed and which would not. Additionally they wanted us to explain clearly that 
we are not withholding information from them but we simply collect more of it, and that they would 
receive the normal care in case they were randomized in the control group. When we discussed about 
the timing of the consent they would all be happy to be approached in the first or second trimester. 
However, they would prefer to have a second discussion about the randomization at 36 wkGA because 
they would have forgotten the details of the consent form at 12 or 20 wkGA and they would prefer to 
have a longer conversation at that point. 
 
Discussion and Conclusions   
We were able to collect both quantitative and qualitative data the opinions of women on third 
trimester ultrasound screening. We saw a clear interest in having an additional ultrasound scan in the 
third trimester which was also confirmed in the focus group by all but one participant. This also 
confirms the previously published finding by the Stillbirth Priority Setting Partnership198, which 
included responses by over 300 parents and 700 professionals, and concluded that the question 
whether third trimester ultrasound can reduce stillbirth was one of the most important research 
priorities.  We also found that the majority of women would be happy to participate in a future 
randomised trial and we would expect a recruitment rate of at least 2 out of 3 women, which is similar 
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to the recruitment rate of the POP study where ultrasound result was blinded to the women and the 
clinicians. 66% of women were that replied to our questionnaire and all the participants in the focus 
group would be happy with the blinding of the ultrasound if there was no severe problem which we 
will have to define clearly.  
 
Reflections/Clinical perspective   
We managed to acquire a large number of replies (as planned in advance) through a questionnaire 
ǁhiĐh gaǀe us aŶ oǀeƌall ǀieǁ of ǁoŵeŶ͛s opiŶioŶ aŶd ǁilliŶgŶess to paƌtiĐipate iŶ a futuƌe tƌial. 
However, we found it difficult to recruit women for the focus groups. Prior to recruitment, after 
discussion with the collaborators and the PPI office in CUHFT, we made the decision not to include 
pregnant women in the focus groups as the discussion could create anxiety with their care. However, 
it was also difficult to recruit new mothers and they could not easily find the time to participate in a 
focus group. We managed to recruit four women by arranging for childcare and transport (in one 
case). The input from the focus group was valuable because we had the opportunity to listen to 
women that were keen to have an additional scan and a woman that was sceptical about the need of 
those additional scans. We also gained valuable information on what to include in a future consent 
form and the timing that this should be done. Overall, we believe that all the above information would 
affect the design and conduct of a future clinical trial.    
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Chapter 13. Designing a randomised controlled trial of screening and intervention. 
 
Implications of the health economic analysis  
The economic analysis demonstrated that whilst on average, the most cost-effective approach was to 
screen all nulliparous pregnant women with a presentation-only scan, there was only a 44% 
probability that this was true and a scan included fetal biometry had a ~39% chance of being the most 
cost-effective. Moreover, if the timescale was increased, it became likely that such a scan in late 
pregnancy would be the most cost-effective approach. These observations indicate that implementing 
such a scan should be seriously considered. However, one of the major obstacles to implementing 
such a policy is that there is no direct evidence from a randomised controlled trial to show that such 
screening and intervention is clinically effective. The Cochrane review of universal late pregnancy 
ultrasound has failed to show any benefit to the mother or baby. However, as discussed in the 
introduction, this review has a number of methodological issues and it is more accurate to state that 
it does not provide any information to answer the question of whether universal late pregnancy 
ultrasound reduces the risk of perinatal death or not.  
 
Interestingly, the VoI analysis highlighted reducing uncertainty about the costs of IOL. Given the 
above, this may be regarded as somewhat counterintuitive. However, the parameters used in the VoI 
analysis in relation to the screening performance of ultrasound and the effect of intervention were 
known with a degree of precision that meant that reducing their uncertainty was not identified as the 
most cost-effective research question. For example, the ability of ultrasound to predict SGA, the 
relationship between SGA birth weight and the risk of stillbirth and the ability of IOL to reduce the risk 
of stillbirth are all known quite precisely and are based on high quality data. Consequently, even 
though there is no direct evidence to indicate that universal late pregnancy ultrasound would reduce 
the risk of stillbirth, the model estimates quite a high chance that it is the most cost effective approach 
and does not highlight reducing the uncertainty in these parameters in the VoI analysis. In contrast, 
previous health economic analyses of IOL have generated quite wide confidence intervals,179, 195 hence 
the model has identified reducing this uncertainty as the key question.  
 
Case for considering a randomised controlled trial of screening and intervention  
In this chapter we consider the practicalities of designing an RCT of screening and intervention using 
fetal biometry in nulliparous women at 36wkGA. We have done this because, even though the 
parameters in the modelling were reasonably certain, these parameters were calculated from a range 
of different study designs. i.e. we did not perform the VoI analysis based on the uncertainty of 
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parameters calculated from a large RCT of late pregnancy screening and intervention in nulliparous 
women. Rather, we performed the analysis using parameters from a range of observational studies 
and a range of studies of intervention in women who were deemed high risk for other reasons. The 
concern in this case is with external validity. The parameters may be reasonably certain in relation to 
the setting where they were derived but there is an unquantifiable uncertainty in relation to how well 
they inform our research question. The obvious way to address this would be to perform a study in 
the setting of interest. Such a study could be the definitive study or it could be a pilot or proof of 
principle study. The former might be a trial of screening versus not screening with perinatal death as 
the primary outcome. The latter might exploit alterative study designs and use of proxies. Hence, there 
are a number of important considerations to take into account when designing an RCT of screening 
and intervention using universal ultrasound and we will consider each of these in turn.  
 
Candidate primary outcomes   
In relation to primary outcome, we believe that the strongest case can be made for perinatal death. 
First, to lose a baby at term is clearly a devastating outcome for a family. In the absence of a lethal 
anomaly, preventing the death would lead to an entire life gained which, from a healthcare and health 
economic perspective is a gain of unique magnitude. Second, the main intervention available is earlier 
delivery. There is strong evidence that IOL is effective in reducing the risk of perinatal death. Over two 
thirds of perinatal deaths at term are antepartum stillbirths,51 i.e. intra-uterine fetal death prior to the 
onset of labour. Self-evidently, antepartum stillbirth cannot occur after a baby has been delivered.16 
Delivery at or after 38-39 weeks of gestational age carries the same risk of intrapartum stillbirth and 
neonatal death as delivery at later weeks of gestational age.16, 199 These epidemiological observations 
underlie the 67% reduction in the risk of perinatal death associated with IOL at term.15  
 
Proxies  
The main problem with a primary outcome of perinatal death is that the outcome is uncommon and 
this will result in major issues of statistical power. Indicators of perinatal morbidity would be an 
alternative to perinatal death. First, as the same factors might be involved in death and morbidity, the 
latter could be used as proxies of the former. Second, perinatal morbidity is of importance in its own 
right. For example, birth asphyxia is one of the major determinants of the burden of litigation in the 
health service through devastating effects on the later health of the child, such as cerebral palsy. There 
is evidence that supports the use of a single indicator in both roles. A Apgar score of <4 at five minutes 
was associated with a relative risk of early neonatal death of ~360176 and a relative risk of cerebral 
palsy of >400.175 Hence, a primary outcome based on perinatal morbidity, such as Apgar <4, could be 
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clinically important, both as a proxy of death and as a determinant of long term outcome. Morbidity 
could be a more pragmatic outcome as rates of severe morbidity are much greater than the risks of 
death, hence it may be easier to design a trial.  
 
Sub-groups  
A further refinement to the primary outcome is to study sub-groups of the given event that were 
actually associated with the baby being born SGA or LGA. It is self-evident that screening for SGA or 
LGA will primarily impact on outcomes that are related to fetal growth disorder. Many adverse 
perinatal outcomes, both lethal and non-lethal, are unrelated to fetal growth abnormalities. 
Consequently, if a screening study of fetal biometry has a primary outcome which includes babies in 
the full range of birth weight, most of the primary outcomes in both arms of the trial will be unrelated 
to fetal growth disorder hence not preventable by screening for fetal growth disorder and 
intervention. This means that the potential for screening to impact on the rate of death is limited and 
extremely large sample sizes would be required. For example, about one third of perinatal deaths at 
term are related to being SGA or LGA.51 The background rate of perinatal death at term is ~2 per 1,000. 
Even if a screening test was perfect (i.e. detected all cases of growth disorder) and even if the 
intervention was perfect (i.e. prevented all such deaths), a power calculation still indicates that 
>100,000 women would have to be recruited to the trial. However, if the primary outcome was 
perinatal death of an SGA or LGA infant, the sample size would be ~22,000 (note: this is used to 
illustrate the point, it is not a practical proposition as the screening and intervention characteristics 
were perfect). An analogy might be in a trial of breast cancer screening. Screening reduces deaths 
related to breast cancer but does not reduce all-cause mortality.200 This is likely explained by the fact 
that no study could be sufficiently powered to detect an effect of screening for breast cancer on all-
cause mortality because most deaths are due to other causes. Consequently, one approach to 
addressing the problems of statistical power in trials of screening using fetal biometry would be to 
define primary outcomes which were related to fetal growth abnormalities. Insistence on evidence 
that shows reduction in all cause perinatal death would simply remove the possibility of screening and 
intervention being implemented, which could lead to avoidable harm which could have been 
prevented in a cost-effective way.  
 
 
Early delivery and iatrogenic harm  
Routine induction at term had less dramatic effects on the risk of neonatal morbidity, with a 12% 
reduction in the risk of NICU admission and a 30% reduction in the risk of a low Apgar score. Moreover, 
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these effects may be lost or even reversed in the context of early term IOL. Most of the trials in the 
Cochrane review of term induction were at 41wkGA and beyond.15 As post-term pregnancy is 
associated with increased risks of neonatal morbidity, preventing this outcome should improve 
immediate neonatal outcome as well as prevent stillbirth. In the context of IOL <39 weeks, 
epidemiological data indicate that the intervention may actually increase neonatal morbidity.162 The 
potential for earlier intervention to cause harm is increasingly recognised. The AFFIRM study reported 
a stepped wedge RCT of a programme to inform women about reduced fetal movements and to 
standardise intervention. Although it did not show a significant reduction in stillbirth, the intervention 
was associated with increased risks of neonatal morbidity.201 This trial has some parallels with the 
current question. Despite the fact that women were selected on the basis of having a risk factor 
(reduced fetal movements, which is associated with stillbirth), it still failed to demonstrate reduction 
in stillbirth rates and intervention was associated with increased rates of intervention and adverse 
outcomes. The result of the trial underlines two key issues (i) the need for better predictors of adverse 
outcome, (ii) the potential for intervention to cause harm.  
 
Current status of screening tests  
Unfortunately, the results of our systematic reviews of diagnostic effectiveness and a Cochrane DTA 
review22 failed to identify any ultrasonic marker that was clearly predictive of the risk of stillbirth in 
the context of scanning women in late pregnancy. Moreover, if we regard neonatal morbidity as a 
proxy of stillbirth, again, tests performed very poorly. Finally, actual birth weight <3rd percentile was 
associated with a 0.9% to 1% risk of perinatal death at term compared with a background risk of just 
over 0.2%.51 Hence, even knowing that the actual birth weight was <3rd percentile would be 
associated with an LR+ of between 4 and 5. In the POP study, of 562 women with a scan indicating 
that the baby was SGA, only 12% delivered a baby with a birth weight <3rd percentile, a further 23% 
deliǀeƌed a ďaďǇ шϯƌd aŶd <ϭϬth peƌĐeŶtile ďut aďout tǁo thiƌds of the ǁoŵeŶ deliǀeƌed a ďaďǇ шϭϬth 
percentile. Hence, on the basis of the association between estimated fetal weight and actual birth 
weight, and the relationship between actual birth weight and the risk of stillbirth, it is highly unlikely 
that detecting an SGA infant is strongly predictive of the risk of stillbirth. Given the lack of information, 
we model outcomes with variable incidence and assess different screening test values to establish 
what characteristics would be required of a test to make a trial of screening and intervention feasible. 
 
Possible trial designs  
Broadly speaking, there are two main approaches to trial design (Figure 24).31 First, (hereinafter 
referred to as screen versus no screen) women might be randomised (a) to be screened, with the offer 
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of intervention if they screen positive, or (b) to receive routine care, which is currently only to be 
scanned if there is a conventional clinical indication. The result of this trial design is a simple 
comparison between the two groups. In the event of a statistically non-significant result, it is 
impossible to determine whether the result was because the screening test did not work or because 
the intervention did not mitigate the higher risks in screen positive women. The second approach is 
that the whole of the population is screened and high risk women are randomised to intervention or 
ƌoutiŶe Đaƌe ;ŵaskiŶg the ƌesult iŶ the latteƌ gƌoupͿ, heƌeiŶafteƌ ƌefeƌƌed to as ͞sĐƌeeŶ all͟. The 
advantages of the second approach are that the number of women who need to be recruited is 
substantially reduced and that the same trial can assess both the diagnostic effectiveness of the 
screening test and the clinical effectiveness of the intervention. The two approaches are illustrated in 
the figuƌe ďeloǁ, ͞sĐƌeeŶ ǀeƌsus Ŷo sĐƌeeŶ͟ ;leftͿ aŶd ͞sĐƌeeŶ all͟ ;ƌightͿ. 
 
Figure 24. Flowcharts of possible trial designs. 
 
AĐĐeptaďility of the ͞sĐreeŶ all͟ approaĐh  
When discussing the possibility of randomising women with a high risk screening test some of the co-
applicants expressed concerns. Interestingly, however, when we surveyed pregnant women, they 
actually preferred a study design where all participants were scanned. In the focus group, women 
tended to be more concerned about being offered interventions. The observations underline the 
different perspectives of pregnant women and professionals. We envisage that women who were 
ƌeĐƌuited to a ͞sĐƌeeŶ all͟ appƌoaĐh ǁould haǀe soŵe iŶfoƌŵatioŶ ƌeǀealed iƌƌespeĐtiǀe of theiƌ 
randomisation status. For example, we do not feel that it would be practical or ethical not to reveal 
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the presentation of the baby as cephalic or non-cephalic. Hence, this would likely be revealed in a 
screen all trial design. In the POP study, although scans were blinded, breech presentation was 
revealed. Subsequent interviews with participants were highly positive about this element of the study 
where the baby was breech [Dacey 2015; https://www.repository.cam.ac.uk/handle/1810/280595]. 
A drawback of this approach is, however, that a screen all with reveal breech presentation design 
would not capture the health benefits of detecting breech presentation. Other features that should 
be considered for revealing are the presence of previously undiagnosed major congenital anomalies 
and placenta praevia. In the POP study, there was no case of placenta praevia but two patients had 
major anomalies diagnosed where revealing the result optimised care and, in one case (unilateral 
hydrothorax with severe mediastinal shift), likely prevented intra-uterine fetal demise.  
 
Power calculations  
In order to determine the feasibility of a randomised controlled trial we have performed power 
calculations using the two different study designs represented above. The sample size calculations are 
presented in Table 17. All power calculations are performed for P<0.05 (two-sided) with 90% power 
to detect the effect. We have selected a range of possible primary outcomes, perinatal death, severe 
neonatal morbidity, any neonatal morbidity, and delivery of an SGA infants with complications. In 
relation to perinatal death we found no adequately powered studies of the diagnostic effectiveness 
of ultrasound to predict this outcome and the Cochrane DTA review of SGA also found no data in 
relation to this question. We have, therefore, modelled a series of possible screening performances, 
varying the screen positive rate and LR+. In relation to morbidity, we used two studies reporting data 
from the POP study, from the Lancet 20157 and Lancet CAH 2018.145 As described above, the POP 
study was one of only two studies (Perinatal Ireland Genesis study being the other) which performed 
blinded ultrasound in late gestation in nulliparous women. Unfortunately, the Genesis study has not 
reported the association between SGA and morbidity and the only publication in relation to LGA is in 
abstract form only and addresses shoulder dystocia. The two POP study publications address the 
relationship between SGA, SGA combined with reduced growth velocity (which was the best 
performing predictor of morbidity from a range of candidate predictors of FGR) and the Delphi 
consensus definition of late FGR.  
 
In all of these calculations we assumed that intervention would reduce the risk of the given event by 
50%. Given the lack of data, a range of figures could be considered. We employed this figure as we 
felt that it was conservative in relation to perinatal death. It could be argued, based on the discussion 
above, that it is optimistic in relation to neonatal morbidity. However, by concentrating the outcome 
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for morbidity on infants that are actually SGA, it is plausible that the combined effect of making the 
diagnosis and intervening could cause a substantial reduction in the rate of adverse events. It should 
be borne in mind that in the relevant RCT, DIGITAT, randomisation occurred after ultrasonic SGA was 
suspected. Hence, the group randomised to expectant management would still have received 
enhanced monitoring and high risk care during labour as the baby was known to be SGA. In contrast, 
routine care in a trial of screening means that neither antenatal nor intrapartum care are tailored for 
the suspected SGA status of the fetus. 
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Table 17. Sample size calculations for different outcomes, screening tests and trial designs. 
Outcome  Screening test  SPR  PPV    Sample size  Reference  
            Screen all, randomise high risk    
  
  
      Screen vs.   
no screen  
Number   
needed to screen  
Number of   
high risk women  
  
Perinatal death (background = 0.2%)              
  LR+ = 2  10%  0.4%    1,488,448  234,740  23,474    
  LR+ = 3  10%  0.6%    644,156  156,260  15,626    
  LR+ = 5  10%  1.0%    219,382  93,460  9,346    
  LR+ = 2  5%  0.4%    6,110,172  469,480  23,474    
  LR+ = 3  5%  0.6%    2,680,882  312,520  15,626    
  LR+ = 5  5%  1.0%    940,096  186,920  9,346    
  LR+ = 10  5%  2.0%    219,382  92,760  4,638    
Any neonatal morbidity                
  EFW <10th  14%  10.3%    36,910  6,014  842  Sovio et al 2015  
  EFW< 10th + ACGV  4.3%  15.7%    172,522  12,279  528  Sovio et al 2015  
Severe  neonatal morbidity                
  EFW <10th  14%  1.07%    422,336  63,743  8,924  Sovio et al 2015  
  EFW< 10th + ACGV  4.3%  2.33%    965,714  93,256  4,010  Sovio et al 2015  
Complicated SGA                
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  EFW <10th  14%  7.5%    13,920  8,457  1,184  Gaccioli et al 2018  
  EFW< 10th + ACGV  4.3%  11.2%    73,538  17,860  768  Gaccioli et al 2018  
  Delphi  11.3%  8.5%    16,952  9,168  1,036  Gaccioli et al 2018  
 
SPR = screen positive rate, PPV = positive predictive value, EFW = estimated fetal weight, ACGV = abdominal circumference growth velocity in the lowest decile 
(see Sovio et al 2015). Delphi  = fulfilled definition of late FGR using  criteria of Gordjin et al 2016 (except MCA Doppler not included).  Neonatal morbidity and 
severe neonatal morbidity are defined in Sovio et al 2015 and complicated SGA is defined in Gaccioli et al 2018 (in brief =  delivery of a baby with a birth weight 
<10th percentile where either the mother had a diagnosis of preeclampsia or the baby experienced neonatal morbidity). 
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Implications of sample size calculations  
We present the data on sample size calculations but we are not recommending a specific trial design. 
It is also possible that a trial may be considered where the combination of screening parameters, 
intervention effect and outcome are not listed in the Table above. The exact design of the trial would 
depend on the resources available and the research question. We do, however, discuss some of the 
issues which might motivate a choice.  
 
We believe that the calculations above rule out a trial based either on perinatal death or severe 
neonatal morbidity as the sample size required is so great that the trial may not be feasible but would 
inevitably be extremely expensive. Whether the screening test is simple SGA or whether one of the 
FGR indicators is used will depend on the trade-off between labelling much larger numbers of women 
screen positive versus sample size. In all calculations, the screen positive rate was higher with SGA but 
the sample size was lower.   
 
Whether a screen versus no screen or a screen all approach is used will depend on the information 
required and on the screening test evaluated. A problem with the screen all approach is that is does 
not recapitulate the real world of comparing not doing something versus doing it. It would also not 
capture health benefits related to diagnosing non-cephalic presentation at 36wkGA. However, it 
would provide more information about the evidence base as it would allow quantification of 
performance of the screening test and intervention separately. Finally, the complicated SGA outcome 
is delivery of a small baby where either the mother experiences preeclampsia or the baby experiences 
morbidity. This outcome has the attraction of focusing on the cases which are most likely to reflect 
true FGR and it is perhaps in this group where the intervention is most likely to yield a positive result. 
However, a primary outcome that includes morbidity to all infants may be preferred if the priority is 
to determine the overall effect of screening and intervention. It is also worth noting in the 
͞ĐoŵpliĐated “GA͟ outĐoŵe that the sĐƌeeŶ all studǇ desigŶ ǁould aĐtuallǇ iŶǀolǀe peƌfoƌŵiŶg ŵoƌe 
scans than the screen versus no screen design if the screening test was simple SGA or the Delphi 
consensus definition of FGR. 
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Chapter 14. Overall conclusions and assessment of evidence required for a national screening 
programme. 
 
Overall conclusions • Late pregnancy ultrasound is only weakly predictive of neonatal morbidity • Late pregnancy ultrasound is strongly predictive of SGA and LGA birth weight • There is a strong health economic case for implementing a scan in late pregnancy to assess 
fetal presentation • There is a chance that screening for fetal size in late pregnancy may be cost-effective under 
the current NHS recommendations, however: • The balance of probabilities favours a presentation only scan • The case for including assessment of fetal size is sensitive to the assumptions of 
the model • There is no direct evidence from an RCT or meta-analysis that screening and 
intervention is clinically effective • The main uncertainty in relation to the health economic case for universal ultrasound 
(including both presentation and an estimate of fetal size) is uncertainty about the net costs 
of IOL versus expectant management • Randomised controlled trials of late pregnancy screening aimed at directly demonstrating a 
protective effect on the risk of perinatal death or severe morbidity are unlikely to be feasible 
due to the required sample size • Randomised controlled trials of late pregnancy screening aimed at directly demonstrating a 
protective effect on the risk of proxies or sub-groups of outcomes could be feasible due to 
sample size, but would depend on the exact study design 
 
Consultation with the National Screening Committee 
We sent the scientific summary of the project and the chapter on trial design to the UK National 
Screening Committee (NSC) Evidence Lead who has worked for the UK NSC for >15 years. The UK NSC 
would be happy to contribute to any further HTA discussions where this is useful. Following 
preliminary discussion, the applicants plan to submit a proposal to the UK NSC to suggest that they 
recommend a screening programme for breech near term. Their evidence review process is outlined 
on their website (https://www.gov.uk/government/publications/uk-nsc-evidence-review-process). 
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We then discussed the case for a trial of including assessment of fetal size in the same scan. The key 
questions were as follows: 
1. If the uncertainty around the costs of IOL were reduced, how likely is it that the NSC would 
recommend screening for fetal size near term based on a model that lacked direct evidence 
from an RCT that involved screening? For example, if the currently funded HTA trial around 
IOL for suspected fetal macrosomia confirms improved outcomes with intervention, would 
the combination of the diagnostic effectiveness of ultrasound as a screening test for LGA and 
the clinical effectiveness of IOL as an intervention in LGA be regarded as acceptable evidence 
for screening? The issue of interpretation is that screened women are likely to have lower 
prior odds of complications than women identified as having an LGA fetus through a clinically 
indicated scan. Hence, extrapolation of the results of the trial may involve an assumption that 
is untrue. 
2. If direct evidence of a beneficial effect of screening from an RCT was required, would this have 
to come from a screen versus no screen trial or would evidence from a screen all trial suffice? 
3. What outcomes would be acceptable? Specifically: 
(i) would screening be recommended on the basis of an effect on proxies? 
(ii) would screening be considered on the basis of an effect on a sub-group, for 
example, sub-groups of neonatal morbidity or mortality confined to infants which 
were actually small or large at birth? 
(iii) would screening be considered on the basis of an effect on a composite outcome? 
 
Following discussion, the overvieǁ ǁas that the N“C does Ŷot haǀe speĐifiĐ ͞haƌd stops͟ ďut, as oŶe 
would expect, the stronger the evidence across the 20 criteria for assessing the viability of a screening 
programme, the more likely it is that a programme would be recommended. For example, because 
the committee bases recommendations on an assessment of these criteria, it would not necessarily 
reject a screening programme because the main trial supporting the programme reported a composite 
outcome in one criterion. But, all other things being equal, a programme would be less likely to be 
recommended if the study was based on a composite. Hence, none of the questions above were 
answered by a simple yes/no. But the following were key points: 
1. RCTs based on intervention from screen positive women would provide much stronger 
support for a programme than evidence derived from RCTs of high-risk women (i.e. those not 
identified through screening the general population).  
2. Data from a screen versus no screen study would be preferred to a screen all design. However, 
one approach if there were absolute methodological obstacles to screen versus no screen 
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would be to show proof of principle with a screen all study, consider other studies to address 
any shortfall arising from this design and other criteria, and then to perform a stepped wedged 
randomised controlled trial when implementing the new test. 
Although evidence from trials reporting proxies, sub-groups and composite outcomes would be 
considered, a strong case for screening would have a simple substantive outcome that reflected the 
totality of the effect of screening (i.e. benefit to true positives and harm to false positives). 
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Appendix 1. Supporting data for the systematic review of the diagnostic effectiveness of universal 
ultrasonic screening using late pregnancy umbilical artery Doppler flow velocimetry in the 
prediction of adverse perinatal outcome. 
 
 
Literature search strategy for Medline and Embase (from inception to the 19/03/2019) 
 
1. exp pregnant woman/  
2. exp pregnancy/  
3. pregnan*.mp.  
 
4. exp prenatal diagnosis/  
5. exp fetus echography/  
6. exp Doppler ultrasonography/  
 
7. arterial doppler.mp.  
8. doppler velocimetry.mp.  
9. doppler ultraso*.mp.  
10. umbilical arter*.mp. 
  
11. 1 or 2 or 3  
12. 4 or 5 or 6  
13. 7 or 8 or 9 or 10  
14. 11 and 12  
15. 13 and 14 
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Figure 25. POP study inclusion flowchart. 
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Table 18. Maternal characteristics and birth outcomes of POP study. 
      
Characteristic Umbilical artery PI 
>90th centile 
(N=346) 
Umbilical artery PI 
<90th centile 
(N=3269) 
P Value Overall baseline 
characteristics 
(N=3615) 
      
Maternal characteristics  
Age, years  29.7 (26.2-32.7) 30.3 (26.8-33.3) 0.05 30.2 (26.7-33.3) 
      
Deprivation quartile     
 1 (lowest) 97 (28.0) 784 (24.0) 0.14 881 (24.4) 
 2 73 (21.1) 776 (23.7) 849 (23.5) 
 3 92 (26.6) 773 (23.7) 865 (23.9) 
 4 (highest) 71 (20.5) 799 (24.4) 870 (24.1) 
 Missing  
 
13 (3.7) 137 (4.2)  150 (4.2) 
White ethnicity 324 (93.6) 3036 (92.9) 0.53 3360 (93.0) 
 Missing  
 
6 (1.7) 56 (1.7)  62 (1.7) 
Married 229 (66.2) 2238 (68.5) 0.39 2467 (68.2) 
      
Smoker 24 (6.9) 152 (4.7) 0.06 176 (4.9) 
      
Any alcohol consumption 13 (3.8) 155 (4.7) 0.40 168 (4.7) 
 Missing  
 
0 (0) 1(0)  1 (0) 
BMI, kg/m2 24.3 (21.7-28.1) 24.0 (21.8-27.2) 0.44 24.0 (21.8-27.3) 
      
шϭ pƌeǀious ŵisĐaƌƌiage 34 (9.8) 331 (10.1) 0.86 365 (10.1) 
      
Chronic hypertension 25 (7.3) 161 (4.9) 0.06  
      
Pre-eclampsia 29 (8.4) 204 (6.2) 0.12 233 (6.5) 
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 Missing 0(0) 2(0.1)  2 (0.1) 
      
Diabetes     
 Type 1 or type 2 DM 2 (0.6) 10 (0.3) 0.14 12 (0.3) 
 Gestational DM 20 (5.8) 124 (3.8) 144 (4.0) 
     
Birth outcomes  
Birth weight, g  3263 (2970-3560) 3470 (3170-3770) <0.001 3445 (3150-3750) 
     
Gestational age, weeks 40.4 (39.3 – 41.1) 40.4 (39.4- 41.3) 0.74 40.4 (39.4- 41.3) 
 <37 3 (0.9) 34 (1.0) 0.19* 37 (1.0) 
 37 22 (6.4) 133 (4.1) 155 (4.3) 
 38 35 (10.1) 360 (11.0) 395 (10.9) 
 39  71 (20.5) 641 (19.6) 712 (19.7) 
 40 92 (26.6) 1001 (30.6) 1093 (30.2) 
 41 102 (29.5) 909 (27.8) 1011 (30.0) 
 ш ϰϮ 21 (6.1) 191 (5.8) 212 (5.9) 
      
Induction of labor 125 (36.1) 1081 (33.1) 0.25 1206 (33.4) 
     
Mode of delivery     
 Spontaneous vaginal 178 (51.5) 1662 (50.8) 0.20 1840 (50.9) 
 Assisted vaginal 86 (24.9) 821 (25.1) 907 (25.1) 
 Intrapartum cesarean 54 (15.6) 601 (18.4) 655 (18.1) 
 Pre-labor cesarean 27 (7.8) 176 (5.4) 203 (5.6) 
 Missing  1 (0.3) 9 (0.3)  10 (0.3) 
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Figure 26. Literature search PRISMA flow diagram for the systematic review on umbilical artery 
Doppler. 
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Figure 27. Risk of bias and applicability concerns using the QUADAS-2 tool for the studies included 
in the meta-analysis of umbilical artery Doppler. 
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Table 19. Characteristics of studies included in the meta-analysis. 
First Author (Year) Type of Study, 
Setting 
Number of fetuses 
and selection 
(All singleton, non 
anomalous unless 
otherwise stated) 
Index test  
 
Gestational 
age at 
ultrasound 
Reference standard Gestational age at 
delivery 
Other comments 
Akolekar 201939 Prospective 
cohort, 2 NHS 
Hospital, UK 
Between March 
2014 and 
September 2018 
(potential overlap 
with Valino 
studies) 
N= 47,211 
Universal, >36 
weeks.  
 
 
PI >90th centile. 
Not blinded. 
Between 35+6 
and 37+6 
weeks.  
Adverse perinatal 
outcome (composite of 
stillbirth, neonatal 
deaths and HIE grade 2 
or 3), perinatal hypoxia 
(cord artery PH <7.0, 5-
minute Apgar score <7, 
NICU admission), CS for 
fetal compromise, SGA 
<3rd centile.  
Median ga at 
delivery 40.0 
(39.0-40.9) weeks. 
Nulliparous: 45.4% 
for those with no 
adverse outcome, 
58.5% for those 
with adverse 
outcome.  
 
Bolz 201340 Prospective 
cohort, 
Single Hospital, 
Germany 
 N=514 
Low risk, term, 
cephalic only. 
Excluded maternal 
disease, SGA, 
RFM.  
PI>1.2 
Blinded UA 
Doppler. 
Within 1 week 
from delivery. 
Mean ga 39+2 
weeks. 
Neonatal acidosis (cord 
arterial PH <7.10) 
Mean ga 40+1 
weeks 
Nulliparity: Not 
reported. 
IOL: Not reported. 
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Cooley 201141 Prospective 
cohort, 
Single Hospital, 
Ireland 
N=810 
Mixed risk, 
nulliparous only. 
Only included 
Caucasian aged 
18-40 years. 
PI>95th centile 
UA blinded but 
EFW not 
blinded. 
Around 36 
weeks (not 
specified) 
Emergency CS, 
PIH, PET, preterm 
delivery (<37 weeks), 
SGA <10th centile, SGA 
<3rd centile, 5-minute 
Apgar score <7, Cord 
arterial PH <7.10, NICU 
admission, Stillbirth 
Not reported Nulliparity: All 
IOL: 22.4%. 
 
Filmar 201342 Retrospective 
cohort, Single 
Hospital, New 
York, NY, USA 
N=251  
Mixed risk, 
EFW>10th centile. 
S/D ratio >90th 
centile 
(persistent),  
Not blinded.  
Mean ga 35.3 
weeks for 
abnormal UA 
group. Mean 
ga 34.4 for 
control group. 
NICU admission, 5-
minute Apgar score <7 
Median ga 37 
weeks for 
abnormal UA 
group, 39 weeks 
for control group. 
Nulliparity: Not 
reported 
IOL: Not reported. 
Fischer 199143 Prospective 
cohort 
Single Hospital, 
Pennsylvania, USA 
N= 75 
Low risk, post 
dates >41 weeks. 
Excluded maternal 
disease, suspected 
IUGR. 
S/D ratio >3.0 
S/D ratio >2.4 
Blinded UA 
Doppler. 
Mean interval 
from scan to 
delivery 2 days 
Composite perinatal 
outcome: 1) Non-
reassuring intrapartum 
fetal heart rate. 2) 
Umbilical artery PH 
<7.15, or venous <7.2 3) 
5-min Apgar score <7 4) 
meconium stained 
liquor, 5) NICU 
admission, 6) 
Mean ga at 
delivery 292.2 
days 
Nulliparity: 57% 
IOL: Not reported 
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birthweight <10th 
centile. 
Goffinet 199644 Prospective 
cohort, 
17 hospitals, 
France 
N=1903 
Low risk, excluded 
maternal disease, 
suspected IUGR 
RI >90th centile 
Not blinded. 
Between 28 
and 34 weeks 
PIH, PET, Intervention 
for fetal distress, 5-
minute Apgar <7, NICU 
admission, birthweight 
<3rd centile, birthweight 
3-10th centile 
Mean ga 39.2 
weeks for those 
with abnormal UA, 
39.4 weeks for 
those with normal 
UA. 
Nulliparous: 43.0% 
for those with 
abnormal UA, 
45.3% for normal. 
Hanretty 198945 Prospective 
cohort, 
Single Hospital, 
Glasgow, UK 
N=395 
Universal 
AB ratio >95th 
centile. 
Blinded UA 
doppler 
34-36 weeks PIH, SGA <5th centile, 5-
minute Apgar <6, NICU 
admission 
Mean ga 38.9 
weeks for those 
with abnormal UA, 
39.5 for those 
with normal UA. 
Nulliparity: Not 
reported 
IOL: Not reported. 
Moraitis (POPS) Prospective 
cohort, Single 
Hospital, 
Cambridge, UK 
N=3615 
Universal, 
nulliparous only, 
>36 weeks 
PI >90th centile 
Blinded. 
Mean 36 
weeks 
NICU admission, 
metabolic acidosis, 5-
min Apgar score <7, 
composite neonatal 
morbidity (1 or more of 
the above), composite 
severe neonatal 
morbidity, SGA <10th 
centile, SGA <3rd centile 
40.4 (39.3-41.1) Nulliparity: All 
IOL: 36.1% for 
those with 
abnormal UA 
doppler, 33.1% for 
those with normal 
UA doppler.  
Schulman 198946 Prospective 
cohort, 
N=255 
Mixed  
S/D ratio >3 
Not blinded. 
Around 30 
weeks 
SGA <15th centile Not reported Nulliparity: Not 
reported 
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Single Hospital, 
NY, USA 
IOL: Not reported. 
Sijmons 198947 Prospective 
cohort 
Single Hospital, 
Netherlands 
N=368 
Mixed (randomly 
selected) 
PI>95th centile 
Blinded UA 
doppler 
At 28 and34 
weeks 
SGA <10th centile, SGA 
<3rd centile 
Not reported Nulliparity: Not 
reported 
IOL: Not reported. 
Valino 2016a48 
 
Retrospective 
cohort, 3 NHS 
hospitals, South 
East England, UK 
May 2011- August 
2014 
N=8262 
Universal 
PI >95th centile 
PI >90th centile 
Not blinded 
30+0- 34+6 
weeks 
Mean 32.2 
weeks 
Term PET, term SGA 
<10th centile, Stillbirth, 
CS for fetal distress, 
Cord arterial PH <7.0, 5-
minute Apgar score <7, 
NICU admission 
Mean 40.0 weeks Nulliparous: 49.2% 
IOL: 15.5% 
Valino 2016b48 
 
Retrospective 
cohort, 2 NHS 
hospitals, South 
East England, UK 
February 2014- 
December 2014 
(potential overlap 
with above) 
N=3953 
Universal 
PI >95th centile 
Not blinded 
35+0- 37+6 
weeks 
Mean 36.1 
weeks 
PET, SGA <10th centile, 
CS for fetal distress, 
Cord arterial PH <7.0, 5-
minute Apgar score <7, 
NICU admission 
Mean 40.0 weeks Nulliparous: 49.7% 
IOL: 19.1% 
Weiner 199350 Prospective 
cohort, 
Single Hospital, 
Israel 
N=142 
Low risk, term 
only >41 weeks. 
RI >95th centile. 
Not blinded 
After 41 weeks Composite adverse 
outcome:1) 5-minute 
Apgar <7, 2) NICU 
admission, 3) CS for 
Mean 41.8 weeks Nulliparous: n=43 
IOL: Not reported. 
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fetal distress, SGA <5th 
centile 
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Figure 28. Deeks’ fuŶŶel plot for puďliĐatioŶ bias for umbilical artery doppler for the prediction of 
neonatal unit admission. 
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Appendix 2. Supporting data for the systematic review of the diagnostic effectiveness of universal 
ultrasonic screening using late pregnancy cerebro-placental ratio in the prediction of adverse 
perinatal outcome.  
 
Literature search strategy for Medline and Embase (from inception to the 30/05/2019) 
1. exp pregnant woman/  
2. exp pregnancy/  
3. pregnan*.mp.  
 
4. exp fetus echography/  
5. exp prenatal diagnosis/  
6. exp Doppler ultrasonography/  
7. exp fetus monitoring/  
8. ultraso*.mp.  
 
9. exp middle cerebral artery/  
10. middle cerebral artery.mp.  
11. uteroplacental.mp.  
12. utero-placental.mp.  
13. cerebroplacental.mp.  
14. cerebro-placental.mp.  
15. cerebroumbilical.mp.  
16. cerebro-umbilical.mp.  
17. fetal brain doppler.mp.  
18. fetal cerebral doppler.mp. 
  
19. 1 or 2 or 3  
20. 4 or 5 or 6 or 7 or 8  
21. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18  
22. 19 and 20  
23. 21 and 22 
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Figure 29. Literature search PRISMA flow diagram for the systematic review on cerebro-placental 
ratio. 
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Figure 30. Risk of bias and applicability concerns using the QUADAS-2 tool for the studies included 
in the meta-analysis of cerebro-placental ratio. 
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Table 20. Characteristics of the studies included in the meta-analysis of cerebroplacental ratio to predict adverse pregnancy outcome. 
First Author 
(Year) 
Type of Study, 
Setting 
Number of fetuses and 
selection 
(All singleton, non-
anomalous unless 
otherwise stated) 
Index test  
CPR = MCA PI/ 
Umbilical Artery 
PI 
(unless 
otherwise 
stated) 
Gestational 
age at 
ultrasound 
Reference standard Gestational 
age at delivery 
Other comments 
Akolekar 
201554 
Prospective cohort. 
2 NHS hospitals 
;KiŶg͛s College 
London, Medway 
Maritime Hospital), 
UK. 
(Between February 
2014 and December 
2014).  
N= 6038. 
Universal screening.  
 
CRP < 5th 
centile. 
Not blinded.  
35+0 to 
37+6 
Median 36.1 
(IQR 36.0-
36.6) 
Cord arterial PH <7.0, 
5-min Apgar score <7, 
NICU admission. 
Median 39.9 
(IQR 39.0- 
40.7) 
Nulliparous: 49.8% 
IOL: 20% overall. 
Akolekar 
201939 
Prospective cohort, 
2 NHS Hospitals 
;KiŶg͛s Đollege, 
Medway Maritime 
Hospital), UK 
(Between March 
2014 and 
N= 47,211 
Universal screening.   
 
 
CRP < 10th 
centile. 
Not blinded. 
Between 
35+0 and 
37+6 weeks.  
Adverse perinatal 
outcome (composite of 
stillbirths, neonatal 
deaths and HIE grade 2 
or 3), perinatal hypoxia 
(composite of cord 
artery PH <7.0 and 
Median ga at 
delivery 40.0 
(39.0-40.9) 
weeks. 
Nulliparous: 45.4% 
for those with no 
adverse outcome, 
58.5% for those with 
adverse outcome.  
IOL: Not reported. 
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September 2018; 
Significant 
population overlap 
with Akolekar 2015 
study)  
venous <7.1, 5-minute 
Apgar score <7, NICU 
admission for >24 
hours), CS for fetal 
compromise, SGA <3rd 
centile.  
Bakalis 201555 Prospective cohort. 
3 NHS hospitals 
(KCL, UCL, Medway 
Maritime Hospital), 
UK 
(Between May 2011 
to August 2014; 
likely population 
overlap with 
Akolekar 2015 and 
2019 studies) 
N= 30,780. 
Universal screening.  
CRP < 5th 
centile. 
Not blinded. 
30+0 to 
34+6, Mean 
32.3  
(IQR 32.0- 
32.9) 
Stillbirth; Emergency 
caesarean for fetal 
distress (ECFS), cord art 
PH <7.0; cord venous 
PH ,7.1; 5-min Apgar 
score <7; NNU 
admission; NICU 
admission. 
Median 40 
(IQR 39.0-
40.9) 
Nulliparous: 50.2% 
Further analysed in 
SGA vs. AGA and 
delivery < 2 weeks 
from scan vs. > 2 
weeks from scan. 
IOL: 14.5% overall. 
Bligh 2018 
(A)56 
Prospective cohort, 
1 hospital, Brisbane, 
Australia (May 2014 
– August 2016) 
N= 437 
Low risk 
Uncomplicated, term 
only.  
CPR <10th centile 
Blinded.  
From 36+1 
weeks 
forward.  
Within 2 
weeks of 
delivery 
CS for fetal distress. 
Composite adverse 
neonatal outcome 
(cord artery PH <7.10, 
5-min Apgar <7, or 
NICU admission) 
Median 40 
(IQR 39.3-
40.9) 
Nulliparous: 87.4% 
IOL: Not reported. 
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Bligh 2018 
(B)57 
Prospective cohort, 
1 hospital, Brisbane, 
Australia (May 2014 
– August 2016) 
N= 437 
Low risk 
Uncomplicated, term 
only.  
CPR <10th centile 
CPR <5th centile 
Blinded.  
From 36 
Within 2 
weeks of 
delivery 
SGA <10th centile 
SGA <5th centile 
 
Median 40 
(IQR 39.3-
40.9) 
Nulliparous: 87.4% 
IOL: Not reported. 
Flatley 201958 Retrospective 
cohort, 
1 hospital, Brisbane, 
Australia (2010-
2015) 
(Likely some 
population overlap 
with Bligh 2018) 
N= 2425 
Mixed risk 
Excluded preterm 
delivery <37 weeks, 
maternal hypertension 
and diabetes mellitus.  
 
CPR <10th 
centile. 
Not blinded. 
Between 36-
38 wks  
Cord artery PH <7.00, 
5-minute Apgar 3, 
NICU admission, 
perinatal death. 
Composite of all the 
above (SCNO) 
CS for fetal distress. 
SGA <10th centile, SGA 
<5th centile.  
Term only, 
54.5% of those 
with abnormal 
CPR delivered 
<39 wks, 
36,4% of those 
with normal 
CPR 
Nulliparous: 65.4% of 
those with abnormal 
CPR, 48.0% of those 
with normal CPR. 
IOL: 46.4% for those 
with abnormal CPR, 
39.5% for those with 
normal CPR.  
Khalil 201559 Retrospective 
cohort. 
1 tertiary NHS 
hospital (St 
Geoƌge͛sͿ, UK 
(2000-2013) 
N= 9772 
Low risk. 
Term only. For the 
analysis of operative 
delivery for fetal 
distress , the patients 
that had elective CS 
were excluded. 
CPR < 0.6765 
MoM  
Not blinded. 
Within 2 
wks of 
delivery. 
Median 40.4 
for those 
admitted to 
NNU, 40.4 
wks for 
those not 
admitted. 
NNU admission 
Operative delivery of 
fetal distress, (including 
instrumental delivery 
and CS),  
 
Median 41.1 
for both those 
admitted and 
those not 
admitted to 
NNU.  
Nulliparous:  
65.2% of those 
admitted to NNU, 
54.6% for those not 
admitted to NNU. 
IOL: 44.1% for NNU 
39.4% for no NNU. 
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Maged 201460 Prospective cohort 
1 hospital, Cairo, 
Egypt 
N= 100 
Low risk. 
Included those 
delivered between 40-
42 weeks. 
Excluded PPROM , APH, 
patients in labor and 
maternal HTN/DM.  
CPR < 1.05 
Not blinded. 
37.8 weeks 
for those 
with 
adverse 
outcome, 
39.5 weeks 
for those 
with normal. 
C-Section for fetal 
distress (CSFD). 
Composite adverse 
pregnancy outcome 
defined as 1 or more 
of: CSFD, 5-min Apgar 
<7, MAS, NICU 
admission. 
283.1 days for 
those with 
adverse 
outcome, 
281.7 for 
those with 
normal 
outcome. 
Nulliparous: Not 
reported. 
IOL: Not reported 
Monaghan 
201761 
Retrospective 
cohort 
1 NHS hospital (St 
Geoƌge͛sͿ, UK 
January 2008- June 
2016  
(Likely population 
overlap with Khalil 
2015) 
N= 7013 
Mixed risk (had USS 
based on NHS 
indications). 
Only included those 
delivered after 36 
weeks. 
CPR <10th centile 
CPR <5th centile 
Not blinded 
36.4 wks for 
all live 
births, 37 
wks for 
perinatal 
deaths 
Perinatal death Median: 40.1 
weeks for all 
live births, 39 
weeks for 
perinatal 
deaths 
Nulliparous: Not 
reported. 
IOL: Not reported. 
 
Morales-
Rosello 201462 
Retrospective 
cohort 
1 NHS hospital 
(St George͛sͿ, UK,  
2002-2012  
(Likely population 
overlap with Khalil 
N= 11,576 
Mixed risk . 
Term only with USS 
within 14 days of 
delivery. 
CPR <0.6765 
MoM 
Not blinded 
Mean: 40.1 
+/-1.5 
weeks. 
SGA <10th centile. Mean 40.8 +/- 
1.3 
Nulliparous: Not 
reported. 
IOL: Not reported. 
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2015 and Monaghan 
2017) 
Prior 201363 Prospective cohort. 
1 NHS hospital 
;QueeŶ Chaƌlotte͛s 
and Chelsea), UK. 
(March 2011-March 
2014) 
N= 400 
Low risk. 
Term only. Recruited 
before active labor. 
Excluded PET, FGR, 
intrauterine infection. 
CPR <10th 
centile 
Blinded.  
Mean: 40 
weeks + 2 
days. 
(Range: 
37+0 – 
42+1) 
CS for fetal 
compromise, 5-min 
Apgar <7, Cord arterial 
PH<7.20, NNU 
admission 
Within 72 
hours from 
scan  
Nulliparous: 65.5% 
IOL: Not reported. 
Prior 201564  Prospective cohort 
1 tertiary NHS 
hospital (Chelsea), 
UK. 
(Likely population 
overlap with Prior 
2013 study) 
N= 775 
Low risk  
Term only. Recruited 
before active labor or 
IOL (for postdates or 
social). Excluded 
SGA/FGR, PIH/PET, 
PPROM. 
CRP <0.6765 
MoM 
Blinded. 
Median 41 
weeks 
(range 37-
42) 
CS for fetal distress, 5-
min Apgar score <7, 
cord arterial PH<7.20, 
NNU admission. 
Within 72 
hours from 
scan 
Nulliparous: 80.8% 
IOL: Not reported. 
Rial-Crestelo 
201965  
Prospective cohort, 
1 hospital, 
Barcelona. January 
2013- December 
2016 
N= 1030 
Universal screening 
CPR <10th centile 
Doppler blinded 
for those with 
EFW >10th 
centile.  
Between 
32+0 and 
34+6 wks.  
Mean 33 
wks 
SGA <10th centile Mean 40 
weeks  
Nulliparous: 70% of 
those born SGA, 54% 
of non-SGA. 
IOL: Not reported. 
Sabdia 201566 Retrospective 
cohort 
N= 1381 
Mixed risk. 
CPR < 10th 
centile (1.20). 
Not blinded. 
Between 35 
and 37 
weeks 
Operative delivery for 
fetal distress (CS or 
instrumental), 5 min 
Median ga 36 
wks for those 
with abnormal 
Nulliparous: 53.9% of 
those with abnormal 
  
192 
 
1 hospital, Brisbane, 
Australia 
(June 1998- 
November 2013) 
Included cephalic with 
UA PI < 95th centile. 
Apgar score <7, NICU 
admission. 
CPR, 38 wks 
for normal 
CPR 
CPR, 40.4% of those 
with normal CPR 
IOL: Not reported. 
Stumpfe 
201967 
Retrospective 
cohort 
Single tertiary 
centre, Germany 
(January 2016- April 
2017) 
N= 1008 
Low risk,  
Term only, excluded 
those in labour, 
elective CS, EFW <10th 
centile. 
CPR <0.6765 
MoM 
Not blinded. 
Term , 
within 72 
hours of 
delivery 
CS for fetal distress, 5-
min Apgar score <7, 
cord arterial PH <7.10 
Term  
(not further 
specified) 
Nulliparous: Not 
specified 
IOL: 42.4% overall. 
 
Twomey 
201668 
Retrospective 
cohort. 
1 l hospital, 
Brisbane, Australia. 
(January 2007-
December 2013) 
(Population overlap 
with Sabdia 2015) 
n =1224. 
Mixed risk. 
Excluded women that 
had elective caesarean 
section. 
CPR <1. 
Not blinded. 
 
30–34 wks.  
Median 32.1 
wks. 
CS for fetal 
compromise, Cord PH 
<7.0, 5-minute Apgar 3, NNU admission, 
SGA <10th centile, SGA 
<5th centile.  
Mean ga 32 
wks for those 
with CPR <1, 
37 wks for 
those with 
CPR>1. 
Nulliparous: 43.2% 
IOL: Not reported 
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Figure 31. Deeks’ fuŶŶel plot for puďliĐatioŶ ďias for ĐereďroplaĐeŶtal ratio for the prediĐtioŶ of 
neonatal unit admission. 
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Appendix 3. Supporting data for the systematic review of the diagnostic effectiveness of universal 
ultrasonic screening using severe oligohydramnios in the prediction of adverse perinatal outcome.  
 
Literature search strategy for Medline and Embase (from 01/01/2011 to 05/06/2019) 
1. exp Pregnant Women/  
2. limit 1 to yr="2011 -Current"  
3. exp Pregnancy Trimester/ 
4. limit 3 to yr="2011 -Current"  
5. pregnan*.mp.  
6. limit 5 to yr="2011 -Current"  
7. exp Prenatal Diagnosis/  
8. limit 7 to yr="2011 -Current"  
9. exp Ultrasonography, Prenatal/  
10. limit 9 to yr="2011 -Current"  
11. exp Amniotic Fluid/  
12. limit 11 to yr="2011 -Current"  
13. exp Oligohydramnios/  
14. limit 13 to yr="2011 -Current"  
15. oligohydramnio*.mp.  
16. limit 15 to yr="2011 -Current"  
17. exp Polyhydramnios/  
18. limit 17 to yr="2011 -Current"  
19. polyhydramnio*.mp.  
20. limit 19 to yr="2011 -Current"  
21. amniotic fluid index.mp.  
22. limit 21 to yr="2011 -Current"  
23. AFI.mp.  
24. limit 23 to yr="2011 -Current"  
25. maximum pool depth.mp.  
26. limit 25 to yr="2011 -Current"  
27. MPD.mp.  
28. limit 27 to yr="2011 -Current"  
29. single deepest pocket.mp.  
30. limit 29 to yr="2011 -Current"  
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31. SDP.mp.  
32. limit 31 to yr="2011 -Current"  
33. largest vertical pocket.mp.  
34. limit 33 to yr="2011 -Current"  
35. LVP.mp.  
36. limit 35 to yr="2011 -Current"  
37. maximum vertical pocket.mp.  
38. limit 37 to yr="2011 -Current"  
39. MVP.mp.  
40. limit 39 to yr="2011 -Current"  
41. amniotic fluid volume.mp.  
42. limit 41 to yr="2011 -Current"  
43. anhydramnios.mp.  
44. limit 43 to yr="2011 -Current"  
45. liquor volume.mp.  
46. limit 45 to yr="2011 -Current"  
47. quadrants.mp.  
48. limit 47 to yr="2011 -Current"  
49. biophysical profile.mp.  
50. limit 49 to yr="2011 -Current"  
51. BPP.mp.  
52. limit 51 to yr="2011 -Current"  
53. 2 or 4 or 6  
54. 8 or 10 or 12 or 14 or 16 or 18 or 20  
55. 22 or 24 or 26 or 28 or 30 or 32 or 34 or 36 or 38 or 40 or 42 or 44 or 46 or 48 or 50 or 52  
56. 53 and 54 and 55  
57. 8 or 10  
58. 12 or 14 or 16 or 18 or 20 or 22 or 24 or 26 or 28 or 30 or 32 or 34 or 36 or 38 or 40 or 42 or 44 
or 46 or 48 or 50 or 52  
59. 53 and 57 and 58 
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Figure 32. PRISMA flow diagram for the systematic review of severe oligohydramnios. 
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Figure 33. Risk of bias graph of included studies for systematic review of severe oligohydramnios 
using the QUADAS-2 tool. 
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Table 21. Characteristics of studies included in the meta-analysis of severe oligohydramnios. 
First Author 
(Year) 
Type of 
Study, Setting 
Number of fetuses and 
selection 
(All singleton, non 
anomalous unless 
otherwise stated) 
Index test  
 
Gestational 
age at 
ultrasound 
Reference standard Gestational age 
at delivery 
Other comments 
Ashwal 
201472 
Retrospective 
cohort 
Single 
University 
hospital, 
Israel 
N=23,267 
Low risk 
Term only. Excluded 
pregnancies with 
hypertensive disorders, 
diabetes, AFI >25cm, 
and EFW <10th centile. 
AFI <5cm  
Not 
blinded  
Within 1 
week from 
delivery 
C-Section for fetal distress 
(CSFD), operative vaginal delivery 
for fetal distress, 5-min Apgar <7, 
umbilical artery pH < 7.10, NICU 
admission, need for intubation, 
meconium aspiration syndrome 
(MAS) or HIE. Also stillbirth, 
neonatal death, IVH, meconium 
amniotic fluid (not MAS). 
39+8 +/- 1.1 for 
isolated 
oligohydramnios; 
39.3 +/- 1.1 for 
normal AFI 
Nulliparous: N= 442 
(44.8%) for isolated 
oligohydramnios, 
N=6,848 (30.7%) for 
normal AFI  
IOL: N= 273 (27.7%) for 
oligo, N= 824 (3.7%) for 
normal. 
Ghosh 
200273 
Prospective 
cohort, 
Single 
hospital, 
Sweden 
N= 333 
Low risk,  
Term only, in early 
labour or prior to IOL 
AFI <5cm 
Not 
blinded 
In early 
labour or 
before IOL 
Operative delivery for fetal 
distress, C-Section for fetal 
distress, 5-min Apgar <7, cord 
arterial PH <7.10, NICU 
admission. 
Mean ga 283 
days for those 
with AFI <5cm, 
280 days for AFI 
>5cm 
Nulliparous: 26/49 of 
those with AFI <5cm, 
134 for those with AFI 
>5cm. 
Hassan 
200574 
Cross-
sectional, 
N= 260 
Low risk,  
Postdates (after 41+0).  
AFI <6cm 
Not 
blinded 
After 41+0 Neonatal death, caesarean 
section, meconium stained 
amniotic fluid. 
After 41+0 Nulliparous: 34% of 
low AFI, 19.7% of those 
with normal. 
IOL: Not specified.  
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Single 
hospital, 
Pakistan 
Hsieh 199875 Retrospective 
cohort,  
Single 
hospital 
Taiwan 
N=27,506 
Universal  
Excluded those with 
AFI>24cm, PPROM.  
AFI <5cm 
Not 
blinded 
Not 
specified 
Stillbirth, SGA <10th centile, 5-min 
Apgar <7, NICU admission, 
Neonatal death. 
Not specified Nulliparous: Not 
specified 
IOL: Not specified. 
Locatelli 
200476 
Prospective 
cohort 
Single 
hospital, Italy 
N= 3049 
Universal  
Routine scan at 40 
weeks. 
Excluded those with 
PPROM and those with 
other indications for 
USS. 
AFI <5cm  
Not 
blinded 
40 weeks Meconium stained amniotic fluid, 
CS for fetal distress, SGA <10th 
centile, Apgar score <7, Cord 
arterial PH <7.0. 
40+0 – 41+6 
weeks 
Nulliparous: 72% for 
those with low AFI, 
58% for those with 
normal. 
IOL: 83% for those with 
low AFI, 25% for those 
with normal 
Megha 
201377 
Prospective 
cohort 
Single centre, 
India 
N=200 
Mixed. 
Selection not specified. 
AFI <5cm 
Blinded 
34-41 weeks 
Within 7 
days of 
delivery  
C-Section for fetal distress, 
meconium stained fluid, 5-min 
Apgar score <7, cord arterial PH 
<7.10. Admission to NICU for >48 
hours. 
Not specified. 
56% of those 
with low AFI 
delivered <37 
weeks vs. 34.3% 
with normal AFI 
Nulliparous: 68% of 
those with low AFI, 
58.9%  of those with 
normal. 
IOL: 72% of those with 
low AFI, 51% of those 
with normal. 
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Melamed 
201178 
Matched 
cohort (3:1) 
Single 
hospital, 
Israel 
N= 432  
Low risk.  
Excluded pregnancies 
with PET/DM/GDM, 
EFW <10th centile, 
abnormal umbilical 
artery doppler, and 
PROM.  
AFI <5cm 
Not 
blinded 
GA at initial 
USS: 33.9 for 
low AFI , 
33.9 for 
normal. 
GA at last 
scan not 
reported. 
C-Section for fetal distress, 
meconium stained fluid, preterm 
delivery (<37 weeks), admission 
to NICU. 
 
37.3 +/-1.6 for 
cases, 39.1 +/- 
1.8 for controls 
Nulliparous: 62 (57.4%) 
of cases, 186 (57.4% of 
controls) 
IOL: 54 (50%) of cases, 
31 (9.6%) of controls. 
Morris 
200379 
Prospective 
cohort, 
Single 
Hospital, 
Oxford, UK 
N= 1584 
Low risk,  
Term only (>40 weeks). 
Excluded non-vertex 
and those with clinically 
required ultrasound.  
AFI <5cm 
SDP <2cm 
Not 
blinded 
At or after 
40 weeks 
(59% at 40 
wks) 
C-Section for fetal distress, NICU 
admission, 5 min Apgar score <7 
At or after 40 
weeks (615 at 
41weeks) 
Nulliparous: 778 
(49.1%) 
IOL: 643 (40.6%) 
Myles 
200280 
Prospective 
cohort,  
Single 
hospital 
Florida, USA 
N= 266 
Low risk  
Term only. Excluded 
non-vertex, SROM, 
polyhydramnios, and 
any pregnancies with 
fetal or maternal 
complications. 
AFI <5cm 
SDP 
<2.5cm 
Not 
blinded 
Between 
37+0 and 
41+6 (Not 
specified) 
C-Section for fetal distress, NICU 
admission, Meconium stained 
amniotic fluid. 
Not specified.  Nulliparous: Not 
specified 
IOL: Not specified. 
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Naveiro-
Fuentes 
201581 
Retrospective 
cohort 
Single 
hospital, 
Spain 
N= 27,708 
Low risk, 
Term only. Routine 
antenatal scan at 39 
weeks. Excluded 
pregnancies with 
maternal or fetal 
pathology including 
suspected IUGR.  
AFI <5cm  
Not 
blinded 
39 weeks C-Section for fetal distress, 
instrumental delivery for fetal 
distress, meconium stained fluid, 
small for gestational age (<10th 
centile), 5-min Apgar score <7, 
Admission to NICU, umbilical 
artery pH < 7.10. 
279 +/- 7.3 days 
for those with 
oligohydramnios, 
278.2 +/- 7.5 for 
normal 
Nulliparous: 65.1%) of 
those with low AFI.  
IOL: Not reported. 
Quinones 
201282 
Prospective 
cohort, 
2 centres, 
Pennsylvania, 
USA 
N= 308  
Low risk 
Between 37-40 weeks 
Excluded pregnancies 
with maternal or 
obstetric complications 
(including suspected 
FGR). 
AFI <5cm 
AFI <8cm 
AFI <10cm 
SDP <2cm 
37-40 weeks 
(Mean 38.1 
+/- 0.9 
weeks) 
Fetal vulnerability index (FVI) 
which is defined as 1 or more of 
the following: 5 min Apgar <3, 
umbilical cord PH <7.0, 
intrapartum fetal death, neonatal 
seizures, intubation in the 
absence of meconium, or NICU 
admission for >24 hours. 
Mean ga 39.9 +/- 
0.8 
Nulliparous: 50% 
Rainford 
200183 
Retrospective 
cohort,  
Single 
hospital, USA 
N=232 
Low risk  
Term only. Excluded 
those with any maternal 
or fetal complications. 
AFI <5cm 
Not 
blinded 
Within 4 
days of 
delivery 
Operative delivery for fetal 
distress, NICU admission, 5-min 
Apgar score <7, meconium 
stained amniotic fluid. 
Mean ga 40.1 for 
those with 
oligohydramnios, 
40.9 for normal 
AFI. 
Nulliparous: 17% for 
low AFI, 20% for 
normal AFI. IOL: 98% of 
those with low AFI , 
51% of those with 
normal AFI. 
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Shanks 
201184 
Retrospective 
cohort 
Single centre, 
USA 
N= 17,877 
Mixed risk 
Selection criteria not 
specified 
AFI <5cm 
AFI <5th 
centile 
Not 
blinded 
Mean 34.38 
+/- 3.04 
weeks 
NICU admission 
 
 
Mean 38.27 +/- 
2.86 
Nulliparous: n=7069 
(39.5%) 
Zhang 
200485 
Clinical trial 
(USS 
screening vs. 
no 
screening). 
For this study 
data used by 
the screening 
group. 
N=6657 in the low risk 
group. They all had 2 
research scans at 15-22 
weeks and 31-35 weeks. 
Excluded multiple 
pregnancies and those 
with any maternal or 
fetal conditions. 
AFI <5cm 
Not 
blinded  
31-35 weeks CS for fetal distress, 5-min Apgar 
score <7, NICU admission, 
perinatal mortality 
 
Mean ga 39.6 
weeks for those 
with 
oligohysramnios, 
39.8 for those 
with normal AFI 
Nulliparous: 53% of 
oligohydramnios cases, 
45% of normal AFI 
IOL: Not specified.  
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Figure 34. Deeks’ fuŶŶel plot for puďliĐatioŶ ďias for seǀere oligohydraŵŶios for the prediĐtioŶ of 
neonatal unit admission. 
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Appendix 4. Supporting data for the systematic review of the diagnostic effectiveness of universal 
ultrasonic screening using borderline oligohydramnios in the prediction of adverse perinatal 
outcome.  
 
Literature search strategy for Medline and Embase (from inception to 18/06/2019) 
1. exp Pregnant Women/  
2. exp pregnancy/  
3. pregnan$.mp. 
  
4. exp oligohydramnios/  
5. oligohydramnio$.mp.  
6. exp Amniotic Fluid/  
7. amniotic fluid index.mp.  
8. AFI.mp.  
9. liquor volume.mp.  
 
10. low.mp.  
11. borderline.mp.  
12. decreased.mp.  
 
13. perinatal.mp.  
14. peripartum.mp.  
15. fetal.mp.  
 
16. 1 or 2 or 3  
17. 4 or 5 or 6 or 7 or 8 or 9  
18. 13 or 14 or 15  
 
19. 16 and 17 and 18  
20. 10 or 11 or 12  
21. 19 and 20 
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Figure 35. POPS study inclusion flowchart. 
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Table 22. Patient characteristics and birth outcomes of POP study. 
Characteristic Borderline AFI 5-8cm 
(N= 108) 
Normal AFI 8-24cm 
(N= 3279) 
P Value Overall baseline 
characteristics  
(N= 3387) 
      
Maternal characteristics  
Age, years  30.1 (26.7-33.2) 30.3 (26.2-33.7) 0.60 30.1 (26.7-33.2) 
      
Deprivation quartile     
 1 (lowest) 29 (26.9) 808 (24.6) 0.53 837 (24.7) 
 2 28 (25.9) 769 (23.5) 797 (23.5) 
 3 23 (21.3) 776 (23.7) 799 (23.6) 
 4 (highest) 25 (23.2) 783 (23.9) 808 (23.9) 
 Missing  
 
3 (2.8) 143 (4.4)  146 (4.3) 
White ethnicity 96 (88.9) 3052 (93.1) 0.16 3148 (92.9) 
 Missing  
 
3 (2.8) 54 (1.7)  57 (1.7) 
Married 81 (75.0) 2222 (67.8) 0.11 2303 (68.0) 
      
Smoker 3 (2.8) 164 (5.0) 0.29 167 (4.9) 
      
Any alcohol consumption 1 (0.9) 154 (4.7) 0.06 155 (4.6) 
 Missing  
 
0 (0.0) 1(0.0)  1 (0.0) 
BMI, kg/m2 23.4 (21.6-26.5) 23.9 (21.8-27.1) 0.19 23.9 (21.8-27.0) 
      
шϭ previous miscarriage 8 (7.4) 327 (10.0) 0.38 335 (9.9) 
      
Chronic hypertension 4 (3.7) 164 (5.0) 0.54  
      
Pre-eclampsia 9 (8.3) 201 (6.1) 0.35 210 (6.2) 
 Missing 0(0) 2(0.1)  2 (0.1) 
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Birth outcomes  
Birth weight, g  3260 (3005-3520) 3460 (3150-3770) <0.001 3450 (3150-3760) 
     
Gestational age, weeks 40.0 (38.8 – 40.9) 40.4 (39.6- 41.3) <0.001 40.4 (39.6- 41.3) 
      
Induction of labor 41 (38.0) 1016 (31.0) 0.12 1057 (31.2) 
     
Mode of delivery     
 Spontaneous vaginal 70 (64.8) 1685 (51.4) 0.04 1755 (51.8) 
 Assisted vaginal 19 (17.6) 832 (25.4) 851 (25.1) 
 Intrapartum cesarean 13 (12.0) 596 (18.2) 609 (18.0) 
 Pre-labor cesarean 6 (5.6) 157 (4.8) 163 (4.8) 
 Missing  0 (0.0) 9 (0.3)  9 (0.3) 
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Figure 36. PRISMA flow diagram for the systematic review of borderline oligohydramnios. 
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Figure 37. Risk of bias graph of included studies for systematic review of borderline oligohydramnios 
using the QUADAS-2 tool. 
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Table 23. Characteristics of the studies included in the meta-analysis of borderline oligohydramnios.  
First Author 
(Year) 
Type of Study, 
Setting 
Population & 
selection 
(Singletons only 
unless otherwise 
specified) 
Index test  
 
Gestational 
age at 
ultrasound 
Reference standard Gestational age at 
delivery 
(Mean unless 
otherwise 
specified) 
Other comments 
Asgharnia 
201386 
Retrospective 
cohort, 
Single hospital, 
Iran 
N= 235  
Mixed risk. 
Pregnancies >28 wks,  
Excluded PPROM, 
uterine anomalies, 
vaginal bleeding. 
5 <AFI<10cm 
Not blinded 
>28 weeks 
(mean ga not 
reported) 
RDS, 5-minute Apgar 
score <7, NICU, IUGR, 
SGA <10th centile. 
Mean GA not 
reported 
Preterm: 
BAFI 40.4%  
normal AFI 14.9%   
 
Nulliparous: BAFI 
68.1%, normal AFI 
58.2% 
IOL: BAFI 22.3%, 
normal AFI 10.6% 
Banks, 199987 Retrospective 
cohort, 
Single hospital, 
USA 
N= 214 
Mixed risk 
Pregnancies with 
antepartum testing 
within 1 week of 
delivery.  
5cm <AFI <10cm 
Not blinded 
Not reported Intrapartum fetal 
distress, Meconium 
stained amniotic fluid, 
SGA <10th centile. 
Not reported Nulliparous: Not 
reported 
IOL: Not reported 
 
Choi 201688  Retrospective 
cohort 
Single Hospital, 
South Korea 
n=721 
Low risk 
Uncomplicated, term 
pregnancies only.  
Excluded SROM, 
elective CS, breech 
presentation, pre-
eclampsia, and other 
maternal disease. 
5.1 AFI  8.0 cm  Within 1 week 
of delivery 
Meconium stained 
amniotic fluid, C-
Section for fetal 
distress, 5-min Apgar 
score <7, NICU 
admission, SGA <10th 
centile 
 
BAFI: 
39.2 wks 
Normal AFI:  
39.4 wks 
Nulliparous: BAFI 
66.1%, normal AFI 
57.3%  
IOL: BAFI 60.7%, 
normal AFI 27.4%  
Gumus, 200789 Retrospective 
cohort 
Single hospital, 
Turkey 
n= 367 
Mixed risk 
Excluded PROM, 
uterine anomalies, 
PV bleeding 
5cm <AFI< 10cm Not reported Intrapartum fetal 
distress, meconium 
stained amniotic fluid, 
SGA <10th centile), 
NICU admission, RDS 
BAFI 37.7 wks for 
Normal AFI 38.3 
wks 
Preterm: BAFI 
18.9% 
Normal AFI 9.7% 
IOL:  BAFI 73.3% 
Normal AFI 54.5%  
Jamal 201690 Matched cohort 
(matched 1:1), 
n=128 
Mixed risk  
5.1 AFI  8.0 37-40 weeks  Meconium stained 
amniotic fluid, 5-min 
BAFI (median): 37 
wks +5 days 
Nulliparous: Not 
reported 
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Single hospital, 
Iran 
Term only, Excluded 
PPROM, anomalies, 
maternal medical 
diseases, 
contraindications for 
vaginal delivery 
within 1 wk of 
delivery 
Apgar score <7, 
umbilical artery pH 
<7.0, NICU admission, 
SGA <10th centile. 
 
Normal AFI: 38wks 
+6 days  
 
 
IOL: Not reported 
 
 
Kwon 200691 Retrospective 
cohort, 
Single hospital, 
South Korea 
n= 3740 
Mixed risk 
Excluded fetal 
malformations, 
SROM preeclampsia, 
chromosomal 
anomalies, AFI 
>25cm 
5.1 AFI  8.0 Within 2 
weeks of 
delivery 
Perinatal death, NICU 
admission, CS for fetal 
distress, 5-min Apgar 
score <7, SGA <10th 
centile. 
BAFI: 36.3 weeks  
 
normal AFI: 
38.0 weeks. 
Nulliparous: Not 
reported. 
IOL: Not reported. 
 
Moraitis 
(current paper) 
Prospective 
cohort, 
Single centre, 
Cambridge, UK 
N= 3387 
Nulliparous only,  
Universal screening  
5cm <AFI< 8cm 
Blinded  
36 weeks NICU admission, 
metabolic acidosis, 5-
min Apgar score <7, 
composite morbidity 
(all above), composite 
severe morbidity, 
 Nulliparous only. 
 
Petrozella, 
201192 
Retrospective 
cohort 
Regional 
hospitals, 
USA 
 
n= 27,601 
Mixed risk  
Those that received 
USS between 24-34 
weeks.  
Excluded AFI>24cm, 
SROM 
5cm <AFI< 8cm 24+0 to 33+6 
weeks. 
Mean ga 
29.2wks 
CS for fetal distress, 
SGA <10th centile, SGA 
<3rd centile Neonatal 
death 
BAFI 37.1 weeks 
Normal AFI 39.2 
weeks 
Preterm: BAFI 
37%, normal AFI 
8%  
Nulliparous: Not 
reported. 
IOL: Not reported. 
 
Rutherford, 
198793 
Retrospective 
cohort 
Single hospital, 
USA 
n= 286 
Mixed risk 
Those who had 
antepartum 
surveillance.  
Excluded PPROM, 
5cm <AFI< 8cm Not reported Meconium,  CS for 
fetal distress, 5-
minute Apgar score <7 
Not reported Nulliparous: Not 
reported. 
IOL: Not reported. 
 
Sahin, 201894 Prospective 
(matched 1:3) 
n= 430 
Low risk  
5cm <AFI 8cm Between 34+0 
and 36+6 
weeks 
5-minute Apgar <7, CS 
forfetal distress, RDS, 
meconium stained AF, 
BAFI: 37.5 wks 
Normal AFI: 
38.6wks. 
Nulliparous: Not 
reported. 
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Singleton 
hospital, 
Turkey 
Excluded maternal 
disease, IUGR 
chromosomal/ fetal 
abnormalities, 
SROM, abnormal 
Doppler.  
Mean 35,4 
weeks 
meconium aspiration 
syndrome, NICU, 
neonatal death 
Preterm: BAFI 
15.9%, normal AFI 
8,4% 
IOL: BAFI 34.6%, 
normal AFI 23.8%  
Wood 201495 Retrospective 
cohort  
(matched 1:3) 
2 hospitals, USA 
n= 739 
Low risk 
Exclusion criteria: 
AFI чϱ Đŵ, PP‘OM, 
preeclampsia 
 
5cm <AFI 10cm Not reported CS for fetal distress, 
SGA, meconium 
stained amniotic fluid, 
5-min Apgar score <7, 
NICU admission, 
preterm delivery  
BAFI: 
38.3 wks 
normal AFI: 
38.9 wks 
Nulliparous: Not 
reported 
IOL: Not reported. 
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Figure 38. Deeks’ fuŶŶel plot for puďliĐatioŶ ďias for ďorderliŶe oligohydraŵŶios for the prediĐtioŶ 
of SGA <10th centile. 
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Appendix 5. Supporting data for the systematic review of the diagnostic effectiveness of universal 
ultrasonic screening using macrosomia in the prediction of adverse perinatal outcome. 
 
Literature search strategy for Medline and Embase (from inception to the 22/10/2018) 
1. exp fetus echography/  
2. ultrasonography, prenatal.mp.  
3. exp ultrasound/  
4. ultraso*.mp.  
5. sonograph*.mp.  
 
6. exp biometry/  
7. USS.mp.  
8. estimated fetal weight.mp. 
9. EFW.mp.  
10. abdominal circumference.mp.  
11. AC.mp.  
 
12. exp macrosomia/  
13. macrosomi*.mp.  
14. exp fetus weight/  
15. fetal weight.mp.  
16. exp birth weight/  
17. birthweight.mp.  
18. large for gestational age.mp.  
19. LGA.mp.  
20. large fetus.mp.  
21. exp brachial plexus injury/ or brachial plexus injury.mp. 
22. exp shoulder dystocia/ or shoulder dystocia.mp. 
  
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11  
24. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22  
25. 23 and 24  
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26. exp pregnancy/  
27. 25 and 26 
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Figure 39. PRISMA flow diagram for the systematic review of macrosomia. 
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Figure 40. Risk of bias graph of included studies for systematic review of macrosomia. 
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Table 24. Characteristics of the studies included in the meta-analysis of macrosomia. 
First Author 
(Year) 
Type of Study, 
Setting 
Number of total fetuses (LGA 
fetuses), risk, and selection 
(All singleton, non anomalous 
unless otherwise stated) 
Index test  
(Blinding) 
 
Gestational age 
at ultrasound 
Reference standard Gestational 
age at 
delivery 
Other comments 
(Inclusion of  T1DM, 
T2DM and GDM) 
Aviram 201799 Retrospective 
cohort, 
Single Hospital, 
Israel 
 
 
N= 7996 (1618) 
Risk: Mixed 
Selection: Mixed risk, term 
only. Excluded SGA deliveries, 
intrapartum and SROM.  
EFW (20 formulas) 
Hadlock (AC/FL/BPD) 
Hadlock (AC/FL/HC) 
Hadlock (AC/FL/BPD/HC) 
Hadlock (AC/FL) 
Hadlock (AC/BPD) 
Shepard (AC/BPD) 
Threshold: >90th centile 
Blinded: No 
Within 1 week 
from delivery. 
BW >90th centile  Mean for LGA 
group: 39.4 
weeks, mean 
for AGA 
group: 38.3 
weeks 
DM/GDM: Included 
(21% for LGA, 14% 
for AGA) 
Balsyte 2009100 Retrospective 
cohort, 
Single Hospital, 
Switzerland 
N= 1062 (135) 
Risk: Mixed 
Selection: Term only. 
EFW 
Hadlock (AC/FL/HC) 
Threshold: >4000g 
Blinded: No 
Within 1 week 
from delivery. 
BW >4000g  Mean 39.3 
weeks. 
DM/GDM: Not 
reported 
Benecerraf 
1988101 
Retrospective 
cohort,  
Single hospital, 
Boston, MA, USA 
N= 1301 (324) 
Risk: Mixed 
Selection: Included all 
pregnancies apart from breech 
and multiples. 
EFW (Birnholz) 
Threshold: Threshold: 
>4000g, >3800g 
Blinded: No 
Within 1 week 
from delivery. 
BW >4000g Not specified DM/GDM: Included 
Ben-Haroush 
2007102 
Prospective 
cohort,  
Single Hospital, 
N= 259 (23) 
Risk: Universal 
EFW 
Hadlock (AC/FL/BPD) 
Threshold: >90th centile 
Mean 32 weeks BW >4000g Mean 39 
weeks. 
DM/GDM: Excluded 
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Israel Selection: Routine scan. 
Included SGA. Excluded 
hypertensives and diabetics. 
Blinded: No 
Ben-Haroush 
2008103 
Retrospective 
cohort, 
Single Hospital, 
Israel 
 
N= 1925 (140) 
Risk: Mixed 
Selection: Term only. 
EFW 
Hadlock (AC/FL) 
EFW + AFI  
Threshold: EFW >4000g, 
AFI >95mm (60th centile) 
Blinded: No 
Interval from 
USS to delivery 
2.5 days 
BW >4000g Mean for LGA 
40 weeks,  
Mean for 
normal BW 
39.4 weeks 
DM/GDM: Excluded 
Benson 1991104 Retrospective 
cohort, Boston, 
MA, USA 
N= 412 (32) 
Risk: Mixed 
Selection: Not specified. 
Excluded diabetics. 
EFW 
Hadlock (AC/FL/BPD) 
Threshold: >90th centile 
Blinded: No 
Within 1 week 
from delivery 
BW> 90th centile Not specified DM/GDM: Excluded 
Burkhardt 2014105 Retrospective 
cohort 
Single Hospital, 
Zurich, 
Switzerland 
N= 12,794 
Risk: Mixed 
Selection: All term, with vertex 
presentation with scan with 
7days  
EFW, AC 
Hadlock (AC/FL/BPD) 
Threshold:  
>4000g, >4500g 
>35cm, >39cm 
Blinded: No 
Within 1 week 
from delivery 
Shoulder dystocia 281 days fro 
SD 
278 days for 
no SD 
DM/GDM: 7.5% for 
those with SD 
2.7% for those 
without SD. 
Chauhan 2006106 Retrospective 
cohort  
Single Hospital, 
Houston, TX, USA 
N= 1954 (119) 
Risk: Mixed 
Selection: Pregnancies 
undergoing fetal surveillance. 
Included SGA, hypertensives 
(22%) and SROM (5%). 
EFW 
Hadlock (AC/FL/BPD) 
Threshold: >90th centile 
Blinded: No 
  
Within 4 weeks 
from delivery. 
64% within 7 
days from 
delivery. 
BW >90th centile 34% preterm DM/GDM: Included 
(13%) 
Chervenak 
1989107 
Prospective 
cohort  
N= 317 (81) 
Risk: Low 
EFW >41 weeks BW >4000g Mean 42 +/- 
0.6 weeks 
DM/GDM: Excluded 
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Single Hospital, 
New Jersey, USA 
Selection: Uncomplicated 
pƌegŶaŶĐies afteƌ ϰϭ ǁeeks͛ 
gestation. 
Hadlock AC/BPD or AC/FL 
if BPD not available 
Threshold: >4000g 
Blinded: Not clear 
Cohen 2010108 Retrospective 
cohort 
Single Hospital, 
Montreal, Canada 
N= 1099 (105) 
Risk: Mixed 
Selection: Only included 
pregnancies with USS on the 
same or next day as delivery 
EFW 
Hadlock (AC/FL/BPD/HC) 
Threshold: >90th centile 
Blinded: No 
On the same or 
next day of 
delivery. 
BW >4000g Mean 275.2 
days. 
DM/GDM: Included 
(11.6%) 
Crimmins 2018109 Retrospective 
cohort 
Single hospital, 
Baltimore, 
Maryland, USA 
N= 945 (40) 
Risk: Mixed 
Selection: All pregnancies >34 
weeks gestation with normal 
oGCT. 
AFG defined as EFW >90th 
centile (Hadlock- 
AC/FL/BPD) or AC >95th 
centile. 
Polyhydramnios >25cm 
Threshold: As above. 
Blinded: No 
>34 weeks BW >4000g 
Shoulder dystocia 
NICU admission 
Not specified. DM/GDM: Excluded 
Cromi 2007110 Retrospective 
cohort, 
2 hospitals, 
Swtzerland 
N= 1026 (53) 
Risk: Mixed 
Selection: All singletons >34 
weeks gestation with USS 
within 4 weeks of delivery. 
Excluded SROM. 
EFW, AC 
Hadlock (AC/FL/BPD) 
Threshold: >95th centile 
Blinded: No 
Within 4 weeks 
of delivery. 
Mean 37.3 
weeks 
BW >4000g 
BW>4500g 
>34 weeks 
Mean 39.2 
weeks 
DM/GDM: Included 
(8.8%) 
De Reu 2008111 Retrospective 
cohort, 
Single Hospital, 
Netherlands 
N= 3449 (285) 
Risk: Universal 
Selection: Women with no risk 
factors or pathology. Did not 
exclude SGA. 
AC 
Threshold: >75th 
/90th/95th centile 
Blinded: No 
Between 27 and 
33 weeks. 
BW >90th centile, 
BW >95th centile 
 
 
Mean 278.7 
days 
DM/GDM: Excluded 
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Freire 2010112 
(Portuguese) 
Retrospective 
cohort, 2 
hospitals, Brazil 
N= 114 (8) 
Risk: Mixed 
Selection: Those with USS 
within 7 days of delivery 
EFW 
Hadlock (AC/FL/BPD/HC) 
Threshold: >90th centile 
Blinded: No 
Within 7 days of 
delivery 
BW >90th centile 15.6% 
preterm, 
84.4% at term 
DM/GDM: Not 
reported 
Galvin 2017113 
(GENESIS study) 
(Abstract) 
Prospective 
cohort 
Large multi-
centre study, 
Ireland  
N= 2336 
Risk: Low 
Selection: Term, 
uncomplicated, cephalic only. 
EFW (Not specified) 
Threshold: 4000g 
Blinded: Yes 
Between 39+0 
and 40+6 weeks 
Shoulder dystocia 
NICU admission 
Not specified. DM/GDM: excluded 
Gilby 2000114 Retrospective 
cohort, 
Single Hospital, 
Florida, USA 
N= 1996 (318) 
Risk: Mixed  
Selection: All singleton >36 
weeks with USS within 1 week 
from delivery.  
 
AC 
Threshold: >35cm, >38cm 
Blinded: No 
Within 1 week 
from delivery 
BW >4500g >36 weeks 
Mean not 
reported. 
DM/GDM: Not 
reported 
Hasenoehrl 
2006115 
Prospective 
cohort, Single 
hospital, Austria 
N= 200 (33) 
Risk: Low  
Selection: Included those with 
USS within 1 week. Excluded 
only fetal anomaly.  
EFW (Schild) 
Threshold: >4000g 
Blinded: No 
Mean 39.2 
weeks 
BW >4000g Mean interval 
2.0 days. 
DM/GDM: Not 
reported 
Hendrix 2000116 Prospective (RCT)  
Georgia, USA 
N= 367 (39) 
Risk: Low 
Selection: Term only. 
EFW 
Hadlock AC/BPD 
Threshold: >4000g 
Blinded: No 
>37 weeks BW >4000g Mean 39.1 
weeks 
DM/GDM: Not 
reported 
Henricks 2003117 Prospective 
cohort,  
N= 256 (21) 
Risk: Universal 
Selection: Term only. 
AC 
Threshold: >35cm 
Blinded: No 
>37 weeks BW >4000g Mean 39.1 
weeks 
DM/GDM: Not 
reported 
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South Carolina, 
USA 
Humphries 
2002118 
Retrospective 
cohort,  
South Carolina, 
USA 
N= 238 (29) 
Risk: Mixed 
Selection: Term only, with USS 
within 2 weeks.  
EFW 
Combs (AC/FL/FL) 
Threshold: >4000g 
Blinded: No 
Within 2 weeks 
of delivery 
BW >4000g >37 weeks DM/GDM: Not 
reported 
Kayem 2009119 Prospective 
cohort, 
Multiple 
hospitals, France 
and Belgium 
N= 1689 (124) 
Risk: Low 
Selection: As part of a 
prospective cohort for breech. 
Term only, with USS within 10 
days of delivery. 
AC 
Threshold: >36.3cm 
Blinded: No 
Within 10 days 
of delivery. 
BW >4000g Median 39 
weeks 
DM/GDM: Not 
reported 
Kehl 2011120 Prospective 
cohort, Single 
Hospiotal, 
Germany 
N= 258 (30) 
Risk: Universal 
Selection: Term only with 
vertex presentation and USS 
within 3 days of delivery. 
AC 
Threshold: >36cm 
Blinded: No 
Within 3 days of 
delivery 
BW >4000g 
 
40+5 weeks 
for AC>36cm 
39+6 weeks 
for AC <36cm 
DM/GDM: Not 
reported 
Levine 1992121 Retrospective 
cohort,  
Single Hospital, 
New York, USA 
N= 406 (68) 
Risk: Mixed 
Selection: Term only. Included 
pregancies with diabetes (22%) 
and previous CS (20%) 
EFW 
Hadlock (AC/FL/HC) 
Threshold: >90th centile 
Blinded: No 
5-10 days 
before delivery 
BW >90th centile Mean 39.4 DM/GDM: Included 
(22%) 
Melamed 2011122 
 
  
Retrospective 
cohort, Single 
hospital, Israel 
N= 4765 (431) 
Risk: Mixed 
Selection: All deliveries with 
USS within 3 days of delivery. 
DM/GDM and SROM excluded. 
EFW (multiple) and AC 
Hadlock (AC/FL/BPD) 
Hadlock (AC/FL/HC) 
Hadlock (AC/FL/BPD/HC) 
Hadlock (AC/FL) 
Within 3 days of 
delivery 
BW >4000g Mean 38.1 DM/GDM: Excluded 
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Shepard (AC/BPD) 
Threshold: >4000g,>36cm  
Blinded: No 
Miller 1986123 Retrospective 
cohort,  
Single Hospital, 
Luisiana, USA 
N= 150 (28) 
Risk: Mixed  
Selection: Term only, included 
diabetes, PET, prior CS. 
Excluded SGA 
EFW 
Hadlock (AC/FL) 
Shepard (AC/BPD) 
Threshold: >4000g 
Blinded: No 
Within 7 days of 
delivery 
BW >4000g Term  
(Mean ga not 
reported) 
DM/GDM: Included  
Miller 1988124 Retrospective 
cohort,  
Single Hospital, 
Luisiana, USA 
N= 382 (58) 
Risk: Mixed 
Selection: term only, excluded 
SROM 
EFW  and AC 
Hadlock (AC/FL/BPD) 
Threshold: EFW >4100g, 
AC >36.4cm  
Blinded: No 
Within 7 days of 
delivery. 
Mean ga 275.8 
days 
BW >4000g Mean ga 
279.1 days. 
DM/GDM: Not 
reported 
Nahum 2003125 Retrospective 
cohort,  
Single hospital, 
California, USA 
N= 74 (12) 
Risk: Mixed 
Selection: Only included 
Hispanic ethnicity, term only.  
EFW (11 formulas) 
Hadlock (AC/FL/BPD) 
Hadlock (AC/FL/HC) 
Hadlock (AC/FL/BPD/HC) 
Hadlock (AC/BPD) 
Shepard (AC/BPD) 
Threshold: >4000g 
Blinded: No 
Within 3 weeks 
of delivery 
BW >4000g Term  
(Mean ga not 
reported) 
DM/GDM: Included 
(23.0%) 
Nahum 2007126 Retrospective 
cohort,  
Single hospital, 
California, USA 
N= 98 (16) 
Risk: Low risk 
Selection: Term only, Excluded 
medical complications (PET, 
DM) 
EFW 
Hadlock (AC/FL/BPD) 
Hadlock (AC/BPD) 
Hadlock (AC/FL) 
Threshold: >4000g,  
Blinded: No 
Within 3 weeks 
of delivery 
BW >4000g Term  
(Mean ga not 
reported) 
DM/GDM: Excluded 
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Nicod 2012127 
(French) 
Retrospective 
cohort,  
Single hospital, 
Switzerland  
N= 708 (141) 
Risk: Mixed risk 
Selection: Pregnancies with USS 
within 7 days of delivery.  
EFW 
Hadlock (AC/FL/BPD/HC) 
Hadlock (AC/FL) 
Threshold: >4000g 
Blinded: No 
Within 7 days of 
delivery 
BW >4000g Not reported  DM/GDM: Not 
reported 
O͛‘eillǇ-Green 
1997128 
Retrospective 
cohort,  
Single hospital, 
New York, USA 
N= 445 (107) 
Risk: Low 
Selection: Prolonged 
pregnancies defined as ga 
>40+4. 
EFW 
Hadlock (AC/FL/BPD) 
Threshold: >4000g, 
>4500g 
Blinded: No 
Within 3 weeks 
of delivery 
BW >4000g 
BW >4500g 
GA >40+4 DM/GDM: Excluded 
Pates 2007129 Retrospective 
cohort,  
Single hospital, 
Texas, USA 
N= 3115 (239) 
Risk: Mixed 
Selection: Those with clinically 
indicated USS within 7 days of 
delivery.  
EFW and AFI 
Hadlock (AC/FL/BPD/HC) 
Threshold: >4000g, AFI 
>20cm (95th centile) 
Blinded: No 
Within 7 days of 
delivery 
BW >4000g Not reported DM/GDM: Included 
(11%) 
Peregrine 2007130 Prospective 
cohort,  
Single hospital, 
London, UK 
N= 262 (48) 
Risk: Mixed 
Selection: Pregnancies with ga 
>35+6 undergoing IOL, 
Excluded those withIUD or 
antepartum haemorrhage. 
EFW 
Hadlock (AC/FL) 
Shepard (AC/BPD) 
Threshold: >4000g 
Blinded: Yes 
Exactly before 
IOL 
BW >4000g Median ga 41 
weeks.  
DM/GDM: Not 
reported 
Pollack 1992131 Retrospective 
cohort,  
Single hospital, 
New York, USA 
N= 519 (119) 
Risk: Mixed 
Selection: Postdate pregnancies 
>41 weeks 
EFW 
Hadlock (AC/FL) 
Threshold: >4000g, 
>4500g 
Blinded: No  
Within 7 days of 
delivery 
BW >4000g >41 weeks  DM/GDM: Not 
reported 
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Rossavik 1993132 Retrospective 
cohort,  
Single hospital, 
Oklahoma, USA 
N= 498 (36) 
Risk: Mixed 
Selection: Infants with USS 
within 2 weeks of delivery (if ga 
>38w) or within 1 week of 
delivery (if ga <38w) 
EFW 
Hadlock (AC/FL/HC) 
Threshold: >4000g 
Blinded: No  
Within 2 weeks 
of delivery (if ga 
>38w) or within 
1 week of 
delivery (if ga 
<38w) 
BW >4000g Not reported DM/GDM: Not 
reported 
Sapir 2017133 
(Abstract) 
Retrospective 
cohort 
Single Hospital, 
Israel 
N=6214 
Risk: Mixed 
Selection: term only, no GDM 
with scan within 7 days of 
delivery  
EFW, AC  
Threshold: >4000g, 
>4500g, AC>39cm 
Blinded: No 
Wiothin 1 week 
of delivery 
Shoulder dystocia Term (not 
specified) 
DM/GDM: Excluded 
Smith 1997134 Retrospective 
cohort,  
Single hospital, 
Glasgow, UK 
N= 1213 (16) 
Risk: Mixed 
Selection: Non-diabetic 
pregnancies with USS within 7 
days of delivery.  
EFW and AC 
Hadlock (AC/FL) 
Threshold: >4000g, 
>4500g, AC >36cm, AC 
>38cm 
Blinded: No  
Within 7 days of 
delivery 
BW >4500g Not reported DM/GDM: Excluded 
Sovio 2018135 Prospective 
cohort,  
Single hospital, 
Cambridge, UK 
N= 3866 (177) 
Risk: Universal 
Selection: Unselected n 
nulliparous women that 
delivered after 36 weeks.  
EFW, ACGV 
Hadlock (AC/FL/BPD/HC) 
Threshold: >90th centile 
(population/customised) 
Blinded: Yes 
Regular 
research scan at 
36 weeks 
(median 36.4 
weeks) 
BW >90th centile 
BW >97th centile 
BW >4000g, BW 
>4500g, Shoulder 
dystocia, Neonatal 
morbidity 
(composite of 
metabolic acidosis, 
5-min Apgar <7, 
NICU admission), 
Median 40.4 
weeks.  
DM/GDM: Included 
(4.3%) 
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Severe neonatal 
morbidity  
Sritippayawan136 
2007 
Prospective 
cohort, Single 
Hospital, Thailand 
N= 328 (3) 
Risk: Low risk 
Selection: Pregnancies >34 
weeks. Excluded IUFD, any 
medical complication. 
EFW 
Hadlock (AC/FL/BPD/HC) 
Threshold: >4000g 
Blinded: No  
>34 weeks 
Mean interval 
16.9 days from 
delivery 
BW >4000g Mean ga 39.4 
weeks. 
DM/GDM: Excluded 
Sylvestre 2000137 Retrospective 
cohort, Single 
Hospital, New 
York, USA 
N= 656 (147) 
Risk: Low risk 
Selection: Postdate pregnancies 
only (>41 weeks) 
EFW (Hadlock or 
Shepard/Not specified) 
Threshold: >4000g 
Blinded: No 
>41 weeks  BW >4000g 41.3 weeks DM/GDM: Not 
reported 
Weiner 2002138 Prospective 
cohort, Single 
centre, Israel 
N= 315 (134) 
Risk: Mixed risk 
Selection: Offered routine 
clinical screening to all 
womenat term. Those with 
suspected EFW >3700g had 
USS. Only included those with 
USS with 3 days of delivery.  
EFW 
Shepard (AC/BPD) 
Threshold: >4000g 
Blinded: No 
USS with 3 days 
of delivery. 
BW >4000g 
BW >4500g 
Shoulder dystocia 
40.1 weeks 
for both 
groups. 
DM/GDM: Included 
(9.2%)  
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Figure 41. Deeks’ fuŶŶel plot for puďliĐatioŶ ďias for the prediĐtioŶ of LGA (ďirthǁeight >4000g or 
>90th centile). 
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Appendix 6. Brief summary of economic analyses of universal screening for breech presentation, 
large for gestational age, and small for gestational age 
Ultrasound screening can be used to detect several different antenatal conditions. Ultrasound 
assessment could be used to target these conditions individually, or to scan for multiple conditions 
during the same appointment. However, a screening policy that makes sense for one condition may 
not be the most cost-effective for a combination of different conditions. In light of this, determining 
the overall cost-effectiveness of ultrasound screening is a complex task. For this reason, we decided 
to first target individual conditions and construct economic simulation models capable of evaluating 
the merits of universal ultrasound for each of these. Once the cost-effectiveness of universal 
ultrasound for each particular condition had been assessed, we merged these simulation models into 
a framework that enabled a joint analysis of screening for different combinations of conditions. 
 
In this appendix, we present a brief summary of the economic analyses of universal ultrasound 
screening for individual antenatal complications. Though neither of these analyses are integral to the 
final delivery of the study (i.e. the economic analysis of joint screening for different combinations of 
conditions), they serve as a good introduction to the construction of the joint economic model and 
the assumptions underlying it. Further, the cost-effectiveness of universal ultrasound for individual 
conditions may still be relevant for future research and other healthcare systems. 
 
Below we present the economic analysis of universal ultrasound for three conditions: breech 
presentation, large for gestational age (LGA), and small for gestational age (SGA). The economic 
analyses of screening for breech presentation and LGA have been published. It should be noted that 
the term macrosomia was used in the publication of the LGA analysis. Though macrosomia is 
differentiated from LGA, the two are closely related, and the definition used for macrosomia in this 
particular analysis was the same as for LGA. 
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Breech presentation 
 
Background 
Despite the relative ease with which breech presentation can be identified through ultrasound 
screening, the assessment of fetal presentation at term is often based on clinical examination only. 
Due to limitations in this approach, many women present in labour with an undiagnosed breech 
presentation, with increased risk of fetal morbidity and mortality. This study sought to determine the 
cost-effectiveness of universal ultrasound scanning for breech presentation near term (36 weeks of 
gestational age [wkGA]) in nulliparous women. 
 
Methods 
To estimate the effects of universal ultrasound screening for breech presentation we analysed the 
outcomes for women with a breech presentation in the Pregnancy Outcome Prediction (POP) study. 
The POP study was a prospective cohort study between January 14, 2008 and July 31, 2012, where 
nulliparous women in addition to current clinical practice also attended a research screening 
ultrasound examination at 36 wkGA. All cases of breech presentation was revealed to both the woman 
aŶd atteŶdiŶg ĐliŶiĐiaŶ. BǇ aŶalǇsiŶg the patieŶts͛ jouƌŶals, ǁe Ŷoted ǁhetheƌ ďƌeeĐh pƌeseŶtatioŶ 
had been suspected prior to the research scan.  
 
Where breech presentation was detected, an external cephalic version (ECV) was routinely offered. If 
the ECV was unsuccessful or not performed, the women were offered either planned CS at 39 wkGA 
or attempted vaginal breech delivery. We noted whether an ECV had been offered, accepted, 
performed, and successful; where it was not performed we noted the reason. We also analysed the 
mode of delivery as a function of the ECV status. 
 
We then used the data to attempt to estimate the consequences of implementing universal 
ultrasound screening across England. For this purpose, we constructed an economic simulation model 
capable of comparing outcomes for universal screening with those for current clinical practice. 
Outcomes included the mode of delivery, which was then extrapolated into long-term fetal health 
outcomes; due to limited data on long-term morbidity for different modes of delivery, we focused 
exclusively on mortality risks. The model was probabilistic, capturing overall uncertainty in the 
outcomes as a function of uncertainty in its input parameters.  
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Results 
Breech presentation was detected in 179 out of 3,879 women (4.6%). For most women (96), there had 
been no prior suspicion of noncephalic presentation, indicating that up to 54.9% (95% CI: 47.5, 62.1) 
of all breech presentations may have been undetected in the absence of universal ultrasound. ECV 
was attempted for 84 (46.9%) women and was successful in 12 (success rate: 14.3%). Overall, 19 of 
the 179 women delivered vaginally (10.6%), 110 delivered by elective CS (61.5%) and 50 delivered by 
emergency CS (27.9%). There were no women with undiagnosed breech presentation in labour in the 
cohort. 
 
On average, 40 scans were needed per detection of a previously undiagnosed breech presentation 
(95% CI: 33, 49). The economic analysis indicated that, compared to current practice, universal late-
pregnancy ultrasound would identify around 14,826 otherwise undiagnosed breech presentations 
across England annually. It would also reduce EMCS and vaginal breech deliveries by 0.7 and 1.0 
percentage points, respectively: around 4,196 and 6,061 deliveries across England annually. Universal 
ultrasound would also prevent 7.89 neonatal mortalities annually. 
 
We found that a key determinant of the cost-effectiveness of universal ultrasound was the cost of the 
ultrasound scan itself. We also noted that there was a high degree of uncertainty surrounding this 
cost, since no NHS cost data was available for an ultrasound scan for fetal presentation only. We 
therefore estimated the cost thresholds for which universal ultrasound may be cost-effective. We 
found that universal ultrasound would be cost-effective if fetal presentation could be assessed for 
£19.80 or less, assuming a willingness-to-pay (WTP) per quality-adjusted life year (QALY) of £20,000; 
for a WTP-threshold of £30,000, the threshold for cost-effectiveness was £23.10. If the fetal 
presentation could be assessed for less than £12.90 per mother, universal ultrasound would be cost 
saving. 
 
Conclusions 
According to our estimates, universal late pregnancy ultrasound in nulliparous women (1) would 
virtually eliminate undiagnosed breech presentation, (2) would be expected to reduce fetal mortality 
in breech presentation, and (3) would be cost effective if fetal presentation could be assessed for less 
than £19.80 per woman. 
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Large for gestational age (LGA) 
 
Background 
Large for gestational age (LGA) pregnancies, i.e. those with an estimated fetal weight in the highest 
decile, are at increased risk of complications at delivery. This may manifest in increased neonatal 
morbidity and mortality, as well as maternal morbidity. Ultrasound screening can be used to diagnose 
LGA antenatally, but this approach is known to have low predictive value. Further, there is no general 
agreement on how best to manage suspected LGA. Possible interventions include scheduling an 
elective CS, or early induction of labour. However, uncertainty regarding the clinical effectiveness of 
these interventions persists, and intervention may cause unnecessary harm if given without clinical 
need. 
 
There is currently no national programme that couples screening for macrosomia with a proven, 
disease-modifying intervention. Currently, clinical examination of third-trimester pregnancies does 
not routinely include ultrasound, but women may be selected for ultrasound scanning following 
clinical suspicion of LGA (selective ultrasound). An alternative approach would be to prospectively 
scan all women for LGA (universal ultrasound) at around 36 weeks of gestation, but whether the 
benefits of such an approach would justify the increased costs and risk of harmful interventions is 
unclear. 
 
Methods 
We constructed a health economic simulation model to compare long-term maternal-fetal health and 
cost outcomes for different screening programmes for LGA in third trimester pregnancy. The analysis 
was from a payer perspective and included all nulliparous women within the English NHS. Screening 
options included universal ultrasound at approximately 36-ǁeek͛s gestatioŶ ǀersus selective 
ultrasound (i.e. current clinical practice). For suspected LGA, possible interventions included elective 
CS, early induction of labour, or expectant management, i.e. letting the pregnancy take its natural 
cause. 
 
We simulated outcomes at delivery, using sources of data on probabilities, costs and health outcomes 
obtained from literature. Outcomes included mode of delivery, as well as respiratory morbidity, 
shoulder dystocia, acidosis and mortality of the neonate. Long-term neonatal outcomes were then 
modelled based upon the outcomes at delivery; these included permanent brachial plexus injury (BPI), 
severe anoxic brain damage, and neonatal mortality. Maternal health outcomes were based upon the 
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mode of delivery. Probabilistic sensitivity analysis was used to capture overall uncertainty in the 
outcomes as a function of uncertainty in its input parameters. Overall outcomes included expected 
costs to the English NHS and quality adjusted life-years (QALYs) gained from each strategy. To identify 
the most cost-effective screening policy we calculated expected net benefit of each screening-
management strategy and compared these using incremental cost-effectiveness ratios (ICER) and 
cost-effectiveness acceptability curves (CEAC). 
 
Results 
Compared with selective ultrasound, universal ultrasound increased QALYs by 0.0038 (95% CI 0.0012–
0.0076), but also costs by £123.50 (95% CI 99.6–149.9). Overall, the health gains were too small to 
justify the cost increase given current UK thresholds. The most cost-effective policy was selective 
ultrasound coupled with IOL where macrosomia was suspected. 
 
For suspected LGA, early IOL was always the preferred management strategy from a joint maternal-
fetal perspective. However, this was largely explained by the suspected decrease in long-term 
maternal health associated with elective CS. From a fetal only perspective, elective CS was the 
preferred management option. 
 
Results were especially sensitive towards changes in maternal health following elective and 
emergency CS. Our sensitivity analysis also showed that the cost of ultrasound scans and early labour 
induction were important determinants for which policy was preferred. 
 
Conclusions 
The most cost-effective policy for detection and management of fetal macrosomia is selective 
ultrasound scanning coupled with IOL for all suspected cases of macrosomia. Universal ultrasound 
scanning for macrosomia in late-stage pregnancy is not cost-effective. 
 
Weaknesses of the analysis includes that LGA was the only criteria evaluated for intervention. In 
clinical practice, the choice between interventions are typically based upon other factors as well, and 
not all pregnancies suspected of LGA would be managed in the same way. However, by comparing the 
outcomes for different interventions, our analysis estimates the value of universal ultrasound 
screening for LGA. Another weakness was the weak evidence-base for long-term maternal outcomes 
following different modes of deliveries; this is something that should be subject of future research. 
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Small for gestational age (SGA) 
 
Background 
Small-for-gestational-age (SGA) pregnancies are at higher risk of morbidity and mortality. Ultrasound 
screening can be used to detect SGA pregnancies, but current clinical guidelines recommend that 
ultrasound screening be only offered following clinical indications of a problem. Consequently, many 
SGA pregnancies are not detected. This study sought to evaluate the cost-effectiveness of universal 
ultrasound screening for SGA in late pregnancy (approx. 36 weeks).  
 
Methods 
We constructed a decision model to simulate long-term fetal cost and health outcomes for different 
screening strategies in the English NHS. Screening strategies were universal ultrasouŶd at ϯϲ ǁeeks͛ 
gestation versus ultrasound following clinical indication only. Where the estimated fetal weight (EFW) 
was <10th percentile, early labour induction was initiated. Cost-effectiveness was assessed using 
quality-adjusted life years (QALYs), and probabilities, costs, and quality of life weights (QOL) were 
obtained from literature. Probabilistic sensitivity analysis was used to capturing overall uncertainty in 
the outcomes as a function of uncertainty in its input parameters. Overall outcomes included expected 
costs to the English NHS and quality adjusted life-years (QALYs) gained from each strategy. 
 
We focused our analysis on fetal health only, due to the absence of long-term data on maternal quality 
of life following screening versus no screening. Outcomes at delivery included mode of delivery, level 
or neonatal morbidity (none, moderate or severe), and survival beyond the first week of life. Long-
term outcomes included No long-term complications, special educational needs, severe neurological 
morbidity, and neonatal mortality. Each long-term outcome was possible for every level of neonatal 
morbidity, however, the risk of severe outcomes increased with increasing neonatal morbidity. 
 
Results 
Universal ultrasound was expected to have minor impact upon long-term neonatal neurological and 
educational outcomes, but decreased overall fetal mortality slightly (RD: -0.02%; 95% CI: -0.01, -0.03). 
Compared to selective ultrasound, universal screening was expected to improve overall health by 
0.0004 QALYs (95% CI: -0.0001, 0.0002). However, expected costs also increased by £90 (95% CI: -£77, 
£257), yielding an incremental cost-effectiveness ratio (ICER) of £256,735.  
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The results rely upon both data and structural assumptions that are uncertain. Probabilistic sensitivity 
analysis showed that even though the expected ICER was well above the current threshold for cost-
effectiveness (£20,000), universal ultrasound still had a 17% chance to be cost-effective due to 
parameter uncertainty. Further, the assumption that the effect of ultrasound screening upon long-
term outcomes is mediated through neonatal morbidity was crucial for the analysis. When this 
assumption was relaxed, and a direct link between screening and long-term outcomes included in the 
model, the chance that universal ultrasound would be cost-effective increased greatly. 
 
Conclusions 
Universal ultrasound screening in late-stage pregnancy does not appear cost-effective. However, 
there is great uncertainty surrounding the data informing the model. Future research may be 
warranted, especially regarding the long-term health consequences of early labour induction. 
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Appendix 7. Derivation of input parameters for economic simulation model 
Beneficial population 
An estimate of the total population is required for the value of information analyses, defined as the 
total population who could benefit from future research that reduces decision uncertainty. The 
relevant population is all singleton births to nulliparous women in England, excluding those opting for 
elective CS for reasons other than breech presentation.  
 
NHS Maternity Statistics202 state that there were 636,401 births in England in FY2016-17. Of these, 
ϵϭ.ϴ% ǁeƌe at шϯϳ ǁeeks͛ gestatioŶal age, out of ǁhiĐh ϯϯ.ϲ% ǁeƌe to Ŷullipaƌous ŵotheƌs.202 The 
statistics do not disaggregate by reason for elective CS (specifically, whether because of suspected 
breech position or not). Therefore, this means there were: ͸͵͸,ͶͲͳ ∗ Ͳ.ͻͳͺ ∗  Ͳ.͵͵͸ = ͳͻ͸,ʹͻ͹ 
deliveries in England annually meeting our population definition. 
 
Assuming a 10 year time horizon for the value of information analysis (a proxy for the length of time 
for which the decision question remains relevant before technological development changes it), an 
approximately stable number of deliveries per annum and a discount rate of 3.5% yields a beneficial 
population of 1,689,663. 
 
If our analyses are assumed generalisable to all pregnancies, then the beneficial population is 636,401 
per annum, or 5,477,940 over the 10-year horizon (discounted at 3.5%). 
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Probabilities 
 
Prevalence of SGA, LGA, Breech – nodes A1 & A2 
LGA and SGA are defined as a birth weight in the highest and lowest decile of the distribution 
respectively.203, 204 The prevalence of each in the population is therefore 10%. 
 
The prevalence of breech at third trimester scan is estimated at 4.6%, based on the POP study, a large 
prospective cohort study conducted in Cambridge, UK.10 
 
Sensitivity and specificity of ultrasound – nodes B, S_B, L_B, B_B 
Estimates of the sensitivity and specificity of ultrasound scanning were based on the POP study.7, 10, 135 
Note due to the structure of the model, these figures are not the true sensitivity and specificity of the 
tests per se, but the probability of detection if everyone is screeŶed ;͚uŶiǀeƌsal sĐƌeeŶiŶg͛Ϳ ǀeƌsus the 
probability of detection with selective screening. The estimates are thus the actual sensitivity and 
specificities multiplied by the proportion of the population screened. Note we assume the sensitivity 
and specificity of a positioning scan is 100% as this is an extremely simple procedure, requiring solely 
the identification of the scull and spinal column to determine orientation of the fetus. 
 
Interventions for Breech – nodes B_ECV, B_ECVs, B_noECV, B_ECVs_rC and B_ECVf_RC 
Data on the proportion of mothers accepting ECV, the success rate and reversion rates were extracted 
from the POP study7. Methods and results for this has been published separately10. 
 
Delivery mode, true negative (AGA babies) node C1 
An otherwise healthy baby (i.e. true negative for SGA, macrosomia and breech, node C1) can be 
delivered via emergency CS or vaginally.  
 
A study of 14,100 singleton live and stillborn infants in French maternity units in 2010 found 
approximately 19.4% (n=2504/12881) of non-SGA babies were delivered via emergency CS.21 The POP 
study (a study of singleton nulliparous pregnancies between Jan 14, 2008, and July 31, 2012 in 
Cambridge, UK) found 19.9% (735/3689) of non-breech position babies were delivered via emergency 
CS.10 A 2018 Cochrane systematic review of IOL versus expectant management in women at or beyond 
term(Middleton et al., 2018) found an 18.42% (1056/5734) CS rate in the expectant management arm 
(analysis 1.1315).  
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The most relevant population to this analysis is the POP study.10 Of the 3689 deliveries, 141 were 
elective CS. Our defined population excludes elective CSs for indications other than breech therefore 
we assume 735/3548 = 20.7% of AGA deliveries result in emergency CS (95%CI 19.4%, 22.06%), with 
79.3% being delivered vaginally.  
 
We chose to use data from the POP study10 (a prospective cohort study) for the risk of emergency CS, 
rather than from Monier et al.21 (a population based setting), because the study design of the former 
made the validity of the numbers easier to verify. Compared to a network meta-analysis (NMA), 
relying on a single study risks potentially overestimating uncertainty, however, due to time constraints 
conducting a NMA was unfeasible. 
 
Delivery mode, false negatives for SGA and LGA - nodes S_C2, L_C2 
If a baby is SGA and this is not spotted (i.e. is a false negative, node S_C2), the relative risk of 
emergency CS is taken from the French cohort study, which reported an adjusted relative risk of 
͞CaesaƌeaŶ afteƌ oŶset of laďouƌ͟ ;assuŵed to ŵeet the defiŶitioŶ of eŵeƌgeŶĐǇ CS) in low risk 
pregnancies of 1.9 (95%CI 1.4, 2.5, Table 3, Monier et al.21, figures only reported to 1 decimal place). 
 
If LGA is not spotted (i.e. is a false negative, node L_C2), the odds ratio of emergency CS versus an AGA 
baby is assumed 1.792 (95%CI 0.718, 4.471). This probability was obtained from a retrospective 
analysis from 2005 based in the USA that included 241 nulliparous women whose pregnancies were 
induced and delivered at term (Blackwell et al.141). Breech position, stillbirth and pregnancies with 
other abnormalities were excluded. All underwent estimation of foetal weight via ultrasound prior to 
labour. 23 of 241 (9.5%) overestimated the EFW by 15% or more. Caesarean delivery rates for labour 
arrest (assumed to be emergency CS) were 34.8% in the overestimated group and 13.3% in the no-
overestimation group. This equates to 8/23 and 29/218 in each group respectively, yielding an odds 
ratio of 1.792 with a standard error of the log of the odds ratio of 0.466.  
 
Delivery modes – true positives for SGA and LGA– nodes S_C3, L_C3 
The ƌelatiǀe ƌisk of ͞CaesaƌeaŶ afteƌ oŶset of laďouƌ͟ ;assuŵed to ŵeet the defiŶitioŶ of eŵeƌgeŶĐǇ 
CS) in true positive SGA babies following induction versus true negatives (i.e. AGA babies) is assumed 
to be 2.9 (node S_C3). This may be an overestimate as according to the data source (Monier et al.21) 
this is the relative risk of emergency CS for true positive SGAs, whether or not they were induced, and 
only 27.1% (36/133) were induced <39 weeks. 
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We could not identify data for how early IOL would affect the risk of emergency CS among true LGA 
pregnancies. For this reason, we used data from Middleton et al.15, implicitly assuming the same 
relative risk reduction for LGA pregnancies as for non-LGA pregnancies. The relative risk for induced 
versus non-induced LGA pregnancies was 0.92 (95% CI: 0.85, 0.99) and was modelled using lognormal 
distribution (mean: -0.08, standard error: 0.037).  
If the policy for handling macrosomic babies is expectant management (node L_C2), then the 
emergency CS rate is assumed the same as for a false negative diagnosis. 
 
Delivery modes – false positives for SGA and macrosomia– nodes S_C4, L_C4, L_C1 
False positives for SGA will be induced. False positives for macrosomia will be handled depending on 
the selected management strategy: expectant management or IOL. 
 
A prospective RCT (n=6106) of IOL at 39 weeks in low-risk nulliparous women yielded a relative risk of 
(emergency) CS of 0.84 (95%CI 0.76, 0.93) associated with induction.148 Note that the Monier study21 
described above reported a relative risk of emergency CS in false positives for SGA of 1.0 (95%CI 0.5, 
2.2). However, as an RCT is generally considered at lower risk than an observational study, we opted 
for the RCT results148 and applied this to nodes S_C4 and L_C4, representing the probabilities of 
emergency CS following IOL for false positive diagnoses of SGA and LGA respectively.  
 
Where the selected management strategy for LGA is expectant management, the risk of emergency 
CS under a false positive diagnosis (node L_C1) is logically assumed the same as for an AGA baby (node 
C1). 
 
Delivery modes for breech –false negative and true positive - nodes B_C2, B_C3a-B_C3f 
If a baby is breech and is a false negative (i.e. undetected breech, node B_C2), we assume the 
probability of an emergency CS is 57.7% (95%CI 38.67%, 75.62%). No comparative data were identified 
for the risk of emergency CS with unidentified breech versus cephalic. However, a retrospective cohort 
study of the case notes of 131 women in Hong Kong in 1997 found that of those with undiagnosed 
breech at labour, and excluding those in whom ECV was subsequently attempted, 11 (42.3%) had a 
vaginal breech delivery and 15 (57.7%) a Caesarean section (Table 2, Leung et al.163). Caesarean 
sections are labelled as the sum of elective and emergencies, but given that these were undiagnosed 
until labour, we have interpreted these as all emergency CS. 
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Nodes B_C3a to B_C3f represent delivery modes with and without external cephalic version, taking 
into account success or failure as well as spontaneous reversion (either to breech or cephalic 
presentation). All estimates are obtained from the POP study10 except for node B_C3b, representing 
delivery modes where ECV was successful but the baby subsequently reverted to breech position. This 
was due to a lack of relevant observations in the POPS data. We assumed the same distribution as per 
a false negative diagnosis of breech (57.69% probability of emergency CS, node B_C2).163 Note we 
assume this to be an independent probability with the same parameters as node B_C2, rather than 
taking the exact same value to reflect that this is a different outcome measure to B_C2, but with the 
same likelihood. 
 
Perinatal morbidity – true negative (AGA babies) - node D1 
Node D1 represents the baseline risk of neonatal morbidity from expectant management of an 
otherwise healthy, non-SGA baby, taken from the POP study (Table 25), (Table 11), and systematic 
review.51 Outcomes include no, moderate, and severe neonatal morbidity, and perinatal death. 
Moderate neonatal morbidity was defined as one or more of the following criteria: a 5 min Apgar 
score of less than 7, delivery with metabolic acidosis (defined as a cord blood pH <7.1 and base deficit 
>ϭϬ ŵŵol/LͿ, oƌ adŵissioŶ to the ŶeoŶatal uŶit at teƌŵ ;defiŶed as adŵissioŶ <ϰϴ h afteƌ ďiƌth at шϯϳ 
ǁeeks͛ gestatioŶal age aŶd disĐhaƌge шϰϴ h afteƌ adŵissioŶͿ. “eǀeƌe ŶeoŶatal ŵoƌďiditǇ ǁas defiŶed 
as hypoxic ischaemic encephalopathy, use of inotropes, need for mechanical ventilation, or severe 
metabolic acidosis (defined as a cord blood pH <7.0 and base deficit >12 mmol/L. 
Table 25. Prevalence of no, moderate and severe neonatal morbidity in the POP study by fetal size. 
  No morbidity Moderate 
morbidity 
Total 
Non-SGA 3325 198 3523 
SGA 298 44 342 
Total 3623 242 3865 
  Non-severe 
morbidity 
Severe 
morbidity 
Total 
Non-SGA 3501 22 3523 
SGA 338 4 342 
Total 3839 26 3865 
SGA = Small for gestational age 
 
RCOG guideline 20b12 states that there is a 0.1% risk of perinatal mortality associated with a planned 
cephalic vaginal delivery. However, this figure includes all stillbirths and neonatal deaths. The relevant 
figure for the purpose of our model comprises intrapartum stillbirths and neonatal deaths only: deaths 
prior to this are assumed unrelated to orientation or size of the foetus, and thus do not affect the 
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results of the incremental analysis. To estimate the risk of stillbirth and perinatal mortality, we used 
observational data from Moraitis et al.51, siŶĐe deliǀeƌǇ ďefoƌe ϯϳ ǁeek͛s gestatioŶal age ǁas an 
exclusion criteria for the study. For baseline risk, we used mortality for spontaneous vaginal and 
assisted vaginal deliveries only. In the study, spontaneous and assisted vaginal deliveries accounted 
for 88.07% and 59.48% of antepartum stillbirths and delivery-related perinatal mortality, respectively. 
Data from Tables 2 and 3 showed the risk of stillbirth / perinatal mortality as a function of birth weight. 
Using this data, we estimated that the total number of stillbirths and perinatal mortality for 
spontaneous and vaginal deliveries would have been 809.66 and 455.54 if all babies would have been 
AGA. Multiplying these numbers with the respective proportion of deaths resulting from spontaneous 
and instrumental vaginal deliveries, we estimated that the total mortality for these categories would 
have been 984 cases (n = 635,396). Modelling this using a beta distribution, the baseline risk (i.e. for 
AGA pregnancies delivered vaginally) was 0.155% (95% CI: 0.145%, 165%). 
 
The probabilities of none, moderate or severe morbidity and perinatal death would ideally be 
modelled as a Dirichlet distribution. However, as these statistics are sourced from different sources 
they are modelled as independent beta distributions. This may overestimate the uncertainty in 
morbidity risk. Furthermore, we assume that risk of neonatal morbidity in an AGA baby is independent 
of delivery mode. A priori, an emergency CS is expected to be associated with a higher risk of perinatal 
morbidity. However, the relevant population is babies who are neither breech, SGA nor LGA, but who 
undergo an emergency CS for other reasons. After factoring out these indications for emergency CS 
the assumption may not be so unreasonable. 
 
Perinatal morbidity – false negative SGA babies – node S_D2 
The same sources (POP study and Moraitis et al.51) for node D1 report the odds of adverse outcome 
in SGA babies (i.e. in the bottom decile of the distribution): the odds ratio of moderate and severe 
morbidity and still birth for SGA compared with AGA babies in the absence of intervention (i.e. 
induction) are 2.48, 1.88 and 4.89 respectively (node S_D2). Again, we assume the risk of neonatal 
morbidity in SGA babies is solely a function of their size, and not delivery mode. 
 
Perinatal morbidity – false negative LGA babies – nodes L_D2a & L_D2c 
Baselines 
Neonatal morbidity for undiagnosed LGA babies (false negatives) were modelled to take account of 
specific risks for these babies, and therefore modelled as none (no complications), respiratory 
ŵoƌďiditǇ, shouldeƌ dǇstoĐia, ͚ otheƌ aĐidosis͛ oƌ peƌiŶatal death. Shoulder dystocia can lead to no long-
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term complications, brachial plexus injury (which can be transient or permanent), or acidosis, leading 
to no long-teƌŵ ĐoŵpliĐatioŶs, seǀeƌe aŶoǆiĐ ďƌaiŶ daŵage oƌ peƌiŶatal ŵoƌtalitǇ. ͚Otheƌ aĐidosis͛ 
(secondary to other than shoulder dystocia) has the same long-term outcomes as that secondary to 
dystocia, namely no long-term complications, severe anoxic brain damage or perinatal mortality. The 
risks of neonatal morbidity (and hence mortality) are related to delivery mode. These are modelled by 
estimating a baseline risk for each morbidity for the general population and multiplying this by a 
relevant relative risk. The baseline risks are not used in the model per se as morbidity for otherwise 
healthy infants is captuƌed ǀia ͚ŶoŶe / ŵild / ŵodeƌate / peƌiŶatal death͛ ;Ŷode DϭͿ. 
 
The baseline probability of respiratory morbidity was extracted from a study of the influence of timing 
of elective CS on respiratory morbidity, conducted in Cambridge, UK.205(Benner et al., 2010) All 
deliveries between 1985 and 1993 at the centre (n=33,289) were included in the analysis and all cases 
of respiratory distress syndrome or transient tachypnoea requiring admission to neonatal intensive 
care were recorded. Of the entire sample, 6955 deliveries occurred at term (week 39 to week 39+6 
days) and were delivered vaginally. Of these 22 had respiratory morbidity, reported as 0.32% (95%CI 
0.18%, 0.45%). Assigning a beta distribution to these figures yields a similar (but slightly different) 
95%CI of (0.20%, 0.46%). This was used as the baseline risk (i.e. risk for AGA babies).  
 
The baseline probability of shoulder dystocia was based on figures quoted in RCOG guidelines on the 
management of shoulder dystocia.206 This reported incidences in the literature of between 0.58% and 
0.70%. The best quality study informing the estimate was a retrospective analysis by Ouzounian et 
al.166. This reported 1686 cases of shoulder dystocia among 267,228 vaginal births, yielding an 
incidence of 0.63% (95%CI 0.60%, 0.66%).166 
 
The baseline probability of other acidosis (i.e. not secondary to shoulder dystocia) was based on a 
Cochrane systematic review comparing induction versus expectant management.15 Analysis 1.4 of the 
review reported incidence of birth asphyxia, with 5 of 731 pregnancies in the expectant management 
arm, yielding a base probability of 0.68%.  
 
The baseline risk of perinatal morbidity was assumed to be the same as described above (node D1), 
i.e. an estimated risk of 0.155% (95% CI: 0.145%, 165%), based upon own estimations using data from 
Moraitis et al.51 Since this baseline risk was not specific to fetal size, we used the same baseline risk 
for SGA and LGA fetuses and distinguished their risk using their respective odds ratios instead.  
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To estimate the baseline risk of perinatal death, we used observational data from Moraitis et al.51, 
siŶĐe deliǀeƌǇ ďefoƌe ϯϳ ǁeek͛s gestatioŶal age ǁas aŶ eǆĐlusioŶ Đƌiteƌia foƌ the studǇ. Foƌ ďaseliŶe 
risk, we used mortality for spontaneous vaginal and assisted vaginal deliveries only. In the study, 
spontaneous and assisted vaginal deliveries accounted for 88.07% and 59.48% of antepartum 
stillbirths and delivery-related perinatal mortality, respectively. Data from Tables 2 and 3 showed the 
risk of stillbirth and perinatal mortality as a function of birth weight. Using this data, we estimated 
that the total number of perinatal deaths for spontaneous and vaginal deliveries would have been 
809.66 and 455.54 if all babies would have been AGA. Multiplying these numbers with the respective 
proportion of deaths resulting from spontaneous and instrumental vaginal deliveries, we estimated 
that the total mortality for these categories would have been 984 cases (n = 635,396). Modelling this 
using a beta distribution, the baseline risk (i.e. for AGA pregnancies delivered vaginally) was 0.155% 
(95% CI: 0.145%, 165%). 
 
Ideally, these mutually exclusive probabilities would be modelled with a Dirichlet distribution. 
However, as they are from different sources, they are modelled with their respective distributions. 
This risks generating a set of probabilities that sum to greater than 1. However, given the low absolute 
percentages, this is highly unlikely. Sampled values were verified in the model code to ensure all were 
contained within [0,1]. 
 
Undetected macrosomia (false negative), vaginal delivery (L_D2a) 
No data were available on the relative risk or odds ratio of respiratory morbidity for undetected 
macrosomia with a vaginal delivery (node L_D2a). Expert opinion estimated that these babies were 
either at the same or lower risk of respiratory morbidity than AGA babies. We therefore used a point 
estimate relative risk of 0.75, and assigned a uniform distribution between 0.5 and 1. Note relative 
risks are more intuitive than odds ratios from an elicitation point of view, we therefore report this as 
an RR not OR.  
 
The odds ratio of shoulder dystocia in a macrosomic baby delivered vaginally (versus an AGA baby) is 
assumed 7.18 (95%CI 2.06, 25.00). This is based on a systematic review reporting incidence of shoulder 
dystocia in all babies with a birth weight >=4000g (Table 2 of Rossi et al.167). Two source studies were 
meta-analysed with a random effects model. Importantly, these data are not disaggregated by 
delivery method. However, it is reasonable to assume that CS eliminates the risk of shoulder dystocia, 
and therefore this represents the odds ratio of LGA babies delivered vaginally. 
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The same table in the review167 also reported the odds ratio of asphyxia in a macrosomic baby (versus 
aŶ AGA ďaďǇͿ of Ϯ.ϴϴ ;ϵϱ%CI ϭ.ϯϰ, ϲ.ϮϮͿ. We assuŵe this ŵeets ouƌ defiŶitioŶ of ͚otheƌ aĐidosis͛ aŶd 
apply the figures accordingly, but with the caveat that this is not disaggregated by delivery mode and 
so may overestimate the risk (for example, asphyxia may be the reason for an emergency CS). 
 
The same table in the review167 also reported the odds ratio of perinatal death in a macrosomic baby 
(versus an AGA baby) of 1.77 (95%CI 0.30, 10.34). We apply this to our definition of perinatal mortality, 
again noting that this is not disaggregated by delivery mode. The rarity of the outcome is also reflected 
in the wide confidence interval, implying a high degree of uncertainty. 
 
Undetected macrosomia (false negative), emergency Caesarean section (node L_D2c) 
The relative risk of respiratory morbidity for a macrosomic baby delivered via emergency CS versus an 
AGA baby (Table 26) delivered vaginally was taken from the Cambridge cohort described in the 
baseline probabilities section above (Table 2, Morrison et al.165). As stated above, this study was not 
specific to LGA babies, but the risk of respiratory morbidity is most plausibly associated with 
intervention to speed delivery rather than the presence of macrosomia. The source table reports the 
odds ƌatio of ƌespiƌatoƌǇ ŵoƌďiditǇ ǁith ͚C“ laďouƌ͛ ;assumed to meet the definition of emergency CS) 
at 39/0 to 39/6 as 3.2 (95%CI 1.4, 7.4) relative to the baseline of vaginal delivery at 40/0 to 40/6. 
Rebasing relative to vaginal delivery at 39/0 – 39/6 yields an odds ratio of 1.674 (95%CI 1.253, 2.001). 
Table 26. Risk of respiratory morbidity from emergency Caesarean section. 
  OR LCL UCL 
CS 
labour 
0.6 0.4 1 
Vaginal 3.2 1.4 7.4 
Rebased 5.33 3.5 7.4 
ln 1.674 1.253 2.001 
SE 0.167     
 
The relative risk of shoulder dystocia for emergency CS was assumed zero. 
The relative risk of other acidosis for a macrosomic baby delivered via emergency CS versus an AGA 
baby (Table 27) was taken from Chongsuvivatwong et al.168 (as for elective CS described above, and 
thus the same caveats are attached). 
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Table 27. Risk of acidosis from emergency Caesarean section. 
  n Severe asphyxia 
rate/1000 
LCL UCL Implied n 
from raw 
numbers 
Vaginal 12591 4.3 3.2 5.6 54 
EMCS 4328 8 5.5 11.1 35 
  Asphyxia No asphyxia       
Vaginal 54 12537 12591   
EMCS 35 4293 4328   
 
89 16830    
    LCL UCL     
OR: 1.867 1.217 2.865   
LnOR 0.625     
SE(lnOR) 0.218         
 
Finally, the relative risk of perinatal mortality for a macrosomic baby delivered via emergency CS 
versus an AGA baby was taken from the same source168 (Table 28). 
Table 28. Risk of perinatal mortality from emergency Caesarean section. 
  n Dead /1000 
dels 
LCL UCL Implied n 
from raw 
numbers 
Vaginal 12591 7 5.6 8.6 88 
EMCS 4328 12.4 9.3 16.2 54 
  dead alive       
Vaginal 88 12503 12591   
EMCS 54 4274 4328   
 
142 16777    
    LCL UCL     
OR: 1.781 1.266 2.505   
LnOR 0.577     
SE(lnOR) 0.174         
 
Perinatal morbidity – true positive SGA babies – induction of labour – node S_D3 
If an SGA baby is induced, we assume the relative risk of moderate and severe morbidity is 0.7, and 
for perinatal death 0.33 (node S_D3). These data are based on a systematic review of IOL compared 
with expectant management in low risk women at or beyond term (approx. 10,000 observations, odds 
ratios not reported).15 Critically, this is not the treatment effect with SGA babies, for which we were 
unable to identify any data, and the relative risk for moderate and severe morbidity was based on 
data reporting 5-minute Apgar score below 7. However, the central estimates of relative risks (0.7 and 
0.33 respectively) were considered plausible by clinical experts (GS, AM), and that the confidence 
intervals represented plausible summaries of their epistemic uncertainty. 
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Perinatal morbidity – true positive LGA babies - expectant management and induction of labour – 
nodes L_D3a and L_D3c 
An expectant management policy for true positive diagnoses of LGA (at node MGT_LGA_TP) is 
identical in management to expectant management under a false negative and the risk of perinatal 
ŵoƌďiditǇ is logiĐallǇ the saŵe as uŶdeƌ ͞uŶdeteĐted ŵaĐƌosoŵia ;false ŶegatiǀeͿ, spoŶtaŶeous 
ǀagiŶal͟ aŶd ͞ uŶdeteĐted ŵaĐƌosoŵia ;false ŶegatiǀeͿ, eŵeƌgeŶĐǇ CS͟ desĐƌiďed aďoǀe. Nodes L_DϮa 
and L_D2c are therefore replicated at this point in the tree (following MGT_LGA_TP >> L_C2). 
Under an IOL policy for positive diagnoses of LGA (MGT_LGA_TP >> L_C3a), delivery modes can again 
be spontaneous vaginal or emergency CS. Where data allow, risks of perinatal morbidity are assumed 
related to IOL and the presence of macrosomia as well as delivery model (vaginal or emergency CS). 
 
Respiratory complications 
A retrospective cross-sectional study of maternal and neonatal outcomes in induced low-risk term 
pregnancies (N = 131,243) reported neonatal complications by week of delivery comparing IOL with 
expectant management (Gibson et al.169). The adjusted odds ratio of respiratory complications at week 
39 is reported as 0.540 (95%CI 0.373, 0.783, Table 4169). This was used as odds relative to an AGA baby, 
whether vaginally delivered or emergency CS (L_D3a and L_D3c respectively). Of note is that these 
data are not macrosomia-specific. 
 
Shoulder dystocia 
A Cochrane systematic review98 of IOL versus expectant management for suspected fetal macrosomia 
estimated a relative risk of shoulder dystocia of 0.6 (95%CI 0.37, 0.98) (analysis 1.3 of Boulvain et al.98). 
We therefore applied this relative risk, noting the baseline comparator is MGT_LGA_TP >> L_C2 or 
MGT_LGA_TA >> L_C3. That is: 
P(dystocia | vaginal delivery at node L_D3a) = P(dystocia | vaginal delivery at node L_D2a) * RR 
And: 
P(dystocia | EmCS at node L_D3c) = P(dystocia | EmCS at node L_D2c) * RR 
Data aƌe foƌ ͚suspeĐted͛ ŵaĐƌosoŵia, Ŷot disaggƌegated ďǇ tƌue aŶd false positiǀes. We theƌefoƌe 
applǇ due ĐautioŶ aŶd sĐoƌe the ƌeleǀaŶĐe of the data as ͚ŵodeƌate͛. 
 
Acidosis 
The Boulvain Cochrane review98 did not report incidence of acidosis or asphyxia. Therefore we sourced 
data from the Middleton Cochrane review,15 which compared induction versus expectant 
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management in all pregnancies at term. Analysis 1.4 reported a relative risk of birth asphyxia of 1.66 
;ϵϱ%CI Ϭ.ϲϭ, ϰ.ϱϱͿ. We used this to ƌepƌeseŶt the ƌelatiǀe ƌisk of ͚otheƌ aĐidosis͛. 
 
Perinatal mortality 
The Cochrane systematic review98 of IOL versus expectant management for suspected foetal 
macrosomia observed zero events in the included studies. We therefore used the Middleton Cochrane 
review, Analysis 1.1,15 reporting a relative risk of 0.33 (95%CI 0.14, 0.78) compared with not non-
induced AGA babies. 
 
The odds ratios and relative risks for node L_D3c are identical to those for L_D3a. However the implied 
probabilities at the nodes will differ due to the different baseline comparators: for respiratory 
morbidity, acidosis and perinatal death the ratios are relative to expectant management for AGA 
babies. For dystocia, macrosomia-specific data were available, comparing induction with expectant 
management in cases of suspected macrosomia, so the ratio is relative to vaginal delivery or 
emergency CS for an expectant management policy. 
 
Perinatal morbidity – false positive SGA or LGA babies – induction of labour– node D4 
Following an incorrect diagnosis of SGA or following an incorrect diagnosis of LGA under the IOL policy, 
an AGA baby will be induced. Evidence suggests this reduces the risk of stillbirth, but with the 
consequence of increasing perinatal complications: a retrospective database analysis of induction 
versus expectant management at 37 weeks found an odds ratio of 0.15 (95%CI 0.03, 0.68) for perinatal 
death and 1.92 (95%CI 1.71, 2.15) for admission to neonatal unit or special care baby unit.162 We 
assumed admission to these specialist units was a proxy for moderate and severe complications, so 
applied these ORs to the baseline risks. 
 
Perinatal morbidity – false positive LGA babies – expectant management  
Following an incorrect diagnosis of macrosomia, and with an expectant management policy, perinatal 
outcomes are logically the same as vaginal and emergency CS perinatal outcomes for AGA babies. 
Therefore, these nodes are labelled as D1. 
 
Perinatal morbidity – breech – false negative and true positive – B_D2a – B_D2c 
Perinatal outcomes are assumed dependent on whether the baby is breech at delivery or not. A breech 
baby who reverts to cephalic positioning either spontaneously or following ECV is assumed as the 
same risk of perinatal outcomes as an AGA baby. 
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Vaginal breech delivery (B_D2a) – Perinatal death 
RCOG guideline 20b12 states that vaginal delivery in the breech position is associated with a risk of 
perinatal mortality of 2/1000, but 0.5/1000 with elective CS, compared with a 1.0/1000 risk for a 
cephalic vaginal delivery. This is based largely on a Cochrane systematic review of planned CS for term 
breech delivery,13 the largest contributor to which was the Term Breech Trial (TBT).207  
 
As desĐƌiďed aďoǀe ;͚peƌiŶatal ŵoƌďiditǇ – true negative (AGA babies) - Ŷode Dϭ͛Ϳ, the ϭ.Ϭ/ϭϬϬϬ ƌisk 
of perinatal mortality includes all deaths around the time of delivery. However, our figure of interest 
is solely intrapartum stillbirth and neonatal death (the implicit assumption is that pre-partum deaths 
are due to causes other than breech, LGA or SGA). A retrospective cohort study of all term singleton 
births in delivery units in Scotland between 1992 and 2008 (n = 784,576) observed a mortality rate of 
0.04% (234/537745) associated with cephalic vaginal deliveries.51 The same study reported a mortality 
rate of 0.29% (5/1719) associated with breech vaginal deliveries, yielding an odds ratio of 6.68 (95%CI 
2.75, 16.22).  
 
Vaginal breech delivery (B_D2a) - Moderate & Severe morbidity 
We estimate the relative risk of moderate and severe morbidity associated with breech vaginal 
delivery versus cephalic vaginal delivery at 6.7 (95%CI 5.9, 7.6). This is based on a large retrospective 
cohort analysis of the Swedish Medical Birth Registry from 1988 to 1997 reporting the odds ratio of 5 
minute Apgar below 7.172 We assume the odds ratios are identical for moderate and severe morbidity. 
This may be a reasonable assumption: the odds ratio for perinatal death calculated above is 6.68, 
extremely close to the 6.7 reported here.  
 
Elective Caesarean section delivery (B_D2b) – Perinatal death 
A Cochrane systematic review of elective CS versus vaginal delivery for term breech delivery (Hofmeyr 
et al.13 Analysis 1.3) observed an overall global relative risk of perinatal death of 0.29 (95%CI 0.10, 
0.86).  
 
Elective Caesarean section delivery (B_D2b) - Moderate & Severe morbidity 
The same review13 reports a relative risk of 5 minute Apgar score <7 of 0.43 (95%CI 0.12, 1.47), and 
Apgar score <4 of 0.11 (95%CI 0.01, 0.87, Analyses 1.4 and 1.5 respectively). We therefore use this as 
the relative risk of moderate and severe perinatal morbidity respectively associated with elective CS 
versus planned vaginal breech delivery. 
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Emergency Caesarean section delivery (B_D2c) – Perinatal death 
A study of 32776 breech presentations in Scotland between 1985 and 2004 (Pasupathy et al.173) 
observed 9018 emergency CS deliveries (4108 pre- and 4910 post-labour), of which 14 lead to 
perinatal and neonatal death (0.16%). As stated above, the Moraitis review51 reported a mortality rate 
of 0.29% (5/1719) associated with breech vaginal deliveries. This yields an odds ratio of 0.533 (95%CI 
0.192, 1.482). As this odds ratio is based on combining data from different sources, we explore this 
parameter in greater detail in one-way sensitivity analysis. 
 
Emergency CS delivery (B_D2c) - Moderate & Severe morbidity 
In the absence of evidence on the effect of emergency CS versus vaginal breech delivery for the risk 
of moderate and severe neonatal morbidity, we assumed the odds ratio to be the same as the odds 
ratio of perinatal death, i.e. 0.533 (95%CI 0.192, 1.482). 
 
Long term outcomes following no, moderate and severe perinatal morbidity (AGA, SGA and breech) 
– nodes E1 – E3 
Long-term outcomes were no complications, Special Educational Needs (SEN), Severe neurological 
morbidity (SNB), and Neonatal/Infant death. The risks of each were assumed dependent solely on 
level of perinatal morbidity (where perinatal morbidity is a function of abnormality and delivery 
management).  
 
A large retrospective cohort study of school children reported the risk of special educational needs 
(SEN) by 5-min Apgar score inter alia.174 4.7% [=18,736/(18736+376,891)] of children with a 5-minute 
Apgar score at birth of 8-10 required SEN. We used this as the risk of SEN for children with no neonatal 
complications (node E1). The same study also reported odds ratio for Apgar scores of 4-7 and 0-3, 
which were used as the increase in risk for moderate and severe neonatal morbidities (nodes E2 and 
E3). 
 
We used cerebral palsy (CP) as a proxy for severe neurological morbidity. A large retrospective cohort 
study of births in Sweden analysed the risk of cerebral palsy by 5-minute Apgar score.175 We calculated 
the baseline risk of CP as the sum of the number of children with CP with Apgar score >7 divided by 
the total number of children with Apgar > 7 (=(69+163+674)/(27,664+129,096+1,037,793) = 0.08%, 
node E1). The study also reported adjusted hazard ratios (HR) by individual Apgar score, rather than 
grouped categorisations (<4, 4-7 and >7). A weighted geometric mean HR (and 95%CI) was calculated 
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for each group as per the Table below, and divided by the weighted 7-10 results. We interpreted the 
hazard ratio as the relative risk. These are different, but related concepts, the former taking account 
of time whilst the latter assuming all events happen simultaneously. Given the simple structure of our 
model, and the relative rarity of CP, we felt this was a sufficient approximation. 
 
Infant mortality data were extracted from routine Scottish data from 1992 to 2010.176 1,013,363 
neonates had a normal Apgar score at birth (defined as >7) (Table 29). Of these there were 628 
neonatal (birth to 28 days) and 1446 infant deaths (29 days to 1 year), a total of 0.2%. This was 
assumed to form the baseline risk of neonatal/infant mortality (node E1). Adjusted relative risks of 
neonatal and infant mortality were reported in the appendix to the paper. To generate an overall 
relative risk over 12 months, a weighted geometric mean (and 95%CIs) of the risks reported by 
Iliodromiti et al.176 for neonatal and infant mortality was calculated, with weights of 1 and 12 for 
neonatal and infant mortality respectively (representing the relative length of the time periods, Table 
30). Relative risks for Apgar 4-6 and 0-3 were used for moderate and severe neonatal morbidity 
respectively (nodes E2 and E3).
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Table 29. Baseline risk of cerebral palsy by Apgar score (5 min). 
5-minute 
Apgar 
By single score     Grouped     
  Number of 
children 
Number 
with CP 
Adjusted HR 
(95%CI) 
Number of 
children 
Number 
with CP 
Adjusted HR 
(95%CI) 
0 136 13 277.7 (154.4, 
499.5) 
1447 130 145.5 (104, 
204.1) 
1 215 23 238.2 (153, 371) 
   
2 388 29 124 (83.8, 183.4) 
   
3 708 65 148.3 (112.8, 195) 
   
4 1097 53 75.9 (56.4, 102) 17470 185 10.4 (7.8, 13.9) 
5 1830 39 32.6 (23.4, 45.6) 
   
6 4259 42 15.4 (11.2, 21.2) 
   
7 10284 51 6.9 (5.1, 9.4) 
   
8 27664 69 3.8 (3, 4.9) 1194553 906 1 (ref) 
9 129096 163 1.9 (1.6, 2.2) 
   
10 1037793 674 1 (ref)       
Source: Fig 1, Persson et al.175 
Table 30. Relative risk of cerebral palsy by Apgar score (5 min). 
Apgar Neonatal 
weight 
Adjusted RR Infant 
weight 
Adjusted RR Pooled Adjusted RR 
0-3 1/13 188.4 (141.7, 250.5) 12/13 55.14 (44.03, 69.06) 60.61 (48.17, 76.26) 
06-Apr 1/13 34.16 (23.41, 49.86) 12/13 11.81 (8.64, 16.15) 12.82 (9.33, 17.61) 
10-Jul 1/13 1 (ref) 12/13 1 (ref) 1 (ref) 
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Long term outcomes following LGA birth – nodes L_E1, L_F1, L_G 
In our model, LGA babies are at risk of no perinatal complications, respiratory morbidity, shoulder 
dystocia, other acidosis or perinatal mortality. LGA babies developing shoulder dystocia are at risk of 
no long-term complications, brachial plexus injury (BPI) or acidosis. BPI can be transient or permanent. 
Acidosis can lead to no LT complications, SEN, SNM or perinatal mortality. The RCOG Green-top 
guideline No. 42206 state that ͞feǁeƌ thaŶ ϭϬ% ƌesultiŶg iŶ peƌŵaŶeŶt [iŶjuƌies]͟, ďased upoŶ fiŶdiŶgs 
from Gherman et al.208 These figures in turn rely upon the study by Sandmire et al.171 In total, 8 out of 
145 cases of BPI injuries were permanent. We modelled this using a beta distribution, yielding a risk 
of permanent BPI of 5.5% (95% CI: 2.4, 9.8). 
 
Following no perinatal complications, LGA babies are at background risk of long-term complications, 
SEN, SNM and neonatal mortality (node E1). 
 
Following respiratory morbidity, we assume infants are at increased risk of long-term complications 
(SEN, SNM and neonatal/infant mortality) equivalent in severity to severe neonatal morbidity (i.e. 
node E3). 
 
Shoulder dystocia can lead to no injury to the infant (in which case the background risk of SEN, SNM 
and neonatal/infant mortality applies), BPI, which can be transient or permanent, or acidosis. 
Transient BPI leads to background risk of long-term complications, SEN, SNM and neonatal mortality 
(node E1). 
 
Permanent BPI leads to baseline risk of long-term complications, SEN, SNM and neonatal mortality, 
but with a decreased quality of life associated with the injury (node L_G). 
 
Following acidosis, the risk of long-term complications, SEN, SNM and neonatal mortality is assumed 
in severity to severe neonatal morbidity (node E3). 
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Costs 
 
Costs of ultrasound scan for fetal size 
We obtained the cost of an ultrasound scan for fetal size (and presentation) from the national 
schedule of reference costs.177 We used data foƌ ͚AŶte-Natal “taŶdaƌd UltƌasouŶd sĐaŶ ;N)Ϯϭ)Ϳ͛, as 
reported for outpatient procedures. The reference costs contained the mean as well as lower and 
upper inter-quartile range (IQR) for costs, listed by every type of service provider. We calculated a 
weighted average for the mean/inter-quartile ranges based upon the reported numbers of activities 
over the year for each provider. We then fitted a gamma distribution to the weighted mean/ inter-
Ƌuaƌtile ƌaŶge, oďtaiŶiŶg the paƌaŵeteƌs α = ϰ.ϲϵϬϰ aŶd β = ϮϮ.ϴϬϲϮ, aŶd ǇieldiŶg a total Đost of 
£107.06 per scan (95% CI: 70.89, 134.92). 
 
Cost of ultrasound scan for fetal presentation only 
Estimating a cost for an ultrasound (US) scan for fetal presentation alone is challenging, since this type 
of US screening is not part of current NHS routine. We theorized that such a scan could be performed 
by a midwife in conjunction with a standard antenatal visit in primary care, using relatively basic and 
inexpensive equipment. However, it is uncertain whether implementing such a routine is feasible. For 
this reason, we estimated the cost of two different type of scenarios for how a US scan for fetal 
presentation alone could be performed. 
 
Midwife-led screening in primary care setting 
We theorized that an ultrasound scan for fetal presentation alone could be provided by a midwife in 
conjunction with a standard antenatal visit in primary care. While there are NHS reference costs for 
͚AŶte-Natal “taŶdaƌd UltƌasouŶd sĐaŶ ;N)Ϯϭ)Ϳ͛177, such scans frequently involve assessment of fetal 
anatomy and/or biometry and since these require much more time and training to assess than fetal 
presentation alone, we deemed it inappropriate to use this cost as an estimate for the cost of an 
ultrasound scan for fetal presentation alone. 
 
Following the methodology for Wastlund et al.10, we estimated the cost of ultrasound scan for fetal 
pƌeseŶtatioŶ as a fuŶĐtioŶ of the ŵidǁife͛s tiŵe, the eƋuipŵeŶt Đost, aŶd the Đost of the 
room/facilities where the scan would take place. 
 
We oďtaiŶed the Đost of the ŵidǁife͛s tiŵe fƌoŵ the UŶit Costs of Health aŶd “oĐial Caƌe ϮϬϭϳ.178 We 
used the total hourly cost for Band 5 nurses, £36; this cost was consistent with the costs reported for 
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midwives in NHS Staff Earnings 2017.209 On top of the scan itself, time would be needed to make the 
woman feel comfortable in the process, and to document the results of the scan, we estimated that 
the average scan would require 5-10 minutes in total. In the absence of data on how much it would 
cost to provide ultrasound equipment and sufficient training, we guessed that this could be provided 
for a total cost between £1-20k. We assumed that the average machine would be operated 400 to 
3000 times annually over the 5-year time horizon. We assumed that room costs would be between 
£4,500 and £6,000 annually210, and that rooms would be operated 1,573 hours per year178. 
 
We simulated the total cost per scan using uniform distributions and 100,000 simulations. We then 
fitted a gamma distribution to the resulting distribution, based upon the mean and inter-quartile 
range. The resulting parameter estimation was a gamma distribution with alpha = 43.8259, and beta 
= 0.2159. This resulted in a total cost of ultrasound scan for fetal presentation of £9.46 (95% CI: £6.87, 
12.46). 
 
Sonographer-led ultrasound in designated setting 
If implementing US assessment in primary care (as part of a standard antenatal visit) would not be 
possible, the most feasible alternative would be to perform the scan by referral to a designated 
ultrasonography unit. A scan for fetal presentation alone is much swifter and technically less 
complicated than the type of scan typically performed as part of a standard antenatal visit. For this 
ƌeasoŶ, ǁe didŶ͛t ĐoŶsideƌ ͚AŶte-Natal “taŶdaƌd UltƌasouŶds “ĐaŶ ;N)Ϯϭ)Ϳ͛ iŶ the NH“ ƌefeƌeŶĐe 
costs177 to ďe a suitaďle Đost estiŵate. IŶstead, ǁe used the data foƌ ͚UltƌasouŶd “ĐaŶ ǁith duƌatioŶ 
of less thaŶ ϮϬ ŵiŶutes, ǁithout CoŶtƌast ;‘DϰϬ)Ϳ͛ fƌoŵ the ƌefeƌeŶĐe Đosts, diagŶostiĐ imaging. The 
national schedule of reference costs report costs as mean (£52) and inter-quartile range (£37-60) only. 
To capture the uncertainty of this cost appropriately we fitted a gamma distribution to the mean and 
inter-quartile range. The resulting parameter estimation was a gamma distribution with alpha = 
9.2207, and beta = 5.6395. This resulted in a total cost of ultrasound scan for fetal presentation of 
£52.00 (95% CI: £24.05, 90.55). 
 
Cost for base-case scenario 
Since there is genuine uncertainty over the feasibility of providing midwife-led US screening for fetal 
presentation only, quantifying the reasonable cost for this parameter was problematic. For the base-
case scenario, we used a uniform distribution of costs, ranging between the lower end of the 95% cost 
interval if midwife-led screening was possible (£6.87) and the upper end of the confidence interval for 
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sonographer-led screening (£90.55). This way, all plausible cost of ultrasound screening for fetal 
presentation alone was incorporated into the sensitivity and value of information analysis. 
 
Cost per mode of delivery 
We obtained data on costs for different modes of deliveries from the national schedule of reference 
costs.177 For a (cephalic) vaginal delivery, we used data for a normal delivery without epidural or 
assistance. For all modes of deliveries, the reference costs were presented for different levels of 
complications (CC scores), we calculated a weighted average cost for all levels of these. The reference 
costs reports the mean, as well as the lower and upper inter-quartile range (IQR) for costs, listed by 
different types of clinical settings (e.g. elective inpatient, non-elective inpatient, outpatient 
procedures etc.). We calculated a weighted average for the mean/inter-quartile ranges based upon 
the reported numbers of activities over the year for each setting. For each of the three modes of 
deliveries (cephalic vaginal, planned CS and emergency CS), we fitted a gamma distribution to the 
resulting weighted mean/inter-quartile range. For vaginal delivery, this yielded the parameteƌs α = 
ϳ.ϮϲϬϲ aŶd β = ϮϱϮ.ϱϴϮϰ, ǁith a total Đost of £ϭ,ϴϯϰ.ϰϳ ;ϵϱ% CI: £ϭϳϱϬ.ϰϯ, ϮϮϯϲ.ϬϱͿ. The 
ĐoƌƌespoŶdiŶg ǀalues foƌ plaŶŶed C“ ǁeƌe α = ϭϭ.ϭϮϭϮ aŶd β = ϯϬϳ.Ϭϭϲϵ, ǁith a total Đost of £ϯ,ϰϭϭ.ϵϯ 
(95% CI: £2679.80, 4038.29). For emergency CS the values ǁeƌe α = ϭϰ.ϳϯϮϵ aŶd β = ϯϭϴ.ϭϯϱϰ, foƌ a 
total cost of £4,688.27 (95% CI: £3816.15, 5443.02) 
 
Since the National Schedule of Reference Costs does not list separate costs for vaginal breech 
deliveries, we made the simplifying assumption that these costs would have the same ratio to the 
costs of elective caesarean section as reported by Palencia et al. (2006).180 For that study, the costs 
were Ca$7,255 and Ca$8,440 for elective caesarean section and vaginal breech delivery, respectively, 
with a mean cost difference of Ca$1,185 (95% CI: $719, $1663). We fitted a normal distribution (mean 
= 1.1633, sd = 0.0332) to calculate the relative cost increase from vaginal breech delivery compared 
to elective CS. This yielded a relative cost increase of 1.1633 (95% CI: 1.0982, 1.2284). To obtain the 
cost of vaginal breech delivery for our model, we then multiplied the cost of elective CS (as calculated 
above through the NHS reference costs) with the relative cost increase from vaginal breech delivery. 
 
Cost of External Cephalic Version (ECV) 
We obtained the cost of external cephalic version (ECV) from the cost analysis of offering ECV in the 
UK reported by James et al.181 The authors provided two different estimates of costs, using low 
;£ϭϴϲ.ϳϬͿ aŶd high ;£ϭϵϯ.ϯϬͿ staff Đosts, ƌespeĐtiǀelǇ. To ĐoŶǀeƌt to ϮϬϭϳ͛s pƌiĐe leǀel, ǁe used the 
Hospital & Community Health Services (HCHS) inflation index: compared to baseline, the index was 
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302.3 for year 2017,178 and 196.5 for year 2001.211 The resulting cost per ECV was £287.2 and £297.4 
for low and high staff costs, respectively. We interpreted this as the feasible range that costs could 
assume, and let the model sample from this interval using uniform distribution. 
 
Cost of neonatal unit admission 
To capture the cost of admission to neonatal care following delivery we used cost data from the NHS 
reference costs.177 We diǀided ŶeoŶatal ĐƌitiĐal Đaƌe iŶto thƌee leǀels: ͚IŶteŶsiǀe Đaƌe͛, ͚High-
depeŶdeŶĐǇ͛, aŶd ͚“peĐial Đaƌe͛. Foƌ iŶteŶsiǀe aŶd high depeŶdeŶĐǇ Đaƌe ǁe used ĐuƌƌeŶĐǇ Đodes 
XA01Z and XA02Z, respectively, and for special care we used a weighted average of currency codes 
XA03Z to XA05Z. We assumed that the proportion of admittance to each level of neonatal care and 
length of stay was the same as the one reported by Alfirevic et al.182. This meant that 19, 7, and 74 
percent of admitted neonates went to intensive, high dependency, and special care, and that the 
length of stay was 2, 1.5, and 2 days, respectively. To capture the uncertainty in the cost of care, we 
fitted a gamma distribution based upon the mean and inter-quartile values, as reported in the 
reference costs.  
 
To estimate the number of neonates admitted to neonatal care as a function of neonatal morbidity at 
delivery, we reanalysed data from the POP study.7 We used Apgar score (5 min) as a proxy for neonatal 
morbidity at delivery; Apgar score >7, 4-6, and 0-3 were equivalent to no, moderate and severe 
neonatal morbidity, respectively. This meant that the risk of admittance was 7.4% (95% CI: 6.6-8.2%) 
with no morbidity, and 47.4% (95% CI: 31.9-63.1%) with moderate morbidity; we modelled this using 
the Beta distribution. For severe morbidity, we instead made the simplifying assumption that all 
neonates with severe morbidity would be admitted to neonatal unit due to the small sample size of 
severe neonatal morbidity in the POP study. In absence of evidence of how the level of neonatal 
morbidity at birth affects the chance of ending up in each tier of neonatal care, we assumed that the 
proportions were constant, and that the level of neonatal morbidity only affected the level of overall 
admittance. 
 
Cost from Respiratory morbidity 
Morrison et al. (1995) reports the incidence and length of stay at hospital for respiratory morbidity.165 
28% of the morbidities consisted of Respiratory Distress Syndrome (RDS) and the rest of Transient 
Tachypnea of the Newborn (TTN). The average stay at Neonatal Intensive Care Unit (NICU) was 4 days 
for RDS and 0.6 days for TTN. The NHS cost of NICU admission is £1,295 per day (inter-quartile range: 
£1,015-1,541).177 Given this, the average cost for a case of RDS is £5,180 (IQR: £4,060-6,164), and the 
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cost for TTN is £777 (IQR: 609-925). Assuming that RDS and TTN makes up 28% and 72% of respiratory 
morbidities, respectively, the average cost of a case of respiratory morbidity would be £2,010 (IQR: 
£1,575-2,392). Due to the very low mortality rate from respiratory distress among babies born at term, 
we made the simplifying assumption that respiratory distress could lead to NICU admission, but would 
otherwise have no consequences.(Malloy and Freeman, 2000) In order to capture the uncertainty of 
the cost of respiratory morbidity in one parameter, we fitted a gamma distribution based upon the 
mean and inter-quartile range. The resulting distributions had parameters alpha = 10.7125 and beta 
= 187.6316, yielding a total cost of 2011 (95% CI: 993, 3381). 
 
Cost of acidosis without long-term consequences 
In the absence of data on the costs associated with short-term acidosis (i.e. acidosis that require 
neonatal treatment, but resolves without any other health consequences), we made the simplifying 
assumption that treatment would be required at the neonatal intensive care unit (NICU) for 1-4 days, 
with equal probabilities. To obtain per-day costs, we fitted a gamma distribution for the unit cost of 
NICU care using cost data from the NHS reference costs177, based upon mean and interquartile range. 
Combining the time and per-day costs, we obtained a total cost distribution. To be able to capture 
total cost uncertainty in a single parameter, we fitted a gamma distribution to the total cost. The 
resulting parameter (alpha = 3.6143 and beta = 895.6169) had a total cost of £3,240 (95% CI: £806- 
7,328). 
 
Cost of transient and permanent BPI 
To estimate the costs associated with Brachial Plexus Injury (BPI) we assumed the same resource 
usage as reported by Culligan et al. (2010)183. Transient BPI costs included a hospital consultation by a 
specialist, weekly physical therapy for 4 months, and one needle electromyography (EMG) test. 
Permanent BPI costs included the costs from transient BPI but with weekly physical therapy for 3 years 
instead, plus one outpatient visit to a specialist, and magnetic resonance imaging (MRI) of the 
shoulder.183 We obtained costs for the specialist consultations and weekly physiotherapy treatments 
from the unit costs of health and social care; these were £199 and £87, respectively.212 The costs for 
EMG and MRI were taken from the NHS reference costs (AA33D and RD01C)177; these were £269.2 
and £106.59, respectively. All costs were updated to the price year 2016-17 using the HCHS index.178 
We assumed that all costs except for physiotherapy arose in the first year of life and discounted 
accordingly; the discount rate was 3.5% as recommended by NICE.190(National Institute for Health and 
Clinical Excellence, 2013) The total discounted costs from transient and permanent BPI were £2,066 
and £14,133, respectively. 
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To account for uncertainty, Culligan et al.183 expanded their cost estimate into a plausible range of 
costs, which ranged between 50-200% of the point estimate. However, directly incorporating this 
plausible range into our own estimation (after adjusting for cost differences) by using uniform 
distribution would have been inappropriate, since this would overestimate costs. Instead, we 
interpreted the plausible range as a 95% confidence interval (CI) for total costs, and then fitted a log-
normal distribution to the appropriate mean and CI range. This way, the lower and upper 95% CI was 
still 50% and 200% of the point estimate, respectively, but in this case following a log-normal 
distribution. For transient BPI, the resulting distribution had a logged standard error of 0.3536, and 
the total costs were £2,066 (95% CI: £1033 – 4132). The corresponding figures for permanent BPI were 
a logged standard error of 0.3536, and a total cost of £14,133 (95% CI: £7067-28264). 
 
Cost of perinatal death 
We used the cost of stillbirth as a proxy for the cost of perinatal death. The direct costs of stillbirth 
were obtained from Mistry et al.184 The authors estimated that the costs would be between £1,242 
(core investigation and counselling only), up to £1,804 depending on the clinical scenario surrounding 
the stillbirth and what tests were needed. The authors choose not to present a most plausible estimate 
within this estimate, but instead just reported these costs as the full range of costs for stillbirth. For 
this reason, we interpreted these costs as the upper and lower boundaries that the cost of perinatal 
death could reasonably assume. We updated these costs to the price year of 2016-17 (The original 
source used price year 2010) using the HCHS index178, and used a uniform distribution. 
 
Cost of special educational needs 
We obtained the cost of special educational needs (SEN) from Barrett et al.185, using the difference in 
costs to typically developing groups. The cost difference was £6,315 (95% CI: £3798, 8832) These costs 
were estimated for the cost year of 2007-08, hence we inflated this to the value of price year 2016-17 
using the HCHS index178; resulting in a cost difference of £7,428 (95% CI: £4467, 10389). This cost was 
applied annually for years 6-17 of life (the typical school years) and discounted using a discount rate 
of 3.5% as recommended by the National Institute for Health and Care Excellence (NICE)190. 
 
The cost of severe neurological morbidity 
We used cerebral palsy (CP) as a proxy for severe neurological morbidity. In the absence of English 
cost data detailed enough to provide an annual cost for the relevant payer perspective, we instead 
obtained the annual cost of CP from Cerebral Palsy Australia186. We used total per capita cost for the 
health system, as well as indirect costs (e.g. program services, aids, and home modifications), but we 
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omitted productivity losses, dead weight losses from financial transactions, and costs for informal 
carers. The annual average cost per case of CP in 2005 was 5,362 AUD. We converted this to sterling 
pound (£) by the exchange rate of 31-12-2005, and updated to the price level of 2016/17 using the 
hospital & community health services (HCHS) index.178 This meant a total annual cost of £2,929.6. 
Since the data was derived from the nationwide population of people with CP, this average annual 
cost is applicable for any year of life. 
 
Capturing the uncertainty in these costs were problematic as costs are not easily transferable between 
different healthcare systems. Further, Cerebral Palsy Australia did not provide any estimates of cost 
uncertainty. For this reason, we chose to assume that English costs could reasonably fluctuate 
between half and double those quoted in Australia. We interpreted this as a 95% confidence interval 
stretching between £1465 and £5859, and fitted a log-normal distribution to this interval. 
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Quality of life 
 
Baseline long-term Quality-Adjusted Life Years 
In the absence of neonatal morbidity at birth, lifetime quality-adjusted life years (QALYs) were 
calculated using survival and Quality of Life (QoL) weights for a general UK population. Survival rates 
were obtained from the Office for National Statistics.188 These were adjusted using age-specific QoL 
data from EuroQol. The QoL for each age group was modelled using a normal distribution with mean 
and standard errors as provided by EuroQol for the UK using the time trade-off (TTO) method.187 We 
fiŶallǇ liŵited the total QALYs to the ŵodel͛s tiŵe hoƌizoŶ aŶd disĐouŶted these QALYs, using a 
discount rate of 3.5% as recommended by NICE.190 
 
Quality of life for brachial plexus injury (BPI) 
We obtained the estimated quality of life following brachial plexus injury (BPI) from Culligan et al.183 
These data were estimated as a plausible range by an expert panel, and the authors used a uniform 
distribution within the plausible range. The authors provided separate estimates for different 
complexity levels of BPI. We assumed that long-term BPI in the context of our model would be 
eƋuiǀaleŶt to eitheƌ ͚PeƌŵaŶeŶt ďƌaĐhial pleǆus iŶjuƌǇ ;ŵild to ŵodeƌateͿ͛, oƌ ͚PeƌŵaŶeŶt ďƌaĐhial 
plexus iŶjuƌǇ ;seǀeƌeͿ aŶd uŶĐoŵpliĐated deliǀeƌǇ͛. We theƌefoƌe Đhose to ĐoŶsideƌ the plausiďle 
range to stretch between 0.30 (the lower boundary for severe BPI) and 0.70 (the upper boundary for 
mild to moderate BPI). 
 
Long-term health outcomes following severe neurological morbidity 
To get an estimate of the long-term consequences from severe neurological morbidity, we 
constructed a model based upon the work by Leigh et al.189, using cerebral palsy as a proxy for severe 
neurological morbidity. Analogous to Leigh et al., we divided all cases of cerebral palsy into five levels 
according to the Gross Motor Function Classification System (GMFCS), system describing the 
ambulatory functionality of people with CP.213 We obtained the GMFCS-specific quality of life (QoL) 
by letting the model sample values from the gamma distribution provided by Leigh et al., subtracting 
these values from 1 (highest possible QoL) to provide utility weights. A benefit of using these QoL 
weights was that they were derived using EQ-5D214, facilitating comparison to the QoL of the general 
population. We let QoL decrease over time at the same rate as Leigh et al. hence indirectly assuming 
that ageing has no greater effect on QoL for those with CP than otherwise healthy members of the 
UK. 
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Since cerebral palsy affect mortality as well as QoL, we had to adjust the model for survival. We 
calculated GMFCS-specific survival rates, using the average mortality rates provided by Leigh et al. for 
each GMFCS and age group (0-10 years, 11-20 years, and 21-30 years). Unlike for Leigh et al., our 
model was not probabilistic in regards to survival; parameter uncertainty was restricted to QoL only. 
In the absence of evidence on GMFCS-specific mortality rates beyond 30 years of life, we made the 
conservative assumption that the mortality rate for those born with severe neurological morbidity 
would mimic the general population in the UK after this age. 
 
We obtained the distribution of GMFCS states from Young et al.215 and captured the parameter 
uncertainty of the distribution by letting the model sample input values from the data; we sampled 
using Dirichlet distribution. 
 
Combining QoL with survival, we obtained expected lifetime QALYs for neonates born with severe 
ŶeuƌologiĐal ŵoƌďiditǇ. We fiŶallǇ liŵited the total QALYs to the ŵodel͛s tiŵe hoƌizoŶ aŶd disĐouŶted 
these QALYs, using a discount rate of 3.5% as recommended by NICE.190 
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Appendix 8. Questionnaire for attitudes towards universal ultrasound screening in late pregnancy. 
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Thank you for taking the time to read the background of our research project and considering the 
following five questions.  
Background 
As part of routine NHS care all pregnant women are offered two scans. The first scan is usually done 
at about 12 weeks. This scan dates the pregnancy, checks for twins and contributes to screening for 
DoǁŶ͛s syndrome. The second scan is usually performed at around 20 weeks. This scan looks for some 
physical abnormalities and can often check to see if  the baby is a boy or girl.  Healthy women with an 
uncomplicated pregnancy are NOT routinely scanned after 20 weeks but a scan may be suggested if 
their doctor or midwife has concerns.   
We want to carry out research to find out whether offering all women expecting their first baby a third 
scan at around 36 weeks would result in better outcomes for babies. By this we mean fewer babies 
having to be admitted to special baby units because they are born unwell, fewer babies being born 
who are smaller than expected and the worst outcome of all which is when a baby dies before he or 
she is born, a stillbirth. The reason for having a scan at 36 weeks would be to check the baby is growing 
normally, check the placenta (the ďaďǇ͛s life line to the mother) is still healthy and check if the baby 
is head down, which is the correct position for birth.  
Research is needed because while having a third scan at 36 weeks as part of normal care may be useful 
in some cases, it may not always give accurate information and could therefore be harmful. For 
example, there might be a difference of up to 10% between the weight of the baby as calculated 
during the scan and the actual weight, which can be up to 1 pound (lb) difference (equivalent to about 
450 grams) for large babies. Similarly, the scan may suggest a baby is not growing well when in fact 
the baby is perfectly healthy. This can lead to unnecessary and potentially harmful interventions such 
as delivering the baby earlier than needed, which can increase the risk of the baby being admitted to 
special care. We would like to plan a study that women would be happy to join.  For this reason your 
views are important, and will help us decide on the design a future research project on whether we 
should be offering women scans in late pregnancy.   
 
1. Were you aware that  women whose pregnancies are straight-forward are NOT routinely scanned 
after 20 weeks? (circle one) 
A) Yes, I was aware that healthy women are NOT routinely scanned after 20 weeks. 
B) No, I thought all women have a scan after 20 weeks.  
 
2. How much do you agree/disagree with the following statement?  
͞I would like to have the option of a scan at around 36 weeks as part of my routine NHS Đaƌe͟. Circle 
one. 
Strongly disagree Disagree Neither agree nor disagree Agree Strongly agree 
;doŶ͛t want scan)        (do want scan) 
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3. Imagine that today you are asked to be in a research study. This study is called ͞A͟. If you agreed to 
take part you would be randomly put into one of two groups. One group would have a scan at 36 
weeks and the other group would not have a scan at 36 weeks (i.e the current standard of care). That 
is, you would agree to take part in the research and, after you had consented, you would find out 
whether or not you were one of the women selected to have a routine scan at 36 weeks.  
How much do you agree/disagree with the following statement? ͞I would be likely to agree to take 
part in such a research pƌojeĐt͟. 
Strongly disagree Disagree Neither agree nor disagree Agree Strongly agree 
;ǁouldŶ͛t want to take part)                  (would take part) 
 
4. Now imagine that you are asked to be in study (B) where you would definitely have a scan at 36 
weeks. All women would be told whether their baby was head first or bottom first and if there was a 
major obvious problem (eg very small amount of fluid around the baby). However, in this new study 
you would also be randomly put into one of two groups. In this study other information from the scan 
(such as the estimated size of the baby – the part that may suggest you should be delivered early) 
would only be told to women and the midwives and doctors looking after women in one of the groups. 
If you were in this group, the care you received might change in the light of knowing your scan results 
(such as being required to deliver in the consultant-led unit and not in the midwife-led unit). If you 
were in the other group the midwives and doctors and you would not be told this extra information 
and you will receive the standard care.  
How much do you agree/disagree with the following statement? ͞I would be likely to agree to take 
part in such a research pƌojeĐt͟.  
Strongly disagree Disagree Neither agree nor disagree Agree Strongly agree 
;ǁouldŶ͛t want to take part)                  (would take part) 
 
5. If you are happy to participate in one of the above research projects which one would you prefer?  
A. The study in which you may or may not have an additional scan at 36 weeks (depending on 
which group you were randomly put in). For women who have a scan the results will be 
revealed to you and your midwife or doctor. 
B. The study in which all women have an additional scan at 36 weeks. If there is any major 
problem (as described above) the results will be revealed to you and your midwife and doctor. 
If there is not a major problem the results might or might not be revealed (depending on which 
group you were randomly put in).   
C. I will be happy to participate in either study. 
About you 
Age (circle one):    <20   20-24   25-29   30-34   35-39     40+ 
EthŶiĐitǇ: …………………………………… 
Age stopped full time education (circle one):      <18       18-21        22-24        25+ 
Have you been told that you are going to have extra NHS scans anyway?                       YES      NO 
Have you had a previous birth (births include stillbirths but not miscarriages)?             YES      NO 
